

A high-magnification histological image of skin tissue, likely from a psoriasis patient. The image shows a cross-section of the epidermis and dermis. The epidermis is thickened, and there is a prominent layer of hyperkeratosis (thickened stratum corneum) on the surface. The underlying epidermal layers show increased cellularity and some disorganization, characteristic of psoriasis. The dermis below shows some inflammatory infiltrate and changes in the collagen structure.

Psoriasis:

Molecular targets
of denervation
and therapy

Ewout Baerveldt

Psoriasis:

*Molecular targets of
denervation and therapy*

Ewout Baerveldt



Molecular Medicine
Postgraduate School

Colofon

Copyright © E.M. Baerveldt

Lay-out and printing: Optima Grafische Communicatie, Rotterdam, The Netherlands

Cover: Carla Offerhaus

The research for this thesis was performed within the framework of the Erasmus Postgraduate School Molecular Medicine.

All rights reserved. No part of this thesis may be reproduced or transmitted in any form of by any means, electronic or mechanically, including photocopying, recording or any information storage and retrieval system, without the permission in writing of the author, or when appropriate, of the publishers of the publications.

ISBN: 978-94-6169-344-0

Psoriasis:

*Molecular targets of
denervation and therapy*

Psoriasis:

*Moleculaire aangrijpingspunten van
denervatie en therapie*

Proefschrift

ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus

Prof.dr. H.G. Schmidt

en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op

woensdag 13 februari 2013 om 15:30 uur

door

Ewout Marinus Baerveldt

geboren 8 april 1979 te Zwolle



PROMOTIECOMMISSIE

Promotoren:

Prof. dr. E.P. Prens

Prof. dr. J.D. Laman

Overige leden:

Prof. dr. S.E.R. Hovius

Prof. dr. H.A.M. Neumann

Prof. dr. J. Schalkwijk

TABLE OF CONTENTS

Chapter

1	General introduction	9
1.1	Skin anatomy, barrier function, and nerves	11
1.2	Clinics and pathophysiology of psoriasis	23
1.3	Neuronal mechanisms in psoriasis Aims and outline of the thesis	39

Neurogenic inflammation in psoriasis

2	Resolution of psoriatic plaques due to skin denervation: Molecular mechanisms underlying a forgotten phenomenon. <i>Submitted for publication</i>	49
3	Surgical denervation of mouse skin prevents imiquimod induced psoriasiform inflammation. <i>Submitted for publication</i>	61
4	CGRP and acetylcholine promote epidermal TLR9 and LL-37 expression in human healthy skin explants. <i>Submitted for publication</i>	85

Novel mechanistic insight into psoriasis and its therapies

5	IL-4 down-regulates IL-1 β and IL-6 and induces GATA3 in psoriatic epidermal cells: a cell type-restricted route of action of a Th2 cytokine. <i>Submitted for publication</i>	99
6.1	Ustekinumab improves psoriasis-related gene expression in non- involved psoriatic skin without inhibition of the antimicrobial response. British Journal of Dermatology 2012: 12175	113

6.2	Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa. Annals of the Rheumatic Diseases 2012; 202392	127
7	Response to treatment with fumaric acid esters in psoriasis patients is linked to suppression of the IL-17 pathway. <i>Submitted for publication</i>	131
8	The efficacy of topically applied cyclosporin in nail psoriasis: a prospective, double-blinded, randomized, placebo-controlled study F1000 research 2012; accepted for publication, in press	147
9	Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis. Lasers in Surgery and Medicine 2010; 42:201-10	155
10	Summary of results, general discussion, and future perspectives	171
11	Samenvatting	187
12	Dankwoord	197
	Curriculum vitae	203
	List of publications	201
	PhD portfolio	204
	Abbreviations	207
	References	209

Chapter 1

General introduction

GENERAL INTRODUCTION

Already during the eighties, Farber and colleagues provided clinical evidence supporting a crucial role for sensory nerves in the pathogenesis of psoriasis.¹ They reported unique clinical cases in which peripheral denervation resulted in the resolution and prevention of psoriatic plaques.²⁻³ However, in the research field of psoriasis the neuronal dimension has remained underexposed and poorly investigated. One could argue that their remarkable observation has been overshadowed by the wealth of data generated in the field of adaptive immunity in psoriasis. Discovery of aberrancies in innate immune mechanisms in psoriasis has led to enhanced interest in the function of resident skin cells. Interruption of the crosstalk between resident and adaptive immune cells by biological therapies proved effective in psoriasis. However, these novel treatments were not capable of inducing complete remission of disease.

In this thesis we investigated the phenomenon in which cutaneous denervation results in long-lasting resolution of psoriatic plaques. In parallel, we assessed the molecular mode of action in relation to the clinical efficacy of selected treatments of psoriasis. In this chapter an introduction is provided on the normal skin architecture and function, the epidermal barrier and the function of peripheral sensory nerves herein. This is followed by an overview on psoriasis and the specific role of peripheral sensory nerves and associated mediators in the pathophysiology of psoriasis.

1.1 SKIN ANATOMY, BARRIER FUNCTION, AND NERVES

Most research in the field of psoriasis has primarily focused on findings in established psoriatic plaques. However, functional data and genetic insights indicate that even clinically healthy appearing skin from patients with psoriasis already has underlying psoriatic aberrancies, especially in the field of innate defence.⁴⁻⁶ As addressed in this thesis, peripheral nerves are an essential part in cutaneous homeostasis, wounding and inflammation such as psoriasis.³ In our view, increasing knowledge of the role of nerves in relation to innate defence and psoriasis is highly warranted. The structure of healthy normal skin reflects the complexity of its functions as a protective barrier, in maintaining body temperature, in interacting via sensory nerves with the environment, and in having an active role in immunity. Below, epidermal and dermal anatomy, physiology and cellular effectors will be addressed, with special emphasis on the cutaneous neuronal architecture. This is followed by the current view on innate defence of the skin. Finally, the role of peripheral nerves in cutaneous homeostasis and pathology is described in more detail.

The epidermis is built to protect and to interact in multiple ways

The epidermis is the outer skin compartment, and forms the interface with the outside world, covering a surface of $\sim 2 \text{ m}^2$.⁷ As such it is built to protect us against mechanical, physical, biological and chemical injury, and to interact with those agents.

The epidermis comprises four strata. The stratum basale (also denoted as stratum germinativum) is the bottom layer of the epidermis, consisting of basal keratinocytes. The epidermis is continuously replenished from a few infrequently dividing undifferentiated cells within this layer and along the hair follicle which are considered to be keratinocyte stem cells (KSC).⁸ These cells are shielded from differentiation or apoptosis by their microenvironmental niche, including specific types of integrins,⁹ and the protein survivin, which belongs to the family of apoptosis inhibitors.⁹⁻¹¹ KSC generate transiently amplifying (TA) cells, which form the majority of the cell population of the stratum basale and can only divide a limited number of times. The proliferation in TA cells is maintained by p63, c-Myc, $\beta 1$ -integrin, transforming growth factor (TGF)- α signalling pathways, and negatively regulated by TGF- β signalling.⁸ These TA cells differentiate, and move into the stratum spinosum to begin the maturation process.¹² The transcription factor GATA3 is a key promoter of the transition of the proliferative state into differentiation of keratinocytes through the p63/IKK α /SMAD pathway.¹³ During gradual migration to the surface, keratinocytes change from being columnar to being polygonal in shape, therefore called stratum spinosum, and start to synthesize specific keratins, and additionally express desmoplakin, involucrin and small proline rich proteins (SPRR).¹⁴ This differentiation is controlled by several signalling pathways, e.g. by Notch and Wnt signalling, and the transcription factors peroxisome proliferator-activated receptor (PPAR)- α , CAAT-enhancer-binding protein (C/EBP)- α/β ,⁸ and nuclear factor erythroid derived 2, like 2 (Nrf2).¹⁵ Signalling of growth factors through their receptors, such as epidermal growth factor receptor (EGFR), insulin-like growth factor receptor (IGFR)⁸ and nerve growth factor receptor (NGFR; p75-NTR)¹⁶ also regulates proliferative behaviour in the epidermis. The third stratum, the stratum granulosum, is characterized by dark clumps of cytoplasmic material and an active production of keratin, proteins and lipids.⁸ The granular layer displays late keratinocyte differentiation markers including filaggrin, loricrin, and caspase 14, which are ultimately all highly involved in healthy barrier maintenance.⁸ The stratum corneum is the outermost epidermal layer which is largely responsible for the intrinsic resistance to infection under physiological circumstances.¹⁸ This layer comprises mainly corneocytes, which are terminally differentiated, non-viable keratinocytes that are devoid of organelles, but full of lipids. These keratinocytes remnants consist of highly cross-linked proteinaceous cellular (late cornified) envelopes (LCE) with extracellular lipid lamellae, containing mainly ceramides, free fatty acids, cholesterol and antimicrobial peptides (AMP).¹⁸ The stratum corneum provides a permeability barrier that excludes many toxic agents and prevents dehydration of our body by preventing water evaporation.¹⁸ Filaggrin is an important protein that interacts with keratin filaments in the stratum corneum,

promoting, whereby cleaved free amino acids serve to retain water in the stratum corneum. Corneocytes are also packed with glycine-rich C-terminal fragments derived from keratin 6A (K6a), which have strong antimicrobial properties.¹⁹

Specialized cell types in the epidermis include melanocytes, which produce pigment (melanin), and CD1a+Langerin+ Langerhans cells (LC), which is a dendritic cell (DC) subset.²⁰ Although rare, T cells, mainly CD8+ cytotoxic T cells, can be found in the stratum basale and stratum spinosum.²¹ Terminal unmyelinated cutaneous nerves penetrate and form a branched network in the epidermis (See page 18).²² Nerves, keratinocytes and melanocytes derive from the same embryonic germ layer, e.g. the ectoderm.

The dermis provides support and is a medium for cellular and molecular interaction

The dermal connective tissue is composed of fibroblasts collagen, elastic fibers and glycosaminoglycan gels that provide a strong framework, the so called extracellular matrix, for hosting blood and lymphatic vessels, and immune cells.²³ Blood and lymphatic vessels are present throughout the dermis, through which migrating cells can traffic.²³ By transmigration, almost any circulating cell type can be attracted into the dermis during states of infection, wounding or inflammation. The dermis is equipped with an impressive diversity of resident immune cells. Dermal DC and macrophages sense invading pathogens and alert innate and adaptive immune cells to potential danger and damage.^{20 24} In addition, macrophages are primarily involved in phagocytosis of cellular debris which is important for maintaining tissue homeostasis.²⁵ In the mouse dermis, over 60% of all interstitial cells are identified as DC or macrophages.²⁶ Dermal subsets of DC and macrophages include various subtypes which are found disseminated throughout healthy skin.²⁰

Currently, the dermal DC are divided into 2 distinct populations: plasmacytoid (p)DC and myeloid DC.²⁷ pDC are capable of producing type I interferons (IFN) and express BDCA-2 and CD123 (IL-3R α), but are relatively rare in normal skin;²⁸ Myeloid cells are classified into CD14+ DC, which can transform into LC under the influence of TGF- β , and CD11C+ DC, which are mainly located in the upper dermis.²⁸ A subgroup of CD11C+ DC are also CD103+ and Langerin+ and are not related to LC.²⁹⁻³¹ These CD103+Langerin+ DC are resident dermal cells involved in steady state host defence against viral infection,³² and they differ from LC in their capacity to activate CD4+ T cell subsets such as T helper (Th)17 cells.³³⁻³⁴ TNF- α and iNOS-producing inflammatory DC (TIP-DC) are a special fraction within the CD11C+ DC, involved in inflammatory processes.^{20 23-24} DC can directly sense pathogen components via pattern recognition receptors (PRR) such as Toll-like receptors (TLR), and respond to this recognition by up-regulating surface co-stimulatory molecules, secreting

cytokines and chemokines, enhancing antigen presentation, and migrating to secondary lymphoid tissues followed by induction of T cell-dependent immune responses.^{23 35}

The macrophage population is subdivided into classically activated (M1) and alternatively activated (M2) cells. M1 cells are regarded as immune effector and antigen-presenting cells (APC), which are activated by pathogen-associated molecular patterns (PAMP; see page 15), such as lipopolysaccharide (LPS) and cytokines including IFN- γ and TNF- α .³⁶ M2 cells are activated by IL-4 and IL-13, and are involved in type 2 immune responses.³⁷ In general, macrophages express CD14, CD68 and CD163.^{28 36} In addition, M1 cells express CD16, CD32 and CD64, whereas M2 cells express CD206, stabilin-1, FXIIIa, MR, and the marker RM3/1, which develop after exposure to IL-4 and IL-10 *in vitro*.^{28 36 38}

Increasing evidence supports the view that the human adult dermis comprises a large fraction of skin resident T cells, also called skin effector memory T (Tem) cells.^{21 39} In contrast to central memory T (Tcm) cells, which reside in the circulation, Tem cells do not recirculate into the bloodstream but remain seated in the dermis.^{21 40} In fact, the dermis comprises high numbers of T cells, approximately 2×10^6 cells/cm², which is twice the number compared to the circulation, and under physiological conditions, almost 100% of the cutaneous lymphocyte-associated antigen (CLA)+ skin-homing lymphocytes are located in the skin.²¹ Both Tem and Tcm types represent subsets of memory T cells,⁴¹ and are thought to derive from effector T cells, which are generated during primary adaptive immune responses directly after infection.⁴² Tem are considered to provide local immune memory, as both their numbers and functional diversity increase following encounters with pathogens.^{39 43} Gamma delta ($\gamma\delta$) T cells are a minor fraction of T cells, which express $\gamma\delta$ TCR instead of the $\alpha\beta$ TCR found on classical T cells.⁴⁴ $\gamma\delta$ T cells are abundantly expressed in most epithelia, but less in human skin. Skin resident $\gamma\delta$ T cells are involved in cutaneous homeostasis, wound healing, and tumour surveillance.⁴⁵⁻⁴⁶

Additional important factors in the dermal defences are innate lymphoid cells (ILC). These cells of hematopoietic origin have, among other important functions,⁴⁷ protective roles in the innate barrier of epithelia to promptly counteract infection.⁴⁷ ILC can be divided into three groups: Natural killer (NK) cells, the ILC2 subset, and a subset of cells including lymphoid tissue-induced (LTi) cells, ILC17, and ILC22 cells, all of which depend on the expression of the transcription factor ROR γ t.⁴⁷ NK cells are divided into two populations based on CD56 expression.⁴⁸ NK cells can have both pro- and anti-inflammatory functions, and play multiple roles in pathology including cancer, autoimmunity and infections.⁴⁹ A subset of NK cells are non-cytotoxic cells denoted as ILC1, which produce interferon IFN- γ and display a T helper 1 (Th1) cytokine-expression profile. LTi cells and ILC17 seem overlapping cell populations, and ILC17 cells are prone to produce IL-17A in response to IL-23. ILC22 display

characteristics of both NK and LT α cells. There is an important overlap between the cytokines produced by Th17 and Th22 variants and ILC subsets. Regulated by IL-23, ILC22 produce large amounts of IL-22, whereas they produce little if any IFN- γ . ILC are able to sense virus-infected cells, microbial and self-ligands.⁵⁰ DC maturation is directly triggered by ILC, which is followed by T cell-dependent immune responses.⁵⁰⁻⁵¹ Current knowledge regarding these cells is merely derived from studies investigating mucosal epithelium.⁴⁷ Future research will elucidate the precise role of ILC in human skin.

The skin deploys innate defence to maintain homeostasis

Because of its contact with the external environment, the skin is inhabited by commensal microorganisms forming a complex microbial ecosystem. The response to potential harmful intruders depends on the activation of several ancient and conserved group of receptors called PRR that bind conserved elements of pathogens, denoted PAMP.⁵²

The skin can respond to non-infectious endogenous stress signals, named alarmins, also referred to as damage or danger-associated molecular pattern molecules (DAMPs).⁵² DAMP are mostly cytosolic products released by damaged or dying cells, and extracellular matrix fragments, following tissue injury. They include heat-shock proteins, HMGB1, S100 proteins, fibronectin, fibrinogen, and other substances like ATP, DNA, RNA, and uric acid.⁵²⁻⁵⁶

Activation of PRR by DAMPs results in the transduction of NF- κ B and MAP kinase (MAPK) signalling cascades, initiating production of pro-inflammatory stimuli,⁵⁷ and factors that kill and control pathogens.⁵³ In addition to the TLR family,⁵⁸ several other PRR families have been described including nucleotide-binding oligomerization domain (NOD)-like receptors (NLR), CD14, C-type lectins (CLR), protein kinase R, AIM2, complement receptors, and RIG-like helicases (RLH) including RIG-I and MDA5.^{53 59-60} Currently, the TLR family is the best characterized PRR, and is highly conserved between species.⁵⁷ It is now believed that each of the 13 murine TLR and 10 human TLR detect a limited number of the signature molecules that herald infection, including bacterial cell wall components such as LPS, lipopeptides, flagellin, unmethylated DNA, and RNA (double stranded (ds)RNA and single stranded (ss) RNA).^{58 61-62} TLR are constructed by three types of domains: extracellular ectodomains containing leucine-rich repeats; a transmembrane domain; and an intracellular Toll-interleukin (IL)-1 receptor (TIR) domain. TLR activation induces multiple innate and adaptive immune responses. Based on their location of cellular expression, two major types of TLR have been identified: surface-expressed TLR, including TLR1, TLR2, TLR4, TLR5 and TLR6, which are predominantly active against bacterial cell wall compounds, and the endosomal receptors TLR3, TLR7, TLR8, and TLR9, which recognize microbial and human DNA and RNA.⁵⁸ Activation of TLR recruits TIR domain-containing adapter proteins such as myeloid differentiation factor (MyD88), TIR-domain-containing adaptor protein-inducing IFN- β (TRIF), TIR-associated protein (TIRAP), and TRIF-related adaptor molecule (TRAM).^{35 57-58} MyD88 is involved in merely all TLR signalling cascades except for TLR3 and associates with IL-1R-associated

kinases (IRAK) and TNFR-associated factor 6 (TRAF6), resulting in activation of NF- κ B and production of pro-inflammatory proteins.⁶²

To avoid harmful and inappropriate inflammatory responses, TLR signalling is negatively controlled by multiple mechanisms, including some regulating each other.⁶³ For example, TLR5 activation inhibits TLR9-mediated responses.⁶⁴ Cytosolic TLR7, TLR8 and TLR9 are known to regulate the expression of each other.⁶⁵ Recent findings show that murine expression of functional TLR9 in spleen and in antigen-presenting cells is regulated by circadian rhythms. The strongest peak in TLR9 expression is displayed at night, when the mice are the most active.⁶⁶

Pattern recognition receptors, especially TLR, are abundantly expressed by important cutaneous innate effector cells, such as keratinocytes,^{23 67-70} DC, macrophages,²³ and mast cells.⁷¹ Keratinocytes express several TLR, located either on the cell surface or in endosomes (TLR3 and TLR9).^{23 67-70} TLR7 expression can be induced through triggering of TLR3 by dsRNA.⁷² Activation of PRR expressed by keratinocytes results in a predominant Th1-type immune response and in the production of type I IFN and antimicrobial peptides,⁷³⁻⁷⁵ including β -defensins and the cathelicidin LL-37.^{74 76} This mechanism is considered an evolutionarily conserved epithelial defence mechanism against wounding and infection.⁷⁷

Depending on their activation and maturation, dermal DC can express PRR such as TLR2,⁷⁸ and TLR4.²⁰ Plasmacytoid DC express both TLR7 and TLR9, indicative of their role in viral infections.⁷⁸⁻⁸⁰ Mast cells express a variety of PRR, including TLR1-10 with the exception of TLR5, stressing the function of mast cells as innate effector cells.⁷¹ The expression of these TLR may account for the release of mediators by mast cells upon contact with bacteria, initiating a cascade of events leading to vasodilatation and increased capillary permeability and to the influx of leukocytes.⁷¹

Antimicrobial peptides are multi-taskers at the cutaneous front

In order to prevent microbial invasion, epithelia such as the skin constitutively express AMP (Table 1).¹⁹ Keratinocytes are an important source of AMP, including β -defensins (hBD),⁸¹ LL-37,^{74 82-83} ribonuclease (RNase)7,⁷⁴ and regenerating islet-derived protein 3-alpha (REG3 α).⁸⁴ Mast cells and neutrophils are additional important sources of AMP in the skin.²³⁸⁵ Cytokine producing immune cells can enhance the production of AMP by keratinocytes via the communication by cytokines, including IL-1 β , IL-12, IL-17A, IL-22 and IL-23.⁸⁶⁻⁸⁷ Mast cell-derived histamine enhances TLR2 expression in keratinocytes during exposure to peptidoglycan, a bacterial cell wall component, and increases the subsequent production of hBD-2.⁸⁸ Apocrine and eccrine glands provide additional cutaneous sources of LL-37,⁸⁹ and dermcidin (DCD).⁹⁰ DCD is transported via the sweat tubuli towards the stratum corneum

Table 1. Common antimicrobial peptides in skin

Family	Peptides	Cellular sources	Target organisms	Mechanisms of action	Ref
β -defensins	hBD1, hBD2, hBD3	KC, MC	Gram+/- bacteria Fungi, viruses, protozoa	Membrane disruption; lipid II binding (hBD3)	74, 76
S100	S100A7 (psoriasin), S100A8-S100A9 (calprotectin)	KC, Neu	Staphylococcus aureus; escheria coli	Metal chelation	442
Cathelicidins	Human LL-37 Mice CRAMP	KC, Neu, MC	Gram+/- bacteria, Group A streptococcus, Fungi, viruses	Membrane disruption	83
Dermcidin	DCD-1	EG	Gram+/- bacteria, E. coli, C. albicans		90, 92
Peptidoglycan recognition proteins	PGLYRP1-4	KC	Gram+/- bacteria	Amidase targeting peptidoglycan	74
RNases	ANG4, RNase7	KC	Gram+/- bacteria	Unknown	435
Keratin-derived AMP	Cytokeratin 6A	KC	Pseudomonas aeruginosa	Causes cell death and membrane disruption	19
C-type lectin family	Regenerating islet-derived protein 3- α (REG3A)	KC	Gram+ bacteria	Controls bacterial proliferation	84
Calcitonin gene-related peptide	CGRP α , CGRP β	KC, SN	Gram+/- bacteria, E. coli, C. albicans	Unknown	130
Tachykinin family	Substance P (SP)	KC, MC, SN	Gram+/- bacteria, E. coli	Unknown	130
Vasoactive intestinal peptide	VIP	KC, MC, SN	Gram+/- bacteria,	Unknown	130
Neuropeptide Y	NPY	KC, MC, SN	Gram+/- bacteria, E.	Unknown	130
Pro-opiomelanocortin	α -Melanin stimulating hormone	Mel	Staphylococcus aureus	Membrane disruption	76

KC, keratinocyte; MC, Mast cell; Neu, neutrophil; EG, eccrine gland; SN, sensory nerve; Mel, melanocyte.

to provide local defence.⁹⁰ Interestingly, the majority of these peptides not only have broad antimicrobial activity, they also trigger chemotaxis, angiogenesis, and keratinocyte migration, proliferation and apoptosis.^{74 84 91-92} In addition, LL-37 is able to temper IL-1 β responses via stimulation of AIM2 expression.⁹³ In addition LL-37 is also involved in foam cell formation and re-endothelialization,⁹⁴ and suppresses collagen synthesis during wound healing.⁹⁵ Recent results point towards broader functions for AMP in innate defence: in parallel to the killing of pathogens and activation of adaptive immune responses, AMP regulate inflammatory responses by interaction with responses to TLR ligands.⁹⁶⁻⁹⁷ TLR9 expression by keratinocytes is increased during in vitro exposure to LL-37 and subsequently TLR9-stimulated keratinocytes produced increased amounts of type I IFN.⁹⁸ This increased production was independent of DNA-LL-37 complexes.⁹⁸

Overall, a complex network of signals control expression and secretion of AMP, which in turn controls inflammation. Pattern recognition receptors such as TLR, and AMP are also essential for shaping the composition and location of indigenous microbial communities.⁷⁴ However, excessive PRR activation and deregulation of AMP expression can disrupt immune homeostasis, and may contribute to the development of inflammatory diseases such as psoriasis.⁶³

The skin is densely innervated by peripheral nerves

Cutaneous nerves are divided into two categories of axons: primary afferent A β , A δ and C fibers, all arising from cell bodies residing in dorsal root ganglia (DRG), and sympathetic postganglionic fibers arising from the sympathetic ganglia. Only A β and A δ fibers are covered by myelin with exception of their dermal and epidermal branches. After reaching the superficial dermis in a vertical direction, a horizontally-oriented sub-papillary plexus is formed.⁹⁹ This is composed of mostly unmyelinated nerve fibers, and a small number of myelinated nerves. The hair follicle has a dense and complex innervation pattern consisting of both unmyelinated and myelinated fibers. Hair follicles show specialized sensory nerve endings at the base and the bulge area along the hairshaft.¹⁰⁰⁻¹⁰¹ Results from recent investigations indicate a functional role for these sensory nerves in promoting wound healing by activation and migration of hair stem cell progeny.¹⁰¹ The arrector pilorum muscles are innervated by autonomic fibers. In the deep dermis unmyelinated nerve endings form a mesh-like network covering larger arteries, in contrast to limited innervation of the more superficial smaller arterioles. Meissner's corpuscles and Merkel cell complexes, both specialized sensory transducers, are innervated by myelinated nerves, and eccrine sweat glands are densely innervated by sympathetic fibers (Figure 1).¹⁰²

Sensory nerve fibers branch from the sub-papillary plexus and enter the epidermis.⁹⁹ These epidermal branches lack a Schwann cell sheath and collagen collar. Within the epidermis they extend between keratinocytes and reach the stratum granulosum.^{99 103} These




Figure 1. Lay out main cutaneous peripheral nerves

fibers include both $A\delta$ terminals and C fibers.²² Previous staining techniques did not reliably visualize C fibers, but the development of sensitive in situ staining techniques offers new opportunities to identify and quantify these small sensory fibers.^{22 104} For example, immunostaining for the protein gene product (PGP)9.5, a neuronal ubiquitin hydrolase, is now widely used to visualize the sub-papillary plexus, and to reveal the epidermal innervation.²²

104

In this thesis, we predominantly focus on peripheral sensory nerves. However, the so-called 'brain-skin axis' comprises numerous neuro-endocrine connections, including the important inflammatory reflex, which functions primarily in an anti-inflammatory fashion via the nervus vagus and the cholinergic route. Since this aspect is out of the scope of this thesis, we refer to excellent reviews on multiple aspects of the 'brain-skin axis'.¹⁰⁵⁻¹⁰⁸

Peripheral nerves express functional PRR

As mentioned previously, the peripheral nerves, including Schwann cells, sciatic nerve, motor neurons and sensory neurons, are capable of expressing a wide range of TLR.¹⁰⁹⁻¹¹⁰ Peripheral nerves also express NOD-like receptors and receptors important in the detection of danger signals,¹¹¹ such as heat, acidity and chemicals, but also endogenous damage signals such as ATP or uric acid.¹¹¹ Stimulation of TLR4 on Schwann cells with LPS results in

activation of the MAPK signalling cascade, and stimulation of TLR3, TLR4, and TLR7 induces robust NF- κ B responses.¹¹⁰ Circumstantial evidence supports the functional relevance of TLR expression in peripheral nerves. In vitro studies have shown that human neuronal cells (NT2-N cells), express TLR1-4, TLR6, TLR7, and TLR9,¹¹²⁻¹¹³ and PKR and RIG-I.¹¹² In response to in vitro stimulation with rabies virus or polyI:C (a synthetic analogue of dsRNA), NT2-N cells produce type I IFN, CCL-5, CXCL-10, IL-6 and TNF- α .¹¹²⁻¹¹³ These results indicate that without support of glia cells or Schwann cells, neurons themselves sense via TLR and actively participate in innate defences.

The functional relevance of TLR expression by peripheral nerves is illustrated by the observation that skin application of TLR7 agonist imiquimod in mice, directly enhances the excitability of sensory DRG neurons and causes pruritis.¹¹⁴ Cumulating evidence suggests a functional role for TLR signalling in the events following axonal damage, orchestrating and facilitating rapid clearance of myelin debris and nerve regeneration.^{110 115}

Peripheral nerves directly counterstrike against potential danger

Following detection of danger by the appropriate receptors, peripheral nerves sound the alarm on potential threats in the epithelium by hardwired neurotransmission to the central nervous system. In parallel, the peripheral nerves directly respond via opposite antidromic reflexes by releasing pro-inflammatory mediators, such as interleukins and neuropeptides at the nerve terminals, also called the axon reflex.¹¹¹ The variety of neuropeptides includes the tachykinin-family member substance P (SP), neurokinin A (NKA), vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), and calcitonin gene-related peptide (CGRP).

These neuropeptides are synthesized in the DRG cell bodies, and transported towards the peripheral nerve terminals. After their release, a subsequent cascade of inflammatory responses ensues which is referred to as neurogenic inflammation. This includes promotion of rapid mast cell degranulation, activation and attraction of DC, macrophages, and neutrophils.^{111 116} They also stimulate synthesis and release of many pro-inflammatory cytokines by mast cells,¹¹⁷ T cells¹¹⁸, DC,¹¹⁸ and fibroblasts. C fibers communicate directly with mast cells via SP. High levels of SP are required for inducing immediate mast cell degranulation. Low concentrations of SP can activate neurokinin receptor (NK1-R), also called SP receptors, on mast cells, leading to sensitization of these cells and increased production of TNF- α .

In keratinocytes both CGRP and SP enhance IL-1 β production via caspase-1 and cathepsin B.¹¹⁹ Vascular responses include induction of angiogenesis, dilatation of vessels and capillaries and increased capillary permeability, NO synthesis, and induction of endothelial expression of vascular adhesion molecules.¹²⁰⁻¹²⁴

Astrocytes express TLR3 and TLR4,¹²⁵⁻¹²⁶ and are responsive to LPS stimulation which leads to their secretion of hBD-2.¹²⁷ In spinal fluid derived from patients with bacterial meningitis, antimicrobial peptides such as LL-37 are increased.¹²⁸ This indirectly suggest that in response to TLR activation also the peripheral nerves are capable of releasing AMP. Several

neuropeptides produced by peripheral nerves, display antimicrobial activity (Table 1), with almost similar antimicrobial efficacy compared to hBD-2 and LL-37.¹²⁹⁻¹³⁰ Overall, rapid deploy of these multifunctional neuropeptides by cutaneous nerves affects both epidermal and dermal homeostasis and pathologic processes.

Acute inflammatory responses to denervation

Denervation is defined as resection or removal of nerves from an organ. In most cases, denervation is a side-effect of surgery. This is usually attributed to the mechanical forces of stretch, compression, contusion or transection (axotomy), or induced by the neurotoxicity from anaesthetics or ischemia.¹³¹ In addition, partial or total cutaneous denervation is highly common in skin affected by the varicella zoster virus, due to loss of myelin sheet and axonal damage corresponding to viral infected DRG.¹³²⁻¹³⁴ Degeneration of an axon distal to the injury site, denoted as Wallerian degeneration, involves a stereotypical pattern of events resulting in local inflammation and axonal death.¹³⁵ Within minutes following nerve injury, the growth factor neuregulin, expressed on the axonal membrane, activates Schwann cells.¹³⁶ In parallel, resident macrophages, which account for ~9% of the cell population in intact peripheral nerves, move into the lesion site.¹³⁷ Macrophages and Schwann cells produce MCP-1 (CCL2) and MIP-1 α (CCL3),¹³⁸ IL-1 β , IL-6, IL-12, and TNF- α .¹³⁹ Schwann cells release growth factors such as NGF to stimulate axonal growth and remyelination.¹⁴⁰ TLR have a regulating role in Wallerian degeneration, as TLR are involved in macrophage activation and their infiltration into the injured area.^{115 141} The release of interleukins and growth factors results in the recruitment of different immune cells, such as T cells, neutrophils, monocytes and M1 macrophages, which invade the injured peripheral nerve and its surroundings.¹⁴² In rats, T cell influx during Wallerian degeneration is associated with a peak of IL-23 mRNA expression after 24 h, followed by increases of IL-15 mRNA and both IL-17A mRNA and protein expression.¹⁴³ The axonal release of vasoactive mediators including CGRP, SP, bradykinin and NO at the lesion site causes hyperaemia and swelling.¹⁴⁴ These vascular changes further facilitate the invasion of immune cells. Upregulation of lysosomal markers and an abundant inclusion of lipid droplets indicate that macrophages transform into active phagocytes after nerve injury.¹⁴⁵ Removal of distally degenerating axons and myelin debris by phagocytosis enables a reorganization of Schwann cells and lays the foundation for the regrowth of injured axons.¹⁴⁶

Denervation interferes with cutaneous function

Permanent cutaneous denervation affects basic physiologic functions of the skin. Both clinical and experimental reports show that sensory nerves are involved in epithelial tissue repair. This appears from the observation that wound healing is inhibited by impaired innervation,¹⁴⁷⁻¹⁵⁰ whereas CGRP and SP are able to accelerate wound healing.¹⁵¹⁻¹⁵² Peripheral sensory nerves and their derived neuropeptides CGRP and SP are regulators of hair stem cell

progeny, which is important for hair growth cycle and epithelial recovery following wounding.^{101 153} In vitro stimulation of epidermal stem cells with CGRP results in detachment of stem cells from their niche, followed by enhanced proliferation, mediated via Wnt/ β -catenin signalling pathway.¹⁵⁴

The eccrine glands are highly innervated by sympathetic nerves, and signals are transmitted via cholinergic mediators such as acetylcholine (ACh). Interestingly, sympathetic denervation results in impaired sweating, however, when denervated, these glands are not able to respond to exogenous ACh.¹⁵⁵ During neurogenic inflammation, mast cells respond to neuropeptides released by terminal sensory nerves. This is in part facilitated by the colocalization of mast cells with SP and CGRP+ nerve fibers.¹⁵⁶ Cutaneous denervation resulted in impaired mast-cell driven inflammation,¹⁵⁷ and decreased or absent axon flare in response to histamine injection.¹³² Peripheral denervation impairs cutaneous thermoregulation,¹⁵⁸ which is reflected by the onset of cold intolerance.¹⁵⁸⁻¹⁵⁹ Another interesting finding is the enhancement of IL-12/IL23-p40 expression in sensory DRG in response to cutaneous IFN- γ stimulation following injection of IFN- γ into the mouse footpad. Remarkably, this *in vivo* enhancement of p40 was eliminated by denervation of the sciatic nerve.¹⁶⁰

Denervation is linked to pathology

Several clinical observations indicate that this combined reduction of nerves and associated neuromediators,¹⁶¹ is followed by local impairment of inflammation and severe local pathology such as cancer. As stated previously, biopsies of skin infected by varicella zoster virus, display a reduction in the dermal nerve network, involving primarily unmyelinated C fibers and thinly myelinated A δ fibers.¹³³ This virus is known to pass from cutaneous and mucosal lesions via sensory nerves into the corresponding DRG, establishing a latent infection.¹³⁴ In patients with severe post-herpetic neuralgia, the density of sensory nerve terminals endings in the papillary dermis and epidermis of the affected dermatome is significantly reduced.¹³⁴ A few reports describe the local occurrence of cancer in denervated skin.^{134 162} This includes a striking report of an angiosarcoma of which the location was confined to the trigeminal areas, which was previously affected by herpes zoster.¹⁶³ Another case showed the development of cutaneous melanoma metastases along 3 dermatomes that had been affected by a herpes zoster infection.¹⁶⁴ The tendency of cancer to occur in denervated skin is confirmed by an early report regarding the effects of cutaneous denervation in mice on the development of cancer.¹⁶⁵ Results show that denervation results in a faster development of cancer in response to carcinogen painting.¹⁶⁵

In conclusion, the skin communicates directly with the outside world and is continuously challenged to maintain homeostasis. Therefore, the skin relies on an effective permeability and antimicrobial barrier. The peripheral nerves are not simple bystanders solely capable of

producing itch, but actively respond in two ways to insults of the cutaneous barrier integrity. First, the peripheral nerves convey specific information to the central nervous system on our microbial homeostasis and invading pathogens. Second, the peripheral nerves respond to PAMP and DAMP insults by modulating innate defence responses, and by inducing chemotaxis and vascular adaptations to increase the influx of immune cells. In parallel, peripheral nerves and derived mediators are strongly involved in the regulation of epidermal stem cell growth and proliferation. Aberrancies in peripheral nerve signalling can result in pathology. The role of peripheral nerves in psoriasis is addressed in section 1.3.

1.2 CLINICS AND PATHOPHYSIOLOGY OF PSORIASIS

The impact of psoriasis on health, science and socio-economy

Psoriasis is a life-long, relapsing, non-infectious inflammatory skin disease, which affects about 2% of people of European descent.¹⁶⁶ This indicates that in Europe more than 5 million people are affected by this disease,¹⁶⁷ suggesting that in The Netherlands, approximately 300.000 people are diagnosed with psoriasis. Onset of disease can occur at any age, from infancy to old age, but the mean age of onset is around 30 years.¹⁶⁸ Population studies show that the incidence of psoriasis vulgaris is greater in first and second degree relatives of patients than in the general population, and the concordance in monozygotic twins is around 70%, all indicative of a strong genetic basis of the disease.¹⁶⁹⁻¹⁷¹ The genetics of psoriasis is discussed in more detail on page 33.

Currently, the disease psoriasis exceeds the borders of dermatology, as it has clinical and treatment implications beyond the care of skin lesions,¹⁷²⁻¹⁷⁴ such as psoriatic arthritis,¹⁷⁵⁻¹⁷⁶ ocular disease,¹⁷⁷ obesity,¹⁷⁸⁻¹⁷⁹ inflammatory bowel disease, associated autoimmune diseases,¹⁸⁰ the highly debated cardio-vascular co-morbidity,^{173 181-185} and psychological and social limitations.^{166 186-190} It is unclear whether the increased occurrence of cancers during immunosuppressive therapy is related to psoriasis or to its treatment.¹⁹¹⁻¹⁹³ In addition, patients with psoriasis, like those with other major medical disorders, have reduced levels of employment and income as well as a decreased quality of life.^{166 186-189 194} According to the National Psoriasis Foundation of the USA, total annual direct and indirect costs of psoriasis are over US\$ 11 billion, with missed working days accounting for 40% of the cost burden. Although therapy with monoclonal antibodies (mAb) shows high efficacy,¹⁹⁵⁻¹⁹⁶ psoriasis can still only be managed but not cured.¹⁹⁷⁻¹⁹⁸

As the skin is the most accessible organ, it is highly convenient for scientific exploration. Hence, there is growing interest by the medical research community in psoriasis because it serves as a model for mechanism of action studies in chronic inflammation.¹⁹⁹⁻²⁰⁰ Phar-

maceutical companies increasingly consider psoriasis as a first-choice disease indication for proof-of-principle studies of new pathogenesis-driven therapeutic strategies (Table 2).^{199 201} In 2008, the worldwide market for topical psoriasis medication was around US\$850 million, overshadowed by a market for biologics approaching US\$2.5 billion.²⁰⁰ In 2011, the top-four overall selling biologic drugs comprised three drugs targeting psoriasis.¹⁹⁹ The very high cost of these biologics, often exceeding US\$20,000 per patient year, underscores the need for thorough understanding of the pathogenesis in order to optimize existing therapy and to develop therapeutic alternatives. Taken together, psoriasis has a significant impact on patients, health care systems, research on inflammatory disease, and on society in general.

The clinical presentations of psoriasis

Psoriasis has a number of clinical presentations, with skin lesions that have their own specific characteristics. Co-occurrence of the different forms of psoriasis is seen in daily practice. Common presentations include punctata and guttate psoriasis, inverse psoriasis, and psoriasis vulgaris. Less frequent presentations are erythrodermic psoriasis, annular, figurate or gyrate psoriasis, and generalized pustular psoriasis (Von Zumbusch type).²⁰¹⁻²⁰² Based on increased knowledge about demographics and the genetic background, palmoplantar pustulosis is currently considered to be a comorbidity rather than a form of psoriasis.²⁰³ Most scientific research, including the investigations described throughout this thesis, refer to the clinical variant psoriasis vulgaris or chronic plaque-type psoriasis, which affects approximately 90% of all patients with the disease.²⁰² Psoriasis vulgaris is usually manifested as round, oval, bright-red plaques, well-delineated from surrounding normal skin, covered by thick, silvery-white adherent scales.²⁰² The primary lesion appears as a pin-head sized papule, salmon pink or dull red in colour, and covered by a dry white or silvery-grey scale. These papules merge together, composing plaques which can be thick, thin, large or small. Plaques are most active at the edge and rapidly progressive lesions may present an annular distribution, with normal skin in the center.²⁰² Psoriatic lesions exhibit the so-called Auspitz sign, which is the occurrence of punctate-bleeding points within lesions as a result of slight scratching or curetting.²⁰⁴⁻²⁰

Although psoriasis can occur on the entire body, lesions preferentially occur at specific body sites, such as the extensor surface of the elbows, knees, scalp, the umbilical region and the sacral region.²⁰² The plaques are mostly symmetrically distributed (Figure 2), following almost identical bilateral occurrence and evolution.²⁰⁶ The extent of the body surface area affected by psoriasis is highly variable, but in most people the location and severity of their psoriasis is quite stable over time.²⁰² Nail involvement, including pitting, onycholysis, dystrophic nails, subungual keratosis and oil drop change, is a common manifestation of psoriasis, occurring in up to 30-50% of patients, with a lifetime incidence of 80-90%.²⁰⁷ Nail involvement is often associated with psoriatic arthritis, which shows prevalence among patients with psoriasis ranging from 6% to 39%.²⁰⁷

Table 2. Current experimental therapies for psoriasis

Topical therapies			
Psoriasis target	Mechanism of action	Drug/compound	Manufacturer
Angiogenesis	VEGFR/cKIT/PDGFR inhibitor	pazopanib	Gsk
Epidermal proliferation	MEK-1/MEKK-1 inhibitor	E6201	Eisai Limited
	HDAC inhibitor	SHP-141C	Shape Pharmaceuticals
Inflammatory cytokines	PDE4 inhibitor (small molecule)	AN2728	Anacor Pharmaceuticals
JAK/STAT signalling	JAK1/JAK2 inhibitor	Ruxolitinib	Selleck/Incyte
Nerve/skin interaction	TRPV agonist	Capsaicin	Multiple companies
	TrkA (NGFR) kinase blocker	CT327	Creabilis Therapeutics
	TrkA kinase MAP2K3 kinase inhibitor	CT340	Creabilis Therapeutics
STAT3	STAT-3 inhibitor	STA-21	Kochi University
TNF- α	Single chain Fv targeting TNF- α	ESBA105	Delenix
Systemic therapies			
Psoriasis target	Mechanism of action	Systemic therapies	Manufacturer
Angiogenesis	Angiogenesis inhibitor	Tetrathiomolybdate	Multiple companies
	Anti $\alpha\beta$ 3 mAb (humanized IgG1)	Etaracizumab	MedImmune
	Mitotic inhibitor	Micellar Paclitaxel	Bristol-Myers Squibb
DC	TLR7 & 9 antagonist	IMO-3100	Idera Pharmaceuticals
DC antigen presentation	Cathepsin-S inhibitor	RWJ-445380	Alza Corp.
Epidermal proliferation	Integrin	BIRT 2584	Boehringer Ingelheim
	P38 MAPK inhibitor	BMS 582949	Bristol-Myers Squibb
	S1P1 receptor agonist	ACT-128800	Actelion/Roche
	Selective inhibitor of P450-mediated all-trans retinoic acid	Talarozole	Gsk
IFN- γ	Anti IFN- γ mAb (fully human)	AMG 811	Amgen
IL-15	Anti IL-15 mAb (fully human)	AMG 714	Amgen
IL-17	Anti IL-17A mAb	Secukinumab	Novartis
IL-17	Anti IL-17A mAb (humanized IgG4)	Ixekizumab	Eli Lilly & Co.
IL-17	Anti IL-17R (fully human)	AMG 827	Amgen
IL-1 β	Caspase-1 inhibitor	VX-765	Vertex Pharmaceuticals
IL-2	Anti IL-2RA mAb (humanized)	Daclizumab	Hoffmann-La Roche
IL-20	Anti IL-20 mAb	109-0012	Novo Nordisk
IL-22	Anti IL-22 mAb	Fezakinumab	Pfizer
	Anti IL-22 mAb	ILV-095	Pfizer
IL-22/STAT3	SIRT1 activator (small molecule)	SRT2104	Gsk

IL-12/IL-23	IL-12/23p40 inhibitor (small molecule)	Apilimod	Synta Pharma Inc.
	IL-12/23p40 inhibitor (phospholipid analog)	VB-201	VBL therapeutics
IL-23	Anti IL-12/23p40 mAb (fully human)	Briakinumab	Abbott
	Anti IL-23p19 mAb	SCH 900222	Merck
	Anti IL-23p19 mAb (Human HuCAL-based)	CNTO1959	Janssen
	Anti IL-23 mAb (fully human)	AMG 139	Amgen/Astra Zeneca
Inflammatory cytokines	A ₃ adenosine receptor agonist decreasing cAMP	IB-MECA	Canfite
	PDE4 inhibitor	Apremilast	CelGene Corporation
	PDE4 inhibitor	Roflumilast	Nycomed
	PDE4 inhibitor	MK0873	Merck
Invariant NKT cells	GLP-1 analogue	Liraglutide	Novo Nordisk
	JAK/STAT signalling	JAK inhibitor	ASP015K
JAK/STAT signalling	JAK1/JAK2 inhibitor	Baricitinib	Eli Lilly & Co./Incyte Corp.
	JAK1/JAK2 inhibitor	INCB18424	Incyte Corp.
	FLT3, JAK2, Trk-A, -B, -C inhibitor	Lestaurtinib	Cephalon
	JAK3 inhibitor	Tofacitinib/Tasocitinib	Pfizer
	JAK3 inhibitor	Tofacitinib/Tasocitinib	Pfizer
Lymphocyte adhesion	Anti VAP-1 mAb (human)	BTT1023	Biotie
	HMG-CoA reductase inhibitor	Atorvastatin	Pfizer
	LFA-1 small-molecule antagonist	BMS 587101	Bristol-Myers Squibb
	LFA-3-IgG fusion protein	Alefacept	Astellas Pharmaceuticals
Nerve/skin interaction	TrkA kinase (NGFR), MAP2K3 kinase inhibitor	CT340	Creabilis Therapeutics
Neutrophils	CXCR2 antagonist	SCH 527123	Merck
T cells	Anti B7RP-1 mAb (fully human)	AMG 557	Amgen
	Anti CD3 mAb (humanized Fc-engineered)	Teplizumab	Eli Lilly & Co.
	Anti CD4 mAb; upregulates Treg	BT061	Biotest; Abbott partner
	Apoptosis inducer of late-stage activated T cells	AbGn168	AbGenomics
	Calcineurin inhibitor	voclosporin	Isotechnika Pharma
	CD40 blocker	ASKP1240	Astellas Pharma Inc
	CTLA4 IgG fusion protein targeting CD80	Abatacept	Bristol-Myers Squibb
	Protein kinase C inhibitor	Sotrastaurin	Novartis
	T-cel inhibitor	IP10.C8	Immune Tech and Med
	TNF- α	Anti TNF- α mAb (fully human)	Golimumab
Anti TNF- α mAb (humanized Fab' fragment)		Certolizumab pegol	UCB
Recombinant human soluble p55 TNF-R		Onercept	EMD Serono

Source ClinicalTrials.gov 2012




Figure 2. Clinical features of psoriasis

Psoriasis vulgaris is characterized by erythematous, scaly, sharply demarcated plaques in different sizes and shapes, most often symmetrical distributed at the elbows, knees, and the sacral region (A). The nails are commonly affected by psoriasis showing nail dystrophy, oil drop discoloration, splinter bleedings, and nail bed disturbances (B). Psoriatic arthritis is primarily known to affect interphalangeal joints of the hand (C). The nails are frequently affected, with nail dystrophy and defects of the nail bed.

The Netter Presenter™ Dermatology Edition Copyright 2008 Elsevier Inc. All rights reserved.

Historical perspective and nomenclature

Psoriasis is one of the longest known diseases.²⁰⁸ The Greek physician Hippocrates, who lived between 460 and 377 BC, described a condition with great similarities to the psoriatic phenotype. Psoriasis is believed to be one of the conditions called Tzaraat in the Bible.²⁰⁸ During the dark ages psoriasis was frequently described as a variety of leprosy.²⁰⁹ In the late 18th century, it became known as Willan's lepra, when English dermatologists differentiated it from other skin diseases and provided the first rational nomenclature based on the appearance of lesions. During the 18th and 19th century, dermatologists started using sunlight and various sources of artificial light to treat psoriasis. It was not until 1841 that the condition was finally given the name psoriasis by the Viennese dermatologist Von Hebra. The name is derived from the Greek word psora which means to itch.²⁰⁹ In 1877, Heinrich Köbner described the appearance of psoriatic lesions in uninvolved skin of patients with psoriasis as a consequence of trauma,²¹⁰⁻²¹¹ such as excoriations, tattoos and horse bites. This type of reaction could also be induced experimentally by epidermal barrier disruption, and became known as the Koebner phenomenon, also called Koebnerization or isomorphic response.²¹¹⁻²¹² This phenomenon is discussed in more detail in section 1.3.3. During the 20th century, psoriasis has been further differentiated into clinical subtypes as described at page 24.

In the last decade, several attempts have been made to provide tools to measure the individual clinical severity of psoriasis vulgaris.²¹³ Currently, the psoriasis area and severity

index (PASI) is the most widely used assessment method. PASI is a scale of disease severity based on the extent of psoriatic-lesion coverage of the body and the severity of individual lesions, ranging from 0 to 72. 'PASI75' is the current broadly accepted standard for a meaningful response to treatment, which means at least a 75% PASI improvement from baseline.²¹⁴ However, the current success rate of the latest biologics has raised the bar, and nowadays the result of 'clear or almost clear' (PASI>90%) is considered the best evidence of treatment efficacy.

The progress in pathomechanistical insights in psoriasis


Despite its frequent occurrence, persistence since antiquity, accessibility, and increase in research funding, many puzzling questions about psoriasis remain unanswered. These include aspects such as the molecular background of the Koebner phenomenon, the onset of disease following streptococcal infections, and the intriguing role of peripheral nerves in the onset and maintenance of psoriasis. Perhaps the most obvious unresolved but highly pursued issue is whether this disorder primarily reflects an abnormality in the epithelium or in bone-marrow derived immune cells, such as T cells or DC. This is a longstanding 'hen or egg' controversy in the research field of psoriasis.²¹⁵

The remarkable and substantial progress made during the last 20 years has fundamentally changed our understanding of psoriasis (Figure 3). Initially, psoriasis was thought to originate from abnormalities in keratinocytes, the predominant cell type in the epidermis, as their enhanced proliferation and abnormal differentiation is the source of the white scaly plaques. This view on psoriasis as an epidermal disease resulted in the use of therapeutics such as methotrexate or arsenic to constrain keratinocyte hyperproliferation. But in the 1980s, the successful use of cyclosporin (a drug specifically targeting T lymphocytes) in psoriasis,²¹⁶ directed research interest toward T cells.²¹⁵ During the following two decades, compelling accumulating scientific evidence tilted the consensus toward psoriasis being primarily a T cell-mediated disease.^{215 217-218}

View on psoriasis as an autoimmune disease

During the last 20 years, psoriasis was regarded as an autoimmune disorder. A current view is that autoreactive T cells recognize a cutaneous autoantigen, via molecular mimicry and thereby start the cascade of cellular and molecular events leading to psoriatic plaques.²¹⁹ The resulting keratinocyte activation and abnormal differentiation would promote the generation of new antigens and epitopes, that enhance T cell stimulation and subsequently psoriasis.²¹⁹

It is believed that autoreactive T cells develop following contact with exogenous superantigens, such as bacterial proteins. These superantigens induce a polyclonal activation of circulating CD4+ T cell subsets, activated by MHC complex class II positive APC bearing the

Figure 3. Historical spiral psoriasis

superantigen.²²⁰⁻²²¹ In a second stage, a subset of autoreactive T cells within this circulating pool bearing the skin-homing receptor CLA enters the skin.^{219 222} The observation of oligoclonal T cell clones in psoriasis lesions prompted a quest to identify disease-initiating antigens, but till date research failed to provide the culprit antigen.

Why are persons with psoriasis susceptible to T cell autoreactivity?

In the last decade, a collection of genes involved in antigen processing has been identified as risk genes for psoriasis.²²³ These include the gene ZAP70,²²⁴ which encodes a tyrosine kinase that is critical for setting the response threshold for the T cell receptor, and is only a risk gene in carriers of HLA-Cw6, also referred to as PSORS1.²²⁴ The expanding collection of genes involved in antigen detection and processing, is consistent with the current notion that psoriasis could be driven by immune responses against a specific set of autoantigens or pathogen derived antigens.⁶ Guttate psoriasis seemed to provide a proof of principle, based on its clinical correlation with β -haemolytic streptococcal infection such as tonsillitis or pharyngitis.^{218 225} The detection of streptococcal antigens in serum of these patients, the simultaneous presence of identical T cell clones in skin lesions and tonsils in patients with streptococcal-driven psoriasis,²²⁶ the presence of autoantibodies against skin, keratinocyte proteins that were also recognized by streptococcal-specific rabbit antibodies,

are altogether highly suggestive of molecular mimicry in the pathogenesis of at least guttate psoriasis.²²⁷

However, guttate psoriasis is relatively rare compared to psoriasis vulgaris and does not generally evolve into disseminated plaque type psoriasis.^{215 228} Despite its relevance in guttate psoriasis, HLA-Cw6 seems not sufficient to automatically drive psoriasis vulgaris.²²⁹ Despite numerous attempts to identify antigens related to psoriasis, no clear disease initiating antigen or autoantigen has been detected.²¹⁵ Overall, the studies on T cells did not rule out an important role for keratinocytes in the pathogenesis of psoriasis. Hence, from a historic perspective we adapted a pathogenesis model presented in 1991 whereby both keratinocytes and T cells are clearly involved.²³⁰ This model stressed the interplay between epidermis, vascular endothelium, and T cells, based on genetic aberrancies and site specific triggers, such as Koebnerization and streptococcal infection. During the following years, investigations into the individual factors comprising psoriasis have resulted in an increased detailed understanding of the pathophysiology of the disease (Figure 4).

Psoriatic plaques display several T helper cell subsets

In the following years, investigations into the T cell infiltrate in psoriatic skin showed that it comprised predominantly CD4+ and CD8+ T cells. Ongoing research further classified the CD4+ T cells involved in psoriasis and pointed to a Th1 signature.²³¹ This was mainly based on Th1 pathway related cytokines found in psoriatic skin such as IL-1 β , IL-12p40, TNF- α , and IFN- γ and IFN- γ -induced proteins.²³¹ The Th1 signature of psoriasis is consistent with the relative under-representation of Th2 diseases, such as atopic dermatitis, in patients with psoriasis.²³² Investigations has spurred further examinations into the contributions of immune mediators such as IL-17A, IL-23, and IL-22 as well as a growing number of CD4+ Th cell subsets (Table 3). During the last decade, a novel Th cell subset has been defined that produces large amounts of IL-17, therefore called Th17 cells.²³³ In parallel, it has been shown that psoriatic skin shows enhanced levels of both IL-23,²³⁴ and IL-17.²³⁵⁻²³⁷ This has led to the identification of Th17 cells in psoriasis and positioned Th17 cells centrally, next to the Th1 cells, in the pathogenesis of psoriasis.²³⁸ Recent studies have shown that some Th cells express IL-22 independently of IL-17, hence denoted as Th22 cells.²³⁹ Th22 cells, like Th17 cells, show an epidermal homing characteristic reflected by a chemotactic response of keratinocytes in response to Th22 derived cytokines. The IL-22R is expressed almost exclusively on epithelial cells such as keratinocytes. In the skin, IL-22 induces AMP, promotes keratinocyte proliferation, and inhibits differentiation, which suggests a role in remodelling, wound healing and in innate defence mechanisms.²⁴⁰⁻²⁴² Overall, Th22 cells represent a Th cell subset, highly involved in the regulation of epidermal responses, and in inflammatory skin diseases such as atopic dermatitis and psoriasis.^{239-240 243} How these Th cells subsets interact with each other and the skin, and form complex signal circuits to drive psoriasis is




Figure 4. Proposed model of the pathophysiology of psoriasis. Trigger 1 and 2 represent potential sites of initiation. Phenotypic changes are placed within the box. Basic model originally proposed in 1991 by Barker.⁽²³⁰⁾ Overlapping boxes comprise crucial subsequent detailed knowledge acquired during the last two decades. A current more comprehensive view on this model is presented in the discussion of this thesis.

starting to become elucidated. The identification of Th17 and Th22 cells provides cellular targets for therapeutic intervention and may shed light on thus far unknown pathways in psoriasis.

Advancement in psoriasis research by the introduction of genetics

First, family-based approaches such as genetic association studies resulted in the identification of at least nine chromosomal loci with statistically significant linkage to psoriasis risk (nomenclature psoriasis susceptibility (PSORS)1-9).²⁴⁴ Although HLA-Cw6 (PSORS1) seems to comprise the major genetic risk factor, it accounts for less than half of the familial aggregation.²²⁹ Therefore it is likely that many other loci contribute to the genetic susceptibility for psoriasis, genes with functions in the immune system and inflammation. Developments in genetic investigations, especially the advent of genome-wide association studies (GWAS),²⁴⁵ formed the basis of the next big step in pathomechanistical insight into psoriasis.^{6 223 246} Interestingly, GWAS findings confirmed the early psoriasis association stud-

ies with genes involved in antigen presentation such as HLA-Cw6.^{223 247} Psoriasis also shows strong association with the IL12B gene which encodes the p40 subunit of both IL-12 and IL-23, the IL23A gene which encodes the p19 subunit for IL-23, and the gene encoding IL23 receptor (IL23R),²⁴⁸⁻²⁴⁹ providing a genetic basis for the observed increase of IL-23 expression in psoriasis.²³⁴ IL-23 directs naïve CD4+ T cells towards the Th17 phenotype.^{233 238}

Genetic evidence for dysregulation of barrier function in psoriasis

In parallel to the finding of genes involved in the activation and regulation of Th cells, there is increasing insight into genetic aberrancies in psoriasis linked to epidermal skin barrier function. On chromosome 1q21, the psoriasis susceptibility locus PSORS4,²⁵⁰ contains the epidermal differentiation complex (EDC). This EDC is a cluster of genes that are crucial for the development, maturation and crosslinking process of the stratum corneum in ter-

Table 3. Relevant cytokines in psoriasis

Pathophysiologic target	Cytokines	Main cellular source
CD11C+ DC	IFN- α	plasmacytoid (p) dendritic cell (DC), IFN- α primed DC
	IL-36- α (IL-1F6)	Keratinocyte (KC)
	IL-36- β (IL-1F8)	KC
	IL-36- γ (IL-1F9)	KC
	IL-6	KC, Th17, fibroblast
Epidermal barrier	IL-1 β	KC
	IL-4	KC, Th2
	IL-15	KC
	IL-17 A/F	T cells, $\gamma\delta$ T cells, NKT cells, MC, ILC17
	IL-22	Th17/22 cells, $\gamma\delta$ T cells, NKT cells, ILC22
	IL-23	CD11C+ DC
	IL-27	Macrophages, DC
	TNF- α	TIP-DC, Th1, KC, MC, fibroblast, macrophage
Th1	Type I IFN	pDC
	IL-12	CD11C+ DC
	IFN- γ	Th1, ILC1
Th2	TNF- α	TIP-DC, Th1, KC, MC, fibroblast, macrophage
	IL-4	KC, Th2
	IL-13	KC, T cells
Th17	IL-15	KC
	IL-17 A/F	Th17 cells, $\gamma\delta$ T cells, NKT cells, MC, ILC17
	IL-23	CD11C+ DC
Neutrophils	IL-8	KC
	IL-17	Th17 cells, $\gamma\delta$ T cells, NKT cells, MC

minal keratinocyte differentiation.²⁵¹ These genes become activated and include involucrin, loricrin, filaggrin, LCE genes, S100 calcium-binding proteins such as S100A7 (psoriasin) and SPRR.²⁵¹ The majority of these genes are upregulated in psoriatic plaques, pointing towards aberrancies in the regulation of the EDC in psoriasis.⁶ Recent results show that psoriasis is linked to a deletional polymorphism inducing loss of LCE3B and LCE3C.^{229 246 252} There is evidence supporting epistatic interaction of this deletion with PSORS1.²²⁹ Overall, these findings are highly suggestive of a compromised skin barrier function in psoriasis, supporting the concept of early epithelial abnormalities as the cornerstone in the pathogenesis of psoriasis.⁶

Genetic and molecular signature of PRR aberrancies in psoriasis

Several of the recently identified single-nucleotide polymorphisms (SNP) linked to the risk of having psoriasis are found in or near genes associated with the innate immune response such as IFIH1 (MDA5), NFKBIA, STAT3, SOCS1, TYK2, and NOS2.^{6 223 253} Several cytosolic innate RNA receptors, including TLR3, PKR, RIG-I, and MDA5, are induced in healthy keratinocytes by IFN- α . This is suggestive of a similar induction in psoriatic skin based on the type I IFN signature of psoriasis.⁷³ Indeed, psoriatic plaques showed increased expression of RIG-1, MDA5 and PKR.⁷³ Expression levels in psoriatic plaques of RIG-I and MDA5 were significantly reduced following effective NB-UVB treatment, without affecting TLR3 expression.²⁵⁴

Earlier results showed that in psoriatic skin, nuclear TLR1 is expressed in the upper layers of both uninvolved and psoriatic epidermis, but not in skin of healthy individuals. TLR2 showed an enhanced expression on keratinocytes in the upper epidermis of psoriatic skin.²⁵⁵ In the same study, TLR5 was downregulated in basal keratinocytes compared with corresponding uninvolved psoriatic epidermis.²⁵⁵ In contrast, another report showed more diffuse epidermal expression of TLR5 in psoriasis.⁶⁸ Contrary results have been reported on TLR9 expression in psoriatic skin, as it has even been stated that psoriatic skin does not express TLR9.²⁵⁶⁻²⁵⁷ Recent evidence shows that psoriasis derived keratinocytes express increased TLR9, which co-localizes with elevated LL-37 expression.⁹⁸ Via TLR9, keratinocytes are known to respond to CpG or genomic DNA by production of type I IFN,⁹⁸ which is of importance in the pathophysiology of psoriasis. One study claims that in psoriatic skin only CLEC7A (dectin-1), TLR4, and mannose receptor C type 1 (MRC1) are differentially expressed.²⁵⁸

Overall, the reported data lack clear consistency. However, most of the reported molecular data is derived from a limited number of psoriasis patients, which could explain the observed discrepancies. Nevertheless, the enhanced expression of AMP in psoriasis,²⁵⁹ is highly suggestive of deregulation of TLR signalling. Taken together, there are cumulating molecular evidence for aberrant PRR expression and function in psoriasis.

Antimicrobial peptides act at multiple levels in psoriasis

Antimicrobial peptides are important effectors of the innate immune response upon epithelial injury and microbial insults.⁷⁴⁻⁹¹ The high levels of AMP observed in psoriatic skin are held responsible for the low occurrence of skin infections clinically observed in patients with psoriasis. Enhanced AMP expression might be responsible for the alteration in the identity and frequency of the commensal microbiota in psoriatic plaques.²⁶⁰ Biological functions of AMP such as chemotaxis, angiogenesis, keratinocyte migration and proliferation, and TLR regulation are all of importance in psoriasis.⁷⁴⁻⁹¹⁻²⁶¹ DEFB4 is a member of the hBD genes on chromosome 8²⁶² and encodes hBD-2.²⁵⁹ Patients with psoriasis show increased DEFB4 gene copy numbers in compared with healthy controls.²⁶³⁻²⁶⁴ This corresponds nicely with the observation that in psoriasis patients, individual disease severity correlates with serum levels of plaque-derived hBD-2.²⁶⁵

Physical injury to the skin results in the extracellular release of self-DNA and self-RNA from dying keratinocytes. Yet, normally this does not lead to innate immune activation due to their rapid degradation by nucleases DNases and RNases, before reaching the endosomal compartments of DC. In parallel to the release of nucleic debris, psoriasis plaques produce LL-37, which is able to form complexes with both self-RNA via TLR7, TLR8,⁹⁷ self-DNA, and TLR9.⁹⁶ As healthy normal skin lacks the abundant expression of LL-37 observed in psoriatic skin, the formation of such complexes presumably remains limited. Uninvolved psoriatic skin shows an increased tendency of producing AMP such as LL-37 and shows elevated numbers of pDC.²⁶⁶ Under these circumstances, it is likely that these complexes are recognized by distinct DC subsets such as pDC, which accumulate in injured skin of patients with psoriasis. Via recognition by TLR expressed by DC, these complexes induce strong type I IFN production.⁹⁶⁻⁹⁷ As a result, the aberrant production of IFN leads to the maturation of myeloid DC that initiate local Th17-mediated inflammation and the development of skin lesions.⁹⁶ Hence, within the appropriate environment, these complexes function as a damage signal, critically associated with the onset of psoriasis.

Serendipity in scientific and clinical advances in psoriasis

Large investments have been made in GWAS with the expectation that this would lead to the identification of novel treatment targets.²⁴⁵ Although genetic studies have clearly provided insight into the pathomechanism of psoriasis, key pathomechanistical findings and therapeutical successes in psoriasis were not without some serendipity, of which we provide a few examples. As mentioned before, the unexpected success of cyclosporin treatment turned out to be the key that set the stage for T cell based research.²¹⁶ The success of TNF- α blocking biologics became apparent only when the use of mAb treatment targeting TNF- α (infliximab) in patients with Crohn's disease, turned out to be highly effective against concomitant psoriasis.²⁶⁷⁻²⁶⁸ Subsequently, the role of Th1 in psoriasis, exemplified by cyto-

kines such as TNF- α , IFN- γ , and IL-12p40 dominated the psoriasis research community for years. Yet, this assumption that psoriasis is driven by IL-12 led to serendipity as it prompted the development of an anti-p40 mAb (ustekinumab), believed to target only IL-12.^{200 269} In parallel to the clinical testing phases of the anti-p40 mAb, the role of the IL-17 producing Th17 cell in psoriasis became clear.^{233 235 238} Unexpectedly, this p40 subunit turned out to be shared with the cytokine IL-23 which was not yet known at the time, and which is now considered essential for Th17 function and the pathogenesis of psoriasis.^{234 238}

In the eighties, the therapeutic use of IFN- α in two patients with metastatic renal carcinoma, resulted in an exacerbation of psoriasis.²⁷⁰ These clinical findings elicited research in type I IFN signalling in psoriasis, which later was demonstrated to be deregulated in psoriasis.^{73 254 271-272} Further insight into the onset of psoriasis was provided by clinical cases showing exacerbation of psoriasis due to the topical use of imiquimod, a ligand of TLR7.^{79 273-275} This member of the imidazoquinoline antiviral immune response modifier family is in clinical use as topical treatment for genital warts, actinic keratosis and superficial basal cell carcinomas.⁷⁹ The imiquimod-induced exacerbation occurred both at the treated area and at previously unaffected distant skin sites.^{79 273-275} Important hallmarks of this imiquimod-induced psoriasis are the infiltration of pDC and type I IFN activity.⁷⁹ These pDC are the foremost producers of IFN- α , and are increased in number and activated in peri-lesional and early human psoriatic lesions.^{78 266} The functional relevance of IFN- α and pDC has been demonstrated in a relevant animal psoriasiform model,^{276 271} Combined, these clinical findings provided important insight into the potential role of pDC and their secretion of IFN- α in the onset of psoriasis. It prompted us to develop a new mouse model in which the imiquimod induces a psoriasiform skin inflammation. This model displays most of the known clinical and inflammatory features in the pathogenesis of psoriasis, including pivotal activation of the IL-23/IL-17 axis.²⁷⁷ A phase 2 trial has started in which the effects of a TLR7/TLR9 antagonist are being assessed in psoriasis (Table 2).

Thus, careful studies of therapeutics that inadvertently trigger psoriasis will lead to a better understanding of disease mechanisms. In addition, further insights provided by genetic studies help to understand the biological pathways triggered by these therapeutics.²⁴⁵ Currently, the pharmaceutical industry investigates a wide range of biological processes that may play a central role in the pathogenesis of psoriasis. This is reflected by a surge in drug development targeting these processes (Table 2).

Exogenous factors can trigger psoriasis

Despite great advancement in our understanding of processes active in chronic psoriatic plaques, the exact etiology of the onset of psoriasis is still unknown. A large number of triggering factors has been identified that are clinically linked to the initiation of new psoriasis.

riatic lesions, the exacerbation of psoriasis, or both. Considering the fact that uninvolved skin and psoriatic lesions are different in cellular composition, regulation and function, it is important to differentiate between triggers that initiate psoriasis, exacerbate it or promote both. As stated earlier, one of the most investigated triggering factors of psoriasis is infection, especially by β -haemolytic streptococci infection.^{225 278}

In a prospective cohort study involving nearly 80,000 female US nurses, active smoking turned out to be a strong independent risk factor for the development of psoriasis. Even passive smoking contributed to a more modest extent.²⁷⁹ The risk of developing psoriasis correlated positively with increasing smoking intensity and duration of smoking.²⁷⁹ Interestingly, smoking worsens the severity of pre-existing psoriasis and reduces responsiveness to treatment.²⁸⁰⁻²⁸¹ Overall, smoking can be considered a trigger factor that enhances the susceptibility to psoriasis.

Many drugs induce, or exacerbate psoriasis, even in patients without a family history of the disease.²⁸² Complete remission or a return to initial status after drug withdrawal is the sole evidence of drug-associated psoriasis.^{278 283} Interestingly, this clinical clearance or inhibition of psoriasis after cessation of treatment is indicative of a highly fragile balance between healthy and inflamed skin. Drugs with firmly established causal associations with psoriasis include beta-blockers, lithium, inhibitors of TNF- α , tetracyclines, and synthetic antimalarials.^{278 283}

Cytokine based therapies for other medical indications such as recombinant IL-2, IFN- α , GM-CSF, G-CSF can exacerbate psoriasis.^{278 283} The exacerbation of psoriasis by the TLR7 agonist imiquimod is likely the result of an IFN- α burst.⁷⁹ Despite the great diversity of triggering factors, not all psoriasis patients are affected by each individual factor. This specificity is indicative of a great heterogeneity in patients with psoriasis.

The strong relationship between the onset and exacerbation of psoriasis and psychological stress will be addressed in section 1.3.

Taken together, these triggering factors can be classified into 3 groups: (1) Factors promoting the susceptibility of uninvolved skin to become more prone to inflammation; (2) Factors capable of directly inducing the transformation of uninvolved skin into psoriatic plaques; and (3) factors that exacerbate existing plaques. With the first two groups there is a possibility of complete resolution of psoriasis when the triggering factor is removed. The great diversity of triggering factors is illustrative of a complex pathophysiology containing multiple essential elements for perpetuating the vicious cycle of inflammation.

Local initiation of psoriasis by skin injury

Local injury of the skin is a well known trigger of cutaneous inflammatory diseases such as vitiligo, lichen planus and psoriasis. This triggering is called the Koebner phenomenon. It is defined as a skin response characterized by the appearance in uninvolved skin of disease-specific skin lesions at sites of trauma, in scars, or at points of friction (clothing). This Koebner phenomenon, also called isomorphic effect, is considered a crucial aspect of the pathogenesis of psoriasis.²¹¹⁻²¹² Some take the extreme view that the initial presentation of psoriasis vulgaris is always the result of local injury, especially at the extensor surfaces.²¹¹ Results show that 25% of patients will develop psoriasis due to Koebnerization, but often the trauma may be unrecognized or forgotten.²¹¹ This could be explained by the variability in lag time between injury and the appearance of psoriatic lesions. Koebnerization is more likely to occur during unstable or flaring periods of psoriasis, and has been reported to occur more frequently in patients who develop psoriasis in early life,²⁸⁴ and patients receiving more types of treatment.²¹¹ Koebnerization is less likely to occur if the patient experiences improvement or total clearance of existing plaques.²¹¹ Interestingly, Koebnerization is not associated with the deletion polymorphism in LCE3B and LCE3C.²⁸⁵ Skin injury results in the release of AMP such as LL-37.⁹⁶ Recent insights into the role of LL-37 in the transformation of nucleic acids into pro-inflammatory complexes, provide a molecular basis for Koebnerization.⁹⁶⁻⁹⁷

Exploring the effects of injury to investigate the Koebner effect

By exerting standardized skin injury, investigations into early events in the development of psoriatic plaques have become feasible. Removal of the stratum corneum by repeated cellophane tape stripping (~40 times) results in disturbance of the epidermal barrier, trans-epidermal water loss and altered calcium ion gradients in keratinocytes.²⁸⁶⁻²⁸⁸ Such mild injury renders the skin permeable to infectious agents and their secreted products such as bacteria-derived PAMP like super-antigens.²²² One of the immediate protective responses after skin barrier perturbation is the release of lamellar bodies containing pre-formed lipid and hydrolytic enzymes, as well as cytokines such as TNF- α and IL-1 β . Cathelicidins and β -defensins are co-packaged along with lipids within these lamellar bodies before their release.^{83 289} Barrier lipid and AMP production is co-ordinately regulated following barrier disruption.²⁹⁰

We recently showed that tape-stripping of uninvolved psoriatic skin results in a down-regulation of GATA3 expression in keratinocytes already after 5 h.²⁹¹ The transcription factor GATA3 is known as the master switch in Th2 cell differentiation.²⁹² The epidermal GATA3 is downregulated in psoriatic plaques,^{291 293} and during wound healing.²⁹¹ Via transactivation of the lipid acyltransferase gene AGPAT5, which is important in lipid synthesis, GATA3 contributes to the formation of an effective epidermal permeability barrier.¹³ Interestingly, epidermal GATA3 knock-out mice showed increased epidermal expression of defensins.¹³

Other early events following tape-stripping include influx of neutrophils, and the increased production of AMP and NGF by keratinocytes.²⁹⁴

Uninvolved psoriatic skin differs from healthy skin

The transition from uninvolved into lesional skin is accompanied by changes in the cellular composition, cellular growth, and expression of multiple genes. Far less is known about the difference between uninvolved skin from psoriatic patients and skin from healthy individuals. In order to unravel the pathomechanistic onset of psoriasis, it is necessary to identify possible baseline differences.

Recent findings show that uninvolved skin already displays aberrancies in genes involved in lipid metabolism, antimicrobial defences, epidermal differentiation, and the cutaneous vasculature.⁵⁻⁶ These results identify a pre-psoriatic gene expression signature, suggesting that decreased lipid biosynthesis and increased innate immunity occur in uninvolved psoriatic skin. Moreover, perilesional skin, uninvolved skin surrounding active psoriatic lesions, displays increased K16, the AMP skin-derived antileukoproteinase (SKALP) and EGFR expression.²⁹⁵⁻²⁹⁶ Uninvolved skin is fully able to activate blood-derived autologous T cells.⁴ Grafting of uninvolved skin on SCID mice, followed by injection of these grafts with activated peripheral blood cells from the same psoriatic patient, results in the formation a psoriatic plaque.²¹⁵ However, this does not occur in skin grafts from healthy individuals.²¹⁵ TLR2 shows enhanced expression in uninvolved skin. The transcription factor C/EBP β , involved in regulation of pro-inflammatory cytokines and K6,²⁹⁷ is normally only expressed in the nucleus in the granular layer.²⁹⁸ However, both lesional and perilesional skin show an abundant expression of C/EBP β .²⁹⁷ Studies on the DC markers such as CD1a and CD11c show that there are clear differences between lesional, perilesional, distant uninvolved skin and healthy skin.²⁹⁷⁻²⁹⁹ CD11c, CD80, CD83, and CD86 show the highest expression in psoriatic and perilesional skin in comparison to distant uninvolved skin, whereas the lowest expression was observed in healthy skin.²⁹⁹ Interestingly, perilesional skin shows elevated expression of CD1a compared to lesional skin,²⁹⁷ whereas BDCA2, a pDC marker, expression was seen in lesional skin and occasionally in perilesional skin.²⁹⁷ CD3+ cells (a pan T cell marker) are highly frequent within psoriatic lesions, and only minimally present in perilesional dermis.²⁹⁷ Overall, these results show that uninvolved skin of psoriasis patients is structurally different from healthy skin, implying an increased risk for development of psoriasis. It is currently unclear whether these aberrancies in clinically uninvolved psoriatic skin is due to circulating inflammatory mediators produced by psoriatic plaques or an underlying genetic predisposition. If the aberrancies in uninvolved skin are driven by plaques, effectively treating plaques will affect also the uninvolved skin.

Therapeutically targeting pre-psoriatic uninvolved skin

In contrast to the general assumption that it is better to prevent disease occurrence than to treat established disease, there has been limited attention for the development or prevention of new lesions in previously uninvolved skin. Few treatment modalities have been used in attempts to delay or inhibit Koebnerization. However, assessment of changes in the pre-psoriatic aberrancies in uninvolved skin during successful systemic therapy of psoriatic plaques could result in the discovery of early therapeutical targets.

Lately, there is growing attention by major psoriasis research groups for the aberrancies of uninvolved skin. Treatment with ustekinumab significantly reduces psoriasis-related gene expression in plaques, including hBD-2 and S100A7, down to levels of uninvolved skin, but not to the levels of healthy skin. These results are indicative of a highly stable nature of this 'pre-psoriatic' gene expression signature in uninvolved skin. With regard to Koebnerization, limited attempts have been made to inhibit this phenomenon. Injection of adrenaline delays Koebnerization possibly due to its vasoconstrictor action. Topical application of white soft paraffin also has an inhibitory action, probably related to the antimetabolic effect that bland ointments have.²¹¹ Topical or intradermal methotrexate, lidocaine, antimycin A and colchicine did not prevent or retard Koebnerization.²¹¹ No studies involving topical steroids, cyclosporin, vitamin D, or state of the art biologics have been carried out to illustrate a similar effect. Furthermore, no attempts have been made to investigate whether an effective psoriasis treatment could inhibit the pro-inflammatory epidermal reaction to skin barrier disruption, such as tape-stripping. So the question remains whether there are therapeutic ways to direct the uninvolved psoriatic skin towards a more healthy pattern similar to skin of healthy individuals.

1.3 NEURONAL MECHANISMS FUELING PSORIASIS

Prevention and clearance of psoriasis by inadvertent denervation

The symmetrical distribution of plaques in the majority of patients with psoriasis might be explained anatomically by viewing peripheral sensory nerves as constituents of an underlying complex symmetrical immunomodulatory network.^{1 111}

Unique clinical cases show that deprivation of neuronal innervation of the skin, for example due to surgical denervation, results in resolution of existing plaques.^{3 300} One report demonstrates a patient with chronic psoriasis vulgaris who experienced complete unilateral remission of his disease within months following brachial plexus palsy due to a shoulder dislocation. The psoriasis reappeared as the nerves and sensations recovered.³⁰¹ From these cases, it has become clear that this immunomodulatory network is functionally active in the onset and maintenance of psoriasis.^{1 302}

Taking these observations into account, one could speculate that cutaneous nerves play a role in the onset and perpetuation of the psoriasis phenotype. Multiple lines of evidence support a crucial role for the cutaneous peripheral nerves and associated neuropeptides in the onset and maintenance of psoriasis (Table 4). Still, perhaps in part due to limited available methods for assessment of these peripheral nerves, this aspect of psoriasis remained underexposed, despite efforts by Eugene Farber in the early eighties.² Facilitated by the development of sensitive immunohistochemical techniques, novel molecular techniques for exploring the role of cutaneous nerves, and improved drug delivery, research in this field of psoriasis has begun to emerge.

Below, an in depth review of clinical and molecular evidence is provided, regarding the crucial role of nerves and neuronal effectors in the pathogenesis of psoriasis.

Evidence for neuronal involvement in psoriasis

Psychological stress precipitates psoriasis

Psychological stress is a prevalent aspect of life, usually triggered by stressors such as marital stress, sudden unemployment and sickness. Stress is perceived by the brain and subsequently activates immune-, endocrine-, and nervous systems (stress response).³⁰³⁻³⁰⁴ Many patients (~40–90%) with psoriasis believe that there is a causal relationship between stressors and their skin disease, and this relationship has received increasing attention over the years. In their study of over 2,000 psoriatic patients, Farber et al. found that 37% had an increase in the severity of psoriasis during periods of chronic stress or following acute stress.¹ Earlier studies have found that over 60% of the patients with psoriasis retrospectively report to have experienced stressful life events in the month before the exacerbation of their skin disease. Reports show that there is a correlation between peaks in number of daily stressors and an increase in PASI.³⁰⁵⁻³⁰⁷ The relationship between the onset and exacerbation of psoriasis and psychological stress is strongly indicative of involvement of neuropeptides.¹ Results show that during the first hours following acute psychological stress, SP, CGRP, VIP and NPY are released by nerve endings in the skin.³⁰⁸⁻³⁰⁹ Psoriasis patients who experience high levels of stress show increased expression of VIP and CGRP in their lesional skin.³¹⁰ Indirect evidence for the importance of stress in cutaneous homeostasis derives from a report showing that epidermal barrier function is negatively affected by psychological stress.³¹¹ Because stress is ultimately perceived as a subjective experience, it remains difficult to define its exact mode of action in psoriasis. For a concept so ambiguous and difficult to define, stress nevertheless plays an obvious role in psoriasis.

Table 4. Signs of peripheral neuronal involvement and aberrancies in psoriasis

Clinical signs	
- Neuropeptides and NGF involved in pruritis in psoriasis	322-323
- Therapeutically targeting neuropeptides improves psoriasis	330
- Topical NGF-R blocker significantly reduces psoriatic plaques	341
- Psoriatic plaques show clear thermo-sensory abnormalities	556
- Surgical denervation of peripheral nerves results in local resolution of psoriasis	1,3,300
Molecular evidence from psoriatic skin	
- Increased expression of neuropeptides and NGF in psoriatic plaques	312, 340
- Increased number and density of sensory nerve fibers in psoriatic plaques	312
- Keratinocytes from uninvolved psoriatic skin produce 10-fold higher NGF levels	337
- NGF synthesized by psoriatic keratinocytes is functionally active	337
Indirect molecular clinical evidence	
- Cutaneous release of neuropeptides following psychological stress	308, 310
- Keratinocytes have functional active neuropeptide-receptors	347
- Both SP and CGRP induce hyperproliferation of keratinocytes	152, 154
- Skin produces TNF- α IL-1 β and IL-8 in response to SP and CGRP	557
- SP, CGRP and NGF have chemoattractive properties for neutrophils	557
- SP, CGRP, and NGF are capable of triggering degranulation of mast cells	157
- Denervation leads to clinical improvement of murine psoriasiform dermatitis	331

The role of neuropeptides in psoriasis

As mentioned earlier, the positive effect of adrenalin in prevention of Koebnerization probably depends on modulation of vasodilatation. As CGRP, SP, and VIP are known for their vasodilatory properties, one could argue that disturbance of their expression results in delay or prevention of Koebnerization. Indeed, experimentally induced Koebnerization in psoriasis patients is paralleled by increased SP and VIP+ nerves.³¹² Psoriatic plaques show a marked increase of C fiber density in epidermal regions, which is accompanied by upregulation of SP, CGRP and VIP expression.³¹³⁻³¹⁵ During the early development of a psoriatic lesion, mast cell numbers increase and their degranulation is one of the first morphological changes.³¹⁶⁻³¹⁹ In psoriatic skin, mast cells are primarily found in the upper dermis, especially at contact sites with SP+ terminal nerves.^{312 320} Psoriasis patients often report mild to severe pruritis at sites of psoriatic skin.³²¹ Neuropeptides are likely candidates for mediating pruritis.³²² A negative correlation between plasma concentrations of neuropeptides such as SP and the severity of pruritis in psoriasis has been reported.³²³

Targeting neuropeptides improves established psoriasis

Capsaicin binds to transient receptor potential vanilloid (TRPV)1 which resides in the membrane of pain- and heat-sensing peripheral nerves.³²⁴ Prolonged activation of TRPV1

results in depletion of presynaptic SP.³²⁴⁻³²⁵ The topical application of capsaicin on psoriatic plaques effectively reduced both pruritis and psoriasis severity.³²⁶ Spantide II is a pharmacological compound with high specificity for the NK-1R.³²⁷ Animal models showed that spantide II effectively reverses pro-inflammatory and pruritic effects of SP.³²⁸⁻³²⁹ A recent report shows that topical use of spantide II using nanoparticles in established imiquimod-induced psoriasiform murine inflammation (5 days of imiquimod treatment), results in a significant reduction of PASI score and the expression of both IL-23 and IL-17A.³³⁰ In the KC-Tie2 chronic psoriasiform murine model, surgical denervation of peripheral nerves innervating psoriasiform skin resulted in a 40% decrease of CD11C+ DC numbers together with a 30% improvement in acanthosis after 7 days and a 30% decrease in CD4+ T-cell numbers by 10 days.³³¹ Restoration of SP signalling in denervated KC-Tie2 skin prevented decreases in CD11c+ and CD4+ cells, without improving acanthosis. Restoration of CGRP signalling reversed the improvement in acanthosis and prevented denervated-mediated decreases in CD4+ cells. Inhibition of SP in KC-Tie2 mice resulted in similar decreases of CD11C+ and CD4+ cell numbers, and inhibition of CGRP resulted in significant reductions in CD4+ cell numbers and acanthosis. The capabilities of these neuropeptides to regulate the influx of immune cells, is explained by the expression of NK-1R by DC, macrophages and T cells.³³²⁻³³⁴ Injecting dorsal skin of KC-Tie2 mice with botulinum neurotoxin A decreases numbers of infiltrating cutaneous leucocytes and improves acanthosis, similar to the effects of surgical denervation.³³⁵

Epidermal role for the neurotrophin NGF in psoriasis

Peripheral sensory nerves are highly dependant on neurotrophic growth factors produced by the skin during embryonic development and in the adult.³³⁶ The neurotrophin NGF, a small polypeptide of ~13 kDa, augments tissue innervation and plays a critical role in regulating the expression of neuropeptides and chemokines.³³⁷⁻³³⁸ NGF has 2 known receptors: the low-affinity p75 neurotrophin receptor (p75-NTR) which belongs to the superfamily of TNF- α receptor, and the thyrosine protein kinase receptor p140-TrkA. NGF mRNA is expressed in healthy human keratinocytes and increasing amounts of NGF protein is secreted by keratinocytes during growth.³³⁹ Both psoriatic and uninvolved skin of patients show increased NGF levels compared to healthy controls.²⁹⁴ p75-NTR is expressed primarily by terminal keratinocytes, and in normal skin, there is a marked upregulation of this receptor located at terminal nerve endings.^{16 339-340} In addition, p75-NTR is crucially involved in apoptosis signalling.¹⁶ Psoriatic keratinocytes show diminished expression of p75-NTR.²⁹⁴ Therapeutical targeting the function of NGF with receptor blockers such as K252A and antibodies resulted in significant improvement of psoriasis.³⁴¹ The topical use of a NGFR blocker is currently under clinical investigation, phase IIB, and preliminary results show a 30% improvement in PASI of selected treated plaques (Table 4). Raychaudhuri et al. investigated the *in vivo* effect of NGF secreted by keratinocytes in psoriatic plaques and

tape-stripped uninvolved skin, using a xenotransplant mice model. The transplanted psoriatic plaques demonstrated marked proliferation of p75-NTR-positive nerve fibers compared with only a few nerves in the transplanted normal healthy human skin. Interestingly, in tape-stripped Koebner+ uninvolved skin, upregulation of NGF and keratinocyte proliferation are early events that precede cutaneous invasion of T cells, and the development of psoriasiform inflammation.²⁹⁴ NGF and its receptors are widely expressed by immune cells, such as activated monocytes, T cells, mast cells, and DC.³⁴²⁻³⁴⁵ The expression of NGF and receptors in monocytes and DC is increased by stimulation with LPS,^{342 345} which is depending on TLR4 signalling.³⁴⁵ Interestingly, NGF promotes the secretion of IL-12p40 and TNF- α by LPS-stimulated murine bone marrow-derived DC,³⁴⁵ suggesting that NGF is involved in the Th1 inflammatory pathway.

Taken together, these data identify a clear role for cutaneous nerves, their derived neuropeptides and neurotrophins in directing skin into development of a chronic established psoriatic plaque. Previous results predict a critical role for neuropeptides in Koebnerization and the onset of psoriatic plaques. However, precise molecular data regarding the prevention of disease by denervation remains unclear. Investigation into the molecular effects of denervation in psoriasis patients combined with assessment of the effects of surgical denervation on the onset of imiquimod-induced psoriasiform murine inflammation could provide important answers.

AIMS AND OUTLINE OF THE THESIS

This thesis addresses the function of peripheral nerve signalling in the skin, and crucial epidermal factors in the onset of psoriasis, notably epidermal barrier formation and innate defence. Although these themes have to some extent been studied before in psoriasis, the data on this subject is either fragmentary or outdated in view of rapid progress in the field.

Aim 1: To determine to what extent peripheral nerves and their neuromediators command the onset and maintenance of psoriasis.

Inadvertent cutaneous denervation results in resolution of psoriatic plaques. The underlying molecular mechanisms of this phenomenon are still unknown. We hypothesized that peripheral nerves and associated mediators have a crucial role in the onset of disease following epidermal barrier disruption. To assess the first aim, we performed three studies. In the first study, we assessed the clinical and molecular epidermal effects of cutaneous denervation in a patient with psoriasis who showed local lesional clearance by denervation.

Promising target molecules were selected and further investigated in mice, in human healthy skin explants, as well as *in vivo* in psoriasis patients during selected types of treatment (Treatment is further addressed by aim 2). Inducing neuropathy in patients to investigate disease-modifying effects of denervation is not acceptable for ethical reasons. Therefore, in the second study we used the imiquimod (IMQ) -induced psoriasiform murine model to investigate the effects of cutaneous denervation on cutaneous innate defences and the clinical and molecular response to IMQ. The third study was based on the marginal knowledge of the effects of the neuromediators SP, CGRP, VIP and ACh on the epidermal innate defence. We hypothesized that these neuropeptides have regulatory capabilities regarding psoriasis-linked cutaneous TLR and AMP expression. We therefore tested the effects of neuropeptides in *ex vivo* healthy human skin explants (Figure 5A).

Aim 2: To assess the clinical efficacy of selected experimental and both novel and established registered treatments of psoriasis, and to delineate their molecular mode of action.

The beneficial effects of recombinant IL-4 on psoriatic inflammation is mainly ascribed to the regulatory role of IL-4 on the leukocyte infiltrate. The influence of IL-4 on epidermal homeostasis has been poorly investigated. We investigated in *ex vivo* skin derived from psoriatic and healthy skin whether IL-4 directly intervenes in epidermal psoriatic aberrancies, such as the suppression of GATA3 and the increase in NGF. The anti-p40 mAb ustekinumab targets both IL-12 and IL-23, which results in inhibition of Th1 and Th17 cells. This latest

addition of registered anti-psoriatic treatment is capable of inducing long lasting clearance and prevention of psoriasis with a limited number of injections. We investigated whether ustekinumab affects epidermal psoriatic aberrancies in uninvolved skin such as the expression of NGF, and modifies epidermal responses of uninvolved skin to barrier disruption. Similar to psoriasis, the pathophysiology of both Behçet's disease and hidradenitis suppurativa shows involvement of Th1 and Th17 cells. We report a case of long term improvement by ustekinumab in a patient with combined psoriasis, Behçet's disease, and hidradenitis suppurativa, suggesting a critical role of IL-12/23 also in the latter two diseases. Fumaric acid treatment is considered a safe option for psoriasis, but it is not clear how fumaric acids interfere in the pathogenesis of psoriasis. We therefore compared gene expression profiles of involved skin during effective fumaric acid treatment with the effects of the anti-TNF- α blocker etanercept. Cyclosporin is a highly effective drug in both psoriasis and nail-psoriasis, but its systemic use is limited by considerable side effects. In a double-blind placebo controlled study we assessed the efficacy of topically applied cyclosporin in nails affected by psoriasis. The last chapter concerns treatment with pulsed dye laser, which targets the increased numbers of tortuous capillaries in psoriatic plaques. This treatment is assumed to prevent the skin homing of leucocytes. However, its exact molecular mode of action is lacking, especially the effect of treatment on the IL-23/IL-17 axis. In this study we set out to investigate the cellular and molecular effects of pulsed dye laser treatment PDL treatment on markers of the IL-23/IL-17 axis in psoriatic skin, in comparison to the effects of NB-UVB treatment (Figure 5B).





Figure 5. Rationale and research questions

Psoriasis plaques display an increased number and density of sensory nerves and increased expression of neuropeptides such as CGRP and SP, and NGF (5A Left panel). Denervation of skin and pharmacologic blocking of neuropeptide function therapeutically targets both human psoriasis and murine psoriasiform inflammation (5A Middle panel). We asked whether nerves and associated mediators are crucial elements in the onset of psoriasis (5A Right panel).

Several successful treatment in psoriasis are poorly understood in regard to their effects on epidermal psoriatic aberrancies and the Th17/IL-23 axis. We assessed the clinical efficacy of selected experimental and established registered treatments of psoriasis, and investigated their molecular mode of action (5B Middle panel). Furthermore, we investigated the effects of anti-p40 mAb treatment beyond psoriatic involved skin (5B Right panel).



Chapter 2

Resolution of psoriatic plaques
due to skin denervation: Molecular
mechanisms underlying a forgotten
phenomenon

Ewout M. Baerveldt^{1,2}, Armanda J. Onderdijk^{1,2}, Marius Kant^{1,2},
Jurr Boer³ and Errol P. Prens^{1,2}

Departments of Dermatology¹, and Immunology², Erasmus MC,
University Medical Center, Rotterdam, The Netherlands; Department
of Dermatology³, Deventer Hospital, Deventer, The Netherlands.

Submitted for publication

Chapter 3

Surgical denervation of mouse skin prevents imiquimod induced psoriasiform inflammation

Ewout M. Baerveldt^{*1,2}, Armanda J. Onderdijk^{*1,2}, Christian T. Wohn², Marius Kant^{1,2}, Edwin F. Florencia^{1,2}, Ineke M. Hekking-Weijma³, Jon D. Laman², William R. Swindell⁴, Johann E. Gudjonsson⁴, Björn E. Clausen^{1,2}, Erik T. Walbeehm³ and Errol P. Prens^{1,2}

Departments of Dermatology¹, Immunology², and Plastic Surgery³, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; and Department of Dermatology⁴, University of Michigan, Michigan, USA. *These authors share first authorship.

Submitted for publication

Chapter 4

CGRP and acetylcholine promote
epidermal TLR9 and LL-37 expression
in human healthy skin explants

Ewout M. Baerveldt^{1,2}, Edwin F. Florencia^{1,2}, Marius Kant^{1,2},
Dorota M. Kurek³, Jon D. Laman², and Errol P. Prens^{1,2}

Departments of Dermatology¹, Immunology² and Cell Biology³,
Erasmus MC, University Medical Center, Rotterdam, The Netherlands

Submitted for publication

Chapter 5

IL-4 down-regulates IL-1 β and IL-6
and induces GATA3 in psoriatic
epidermal cells: a cell type-restricted
route of action of a Th2 cytokine

Armanda J. Onderdijk^{1,2}, Ewout M. Baerveldt^{1,2}, Dorota M. Kurek³, Marius Kant^{1,2}, Edwin F. Florencia^{1,2}, Reno Debets^{4*}, and Errol P. Prens^{1,2*}

Departments of Dermatology¹, Immunology², Cell biology³, and Medical Oncology⁴, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. *These authors share last authorship.

Submitted for publication

Chapter 6.1

Ustekinumab improves psoriasis-related gene expression in non-involved psoriatic skin without inhibition of the antimicrobial response

Ewout M. Baerveldt^{1,2}, Armanda J. Onderdijk^{1,2}, Dorota M. Kurek³, Arne S. Ijpma⁴, Peter van der Spek⁴, Marius Kant^{1,2}, Edwin F. Florencia^{1,2}, Jeroen Bastiaans², Patrick A. Jansen⁵, Jeroen W.J. van Kilsdonk⁵, Jon D. Laman², and Errol P. Prens^{1,2}

Departments of Dermatology¹, Immunology², Cell Biology³, and Bioinformatics⁴, Erasmus MC, University Medical Center Rotterdam, and Department of Dermatology⁵, Radboud University Nijmegen Medical Center, The Netherlands

British Journal of Dermatology, 2012: 12175

BACKGROUND

Ustekinumab is a fully human anti-p40 mAb which neutralizes IL-12 and IL-23, thereby interfering with Th1/Th17 pathways and keratinocyte activation, and is highly effective in psoriasis. During ustekinumab treatment, some of our patients noticed reduced koebnerisation of non-involved skin and less new plaque formation. Our objective was to determine whether ustekinumab improves psoriasis-related gene expression and tape-strip responses in non-involved skin.

MATERIAL AND METHODS

Before and 4 weeks after ustekinumab treatment, non-involved skin was tape-stripped. After 5 h, biopsies were taken from untouched and tape-stripped skin. The mRNA expression of psoriasis-related markers such as NGF, GATA3 and IL-22RA1, and several antimicrobial peptides (AMP) was quantified. Leukocyte counts and a broad range of inflammatory serum proteins were analysed to get insight into the systemic alterations.

RESULTS

4 Weeks following a single ustekinumab injection, NGF showed a significant decrease, whereas GATA3 and IL-22RA1 expression increased, indicative of reduced responsiveness to epidermal triggering. This was accompanied by alterations in inflammation-related serum proteins including SMAD-1, HB-EGF, VEGF-A and E-selectin. The baseline and the tape-strip-induced expression of the AMP DEFEB4, S100A7 and LL-37 remained unaltered. Clinically, after 4 weeks, 8 out of 11 patients showed a 50% PASI improvement, which was accompanied by a significant reduction in serum β -defensin-2 levels. No changes were noted in total leucocytes, CRP, and sedimentation rate.

CONCLUSIONS

These findings indicate that ustekinumab reduces psoriasis-related gene expression in non-involved psoriatic skin, making it more resistant to exogenous triggering, without disturbing its antimicrobial response. In parallel, ustekinumab modulates important circulating inflammation-related proteins.

INTRODUCTION

Psoriasis is an inflammatory skin disease induced by an aberrant interaction between the immune system and the skin, in which the IL-23/Th17 axis is critical.²³⁸ Ustekinumab is a human monoclonal Ab against the shared p40 subunit of IL-12 and IL-23.⁴⁴¹ In clinical trials, ustekinumab achieved PASI-75 (75% reduction in Psoriasis Area and Severity Index) in 60% of patients with moderate-to-severe psoriasis after 8 weeks of therapy.^{196 442} Some patients showed a prolonged PASI-75 response following three injections of ustekinumab.^{196 442} In some of our patients, this prolonged effect was accompanied by the prevention of new plaque formation and less Koebnerization after skin trauma (own observation). The mechanisms underlying this prolonged clinical response to ustekinumab remain unclear. Until now, research has focused on involved skin and on a limited set of systemic inflammatory markers.

Previous studies showed that after 12 weeks of treatment, ustekinumab induced minimal alterations in the percentage of CLA⁺ T cells in plaques with no significant alterations in the percentage of CD45RA⁺, CD45RO⁺, CD25⁺, HLA-DR⁺, and CXCR3⁺ cells.⁴⁴³ Serum levels of IL-8, IL-10, TNF- α , sICAM-1, and CCL27 remained unchanged during clinically effective ustekinumab treatment.⁴⁴⁴ In vitro, ustekinumab effectively neutralized IL-12 and IL-23 produced by activated human PBMC, resulting in decreased expression of skin homing and activation markers, and IL-12- and IL-23-induced cytokine secretion.^{443 445} The latter is critical in the epidermal response to cutaneous triggering by tape-stripping and induction of AMP.^{74 445} AMP can trigger chemotaxis, angiogenesis, and keratinocyte proliferation, which are all important features in the pathogenesis of psoriasis. Among the AMP, especially β -defensin-2 (hBD-2) is over-expressed in psoriatic plaques relative to atopic dermatitis and healthy skin.^{259 433} The importance of hBD-2 in psoriasis is underscored by the increase in DEFB4, the gene coding for hBD-2, genomic copy number in patients with psoriasis.²⁶³ Systemic hBD-2 level shows a positive correlation with disease activity as assessed by the PASI score.²⁶⁵ Strongly increased levels were also found in the urine of psoriasis patients whereas hBD-2 could not be detected in urine of healthy controls. Interestingly, rheumatoid arthritis patients showed hBD-2 serum levels similar to control individuals. These findings suggest that increased systemic hBD-2 levels are almost entirely derived from psoriatic plaques.²⁶⁵ Ustekinumab significantly reduced psoriasis-related gene expression in plaques, including hBD-2 and S100A7, down to levels of non-involved skin, but not to the levels of healthy skin.⁴⁴⁶ The production of AMP is highly dependent on IL-22.⁷⁴ Effects of IL-22 are mediated via the IL-22 receptor, which is composed of two subunits IL-22RA1 and IL-10R2, and subsequently via STAT-3, a psoriasis-associated marker relevant for epidermal hyperplasia.⁴⁴⁷

The prolonged clinical response, together with our observations of prevention of new plaque formation and a reduced Koebner response during ustekinumab treatment, led us

to hypothesize that ustekinumab does not only act on the ongoing pathogenic processes in inflamed skin, but also has protective inhibitory effects in non-involved skin. Non-involved skin has an intermediate gene expression profile that lies in between psoriatic and normal skin, and is also called 'pre-psoriatic' skin.⁵ Little is known about the effects of biologics in non-involved skin in general and specifically about ustekinumab.

Tape-stripping is considered a cutaneous trigger mimicking the Koebner response and the initiation of psoriasis, because it rapidly induces several psoriasis-related histological alterations and molecular markers such as hBD-2 and S100A7,⁴³⁷ and NGF.²⁹⁴ The transcription factor GATA3 is classically involved in Th2 differentiation, but GATA3 is also crucial in epidermal differentiation, epidermal barrier formation and in the formation of lamellar bodies which store several antimicrobial peptides such as LL-37 and hBD-2.^{83, 289} GATA3 is essential for formation of a normal healthy epidermal architecture and proper functioning of the epidermal lipid barrier-innate immune axis.¹³ β -defensins and S100A proteins are upregulated in the skin of epidermis-specific GATA3 knock-out mice.¹³ We recently showed that epidermal GATA3 is downregulated in psoriatic plaques, during wound healing, and in non-involved psoriatic skin 5 h after tape-stripping.²⁹¹

We hypothesized that by blocking IL-12/IL-23, ustekinumab would reduce the 'pre-psoriatic' expression levels of psoriasis-related genes in non-involved skin to levels comparable with healthy skin. Hence, the aim of our study was to assess whether successful ustekinumab treatment inhibited the expression of psoriasis-related markers and AMP in non-involved skin and their response to tape-stripping, thereby preventing new plaque formation. In addition, we analysed the inflammatory changes in serum induced by ustekinumab using a broad cytokine-array, and measured hBD-2 levels as a marker of psoriasis disease activity.

MATERIAL AND METHODS

Patients and ustekinumab treatment

Eleven patients (5 male, 6 female), age range 29-71 years, all from native European/Dutch origin and a PASI score > 10, were enrolled after informed consent. All patients (Table 1) did not receive systemic therapy or UVB treatment for at least three months or topical treatment for at least three weeks prior to the start of the study. At start and 4 weeks after first injection, the clinical severity was assessed using the PASI score. Patients received a subcutaneous injection of 45 mg ustekinumab (Stelara™, Janssen, Belgium) at start. The study was approved by the medical ethical committee of the Erasmus MC (ethical review board registration number 234.237/2003/210) and conducted according to the Declaration of

Table 1. Primer sequences

Gene	Forward primer	Reverse primer
ABL1	TGGAGATAACACTCTAAGCATAACTAAAGGT	GATGTAGTTGCTTGGGACCCA
CAMP (LL-37)	TCGGATGCTAACCTCTACCG	GTCTGGGTCCCATCCAT
DEFB4 (hBD-2)	TCAGCCATGAGGGTCTTGTA	GGATCGCCTATACCACCAAA
GATA3	GCTTCGGATGCAAGTCCA	GCCCCACAGTTCACACT
IL22RA1	CACCTCCCAACTCCCTGA	CGTGCTCTGGATGAAGC
NGF	TCCGGACCCAATAACAGTTT	GGACATTACGCTATGCACCTC
S100A7 (psoriasin)	CTGCTGACGATGATGAAGGA	CGAGGTAATTTGTCCCTTT
STAT3	TGATGCAGTTTGAAATAATGG	CATGTCAAAGGTGAGGGACTC

Helsinki principles. Following this study, the included patients continued with ustekinumab treatment according to national guidelines.

Tape-stripping

Tape-stripping of non-involved psoriatic skin is a model for studying epidermal events in the initiation of psoriasis.^{294,437} At baseline and 4 weeks following injection of ustekinumab, an area of non-involved skin (3x2 cm) was tape-stripped consisting of repeated (40 times) application of sellotape and removal of stratum corneum until the skin got a shiny appearance.⁴⁴⁸ Tape-stripping was standardized for time of the day (all before noon) and anatomical body site (medial side of the knee) and at least 3 cm away from a psoriatic plaque. During the subsequent 6 months, the tape-stripped areas were assessed monthly by clinical scoring (Koebner positive or negative).

Biopsies and RNA extraction

Before initiation of treatment and 4 weeks following first injection of ustekinumab, 5-mm biopsies were taken from tape-stripped and adjacent non-involved skin, five hours after tape-stripping, using local anaesthesia. The biopsies were divided into one part for immunohistochemistry and another for quantitative mRNA analysis. Epidermis was separated from the dermis after incubation in 1 mg/ml protease X (Sigma Aldrich, Zwijndrecht, The Netherlands) for 90 min at 37 °C. Total RNA was isolated from the epidermis, using GenElute Mammalian Total RNA Miniprep kit (Sigma Aldrich). RNA purity and integrity was verified by scanning with an Agilent 2100 Bioanalyzer using the RNA 6000 NanoLabChip.

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

RNA was transcribed into cDNA, and RT-PCR was conducted as previously described^{291,397}. The sequences of the used primers and probes of selected markers were all based on the Exiqon probe library system (Exiqon, Vedbaek, Denmark) and are listed in Table 1. In

order to investigate the short term effects of ustekinumab on the epidermal response to tape-stripping, we measured the expression of the psoriasis-related markers: GATA3, IL-22 receptor alpha 1 (IL-22RA1), NGF, DEFB4 (hBD-2), S100A7, LL-37, and STAT-3. Abelson murine leukemia viral oncogene homolog (ABL1) was used as a reference gene in all qPCR experiments. Expression of this gene remained stable during treatment with ustekinumab.

Immunofluorescence

For immunofluorescent staining, cryosections were fixed for 10 min in 4% paraformaldehyde in PBS. Monoclonal Ab anti-GATA3 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) was used as primary antibody. TxR-conjugated antibodies (1:100, Abcam, Cambridge, MA) were used to detect the primary antibody. Fluorescent images were taken with an Axio Imager fluorescence microscope (Carl Zeiss Microimaging GmbH, Jena, Germany).

Serum sampling

Blood samples were taken at baseline and 4 weeks following single injection of ustekinumab. Samples were centrifuged, and serum was collected and frozen at -80 °C until analysis. As global markers of systemic inflammation, we investigated erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and leucocyte counts (monocytes, immature granulocytes, neutrophils, eosinophils and lymphocytes).

Serum pro-inflammatory cytokine-array analysis

Simultaneous detection of 507 different growth factors, cytokines, and receptors was performed using glass slide-based microarrays (RayBiotech, Inc., Norcross, GA) coated with capture antibodies, according to the manufacturer's instructions. Briefly, serum samples, taken at start and 4 wk following injection of ustekinumab from 4 randomly chosen patients with a PASI reduction greater than 50% at week 4, were independently dialyzed and biotinylated. The biotinylated serum samples were added to 4 individual protein array slides. After incubation with Cy3-labelled streptavidin, the arrays were scanned using a laser confocal scanner (Tecan Benelux; Mechelen, Belgium). Internal controls were included as a control of performance. Total signal strength for specific proteins was based on the average of a triplicate. Since this protein array does not allow for the quantification of proteins by comparison with a standard curve, data were normalized using the internal control as indicated by the manufacturer, and were log₂ transformed. This strategy provided a relative estimate of marker abundance in the sample. Because the protein array detects only relative expression levels and not absolute values, there is no defined lower detection limit.

To increase the specificity, we limited the sensitivity of the test by selecting only the proteins that were differentially regulated (≥ 2 fold change) at week 4 (before treatment) compared to week 0 in three or more donors.

Bioinformatics analysis

Proteins differentially expressed ($p < 0.05$; ≥ 2 fold change) in serum at 4 weeks after ustekinumab injection were subjected to Ingenuity Pathway Analysis (Ingenuity Systems) to identify the role of these proteins within psoriasis.

ELISA

Serum samples of 0 and 4 weeks of patients ($n=11$) were analyzed for hBD-2 concentration using ELISA. Affinity-purified chicken anti-hBD-2 was used to coat 96-well microtiter plates. After blocking with 1% (v/v) BSA, samples were diluted to fit the calibration curve range (33-500 pg/ml), followed by goat anti-hBD-2 (Abcam) as a detection antibody, and amplification using the ABC kit (Vector Laboratories, Inc., Burlingame, CA). All steps were followed by appropriate rinsing in phosphate-buffered saline with 0.05% (v/v) Tween-20. The serum hBD-2 concentrations were read from a calibration curve of recombinant hBD-2 (Pepro Tech, Inc., Rocky Hill, NJ), with a detection limit of 0.03 ng/ml.

Statistics

Experimental data were tested for statistical significance at $P < 0.05$ using a Student's paired t test (one-tailed) with GraphPad Prism v5.04 (GraphPad Software, Inc., La Jolla, CA). P-values are designated as $P < 0.05$ (*) and $P < 0.01$ (**).

RESULTS

Clinical efficacy of ustekinumab treatment

The clinical efficacy of ustekinumab was apparent from the PASI score at week 4. The mean PASI reduction in all patients was 55% (range 0-75%). Overall 8 out of 11 patients achieved a greater than 50% reduction in their PASI score ($\text{PASI} \geq 50$) at week 4, a level of improvement qualifying them as responders. Three patients (numbers 4, 9, and 10) showed high initial PASI (Table 2) and all three did not reach a PASI-50 reduction at week 4 (Figure 1).

Response of psoriasis related markers to tape-stripping of non-involved skin

The mRNA expression in tape-stripped non-involved skin was measured 5 h following tape-stripping (TS) and compared with the baseline expression in non-involved skin (PN). Before treatment, tape-stripping significantly suppressed the expression of GATA3 and IL-22RA1, whereas NGF and STAT-3 expression increased ($p = 0.02, 0.01, 0.02$ and 0.04 respectively). All three selected AMP (DEFB4, S100A7 and LL-37), showed an upward trend following tape-stripping, but this did not reach statistical significance (Figure 2).

Table 2. Demographics, disease characteristics, and medical history of patients

No	Age	PASI Start	Koebner		Psoriasis type	Weight (kg)	Previous treatments	
			wk 0	wk 4				
1	♀	50	11	neg	neg	Plaque	70	NB-UVB, MTX, fumaric acid, etanercept
2	♂	47	17	neg	neg	Plaque	90	NB-UVB, MTX, fumaric acid, etanercept
3	♀	31	15	neg	neg	Plaque/Guttate	56	NB-UVB, MTX, fumaric acid
4	♂	62	25	neg	neg	Plaque; large BSA	90	NB-UVB, PUVA, MTX, fumaric acid, etanercept, infliximab
5	♀	71	11	neg	neg	Plaque	80	NB-UVB, MTX, fumaric acid
6	♀	38	12	neg	neg	Plaque	90	NB-UVB, MTX, cyclosporin
7	♀	67	15	neg	neg	Plaque	100	NB-UVB, PUVA, fumaric acid, etanercept,
8	♀	38	10	neg	neg	Plaque	70	MTX, fumaric acid, etanercept
9	♂	48	25	pos	pos	Plaque; large BSA	>100	NB-UVB, MTX, fumaric acid, efalizumab, infliximab
10	♂	58	25	pos	pos	Plaque; large BSA	80	MTX, fumaric acid, etanercept, infliximab
11	♂	29	13	neg	neg	Plaque	90	NB-UVB, MTX, fumaric acid

NB-UVB: narrow band UVB; MTX: methotrexate; PUVA: psoralen + UVA




Figure 1. PASI response to ustekinumab treatment. Clinical response to ustekinumab treatment. Eight out of eleven patients achieved at least PASI-50 and PASI-75 at respectively week 4 and week 16 (collectively displayed as lower line with full circles). Three patients (4, 9, 10) did not reach 50% improvement at week 4 and therefore received a double dose (90 mg) of ustekinumab. These patients had higher initial PASI scores (note interrupted y-axis) and their mean PASI improvement at week 16 was 57%. The x-axis represents time in weeks, the y-axis mean PASI-score +/- SEM.

Non-involved (PN) versus tape-stripped skin before treatment




Figure 2. Response of psoriasis related markers in non-involved skin to tape-stripping. The x-axis represents non-involved psoriatic skin (PN) and tape-stripped skin (TS), before treatment. Each data point in non-involved skin is linked to the corresponding data point in tape-stripped skin per individual patient. Selected donors comprise only patients showing > 50% PASI improvement to ustekinumab treatment (n = 8). The y-axis represents the gene expression of selected epidermal psoriasis-markers GATA3, IL-22RA1, NGF, DEFB4, S100A7, LL-37 and STAT-3, relative to ABL. (* $P < 0.05$, ** $P < 0.01$, by paired T-test).

Effects of ustekinumab on psoriasis-related markers in non-involved skin

The epidermal mRNA expression of psoriasis-related epidermal markers was first measured in non-involved unmanipulated skin, before and 4 weeks after first injection of ustekinumab. In responders (n = 8), the expression of epidermal GATA3 and IL-22RA1 mRNA showed a significant increase (p = 0.01 and 0.03 respectively) compared to pre-treatment baseline levels. We observed no changes in the expression of NGF, DEFB4, LL-37, S100A7 and STAT-3 (Figure 3a). GATA3 protein expression was also detected *in situ*, in the same biopsies. Before ustekinumab treatment GATA3 was expressed only in the basal layer




Figure 3. Ustekinumab targets non-involved: increased GATA3 and IL-22RA1, reduced NGF, whereas DEFB4, LL-37 and S100A7 remain unaltered in response to tape-stripping. Epidermal mRNA levels of GATA3, IL-22RA1, NGF, DEFB4, S100A7, LL-37 and STAT-3 in non-involved psoriatic skin (a) and tape-stripped skin (b), before (week 0) and 4 weeks following injection with 45 mg ustekinumab. The x-axis represents time in weeks and the y-axis represents the gene expression of selected epidermal markers relative to ABL. Note the interruption of the y-axis with DEFB4, S100A7 and LL-37. Each data point represents an individual patient before and after therapy with > 50% PASI improvement (n = max 8, * $P < 0.05$, ** $P < 0.01$, by paired T-test).




Figure 4. Early response to ustekinumab is paralleled by increased GATA3 expression in non-involved skin. Before treatment, immunofluorescence staining of non-involved skin showed modest GATA3 protein expression in the suprabasal layers of the epidermis (a). After 4 weeks of ustekinumab treatment, a stronger GATA3 protein expression was seen in the basal and the suprabasal epidermal layers (b). Images of representative responder to ustekinumab treatment, and displayed at a magnification of 100x, with scale bar representing 50 μm .

of non-involved skin (Figure 4a). Four weeks after injection of ustekinumab, GATA3 expression increased in intensity and was now present in multiple epidermal cell layers, extending up to the granular layer (Figure 4b).

Effects of ustekinumab on the epidermal response to skin triggering by tape-stripping

Four weeks after injection of ustekinumab, tape-stripped skin showed a significant up-regulation of both GATA3 and IL-22RA1 mRNA compared to tape-stripped skin before treatment ($p = 0.01$). An opposite effect was observed with the induction of NGF by tape-stripping, which was significantly inhibited following ustekinumab injection ($p = 0.01$). In contrast, ustekinumab did not clearly affect the tape-strip-induced expression of DEFB4, S100A7, LL-37, and STAT-3 (Figure 3b).

The Koebner response to tape-stripping of non-involved skin

All patients that were considered responders to ustekinumab ($n=8$), based on a PASI >50 improvement at week 4, did not develop a Koebner response upon first tape-stripping, as assessed by visual scoring. Patients 9 and 10 showed positive Koebner responses to tape-stripping (Table 2).

Ustekinumab does not affect general serum inflammatory markers and leucocyte counts

At start, and 4 weeks following first ustekinumab injection, blood samples from patients were evaluated for the effects of ustekinumab on the general serum inflammatory marker ESR, and leucocyte counts. These were in all patients within normal ranges. No significant

alterations were observed in ESR (Supplemental Figure 1a), or in the leucocyte counts during ustekinumab treatment (Supplemental Figure 1b).

Ustekinumab treatment affects inflammation-related serum proteins.

Four weeks following ustekinumab injection, out of 507 inflammatory proteins, serum levels of tumour necrosis factor receptor type 1-associated DEATH domain (TRADD), MST1 (MSP- β) and osteoactivin (GPNMB) showed a significant upregulation 4 wk following the successful injection with ustekinumab (supplemental Table 2).

Successful ustekinumab treatment of psoriasis is associated with downregulation of serum hBD-2

The release of hBD-2 in serum by psoriatic plaques is thought to be driven by Th1/Th17 stimulation. Serum hBD-2 significantly decreased ($p = 0.0171$) in responders to ustekinumab (Figure 5), whereas three non-responding patients did not show a significant change in hBD-2 (data not shown).




Figure 5. Serum hBD-2 levels correlate with ustekinumab-induced clinical improvement. Serum hBD-2 serum protein levels in responders to ustekinumab treatment, before (week 0) and 4 weeks following 45 mg ustekinumab. The x-axis represents time in weeks, the y-axis hBD-2 in ng/ml. Results displayed as floating boxes +/- SEM. Results were statistically analysed by paired t test (* $P < 0.05$).

DISCUSSION

This study demonstrates that clinically effective ustekinumab treatment improves psoriasis-related gene expression in non-involved psoriatic skin without disturbing its antimicrobial response. Ustekinumab reduced the expression of a 45 of circulating inflammatory proteins, associated with important psoriasis-related inflammatory pathways. This improvement of systemic inflammation may contribute to the observed findings in non-involved skin. Our finding that successful ustekinumab treatment does not influence AMP responses to cutaneous triggering, suggests a stable AMP function in innate skin immune defence during ustekinumab.

Our results show that ustekinumab enhances the epidermal expression of GATA3 and IL-22RA1 in non-involved skin. We recently introduced epidermal GATA3 expression as a marker that is inversely correlated with psoriatic disease activity.^{254,291} The observed increase in GATA3 expression in both non-involved and tape-stripped skin by ustekinumab therapy may reflect a reduction of the pre-psoriatic state.⁵ Interleukin-22R signalling is important in regulating the expression of inflammatory molecules and AMP in epithelia, especially in psoriasis.⁸⁷ Previous studies in psoriasis did not demonstrate any effect of drugs such as cyclosporin or calcipotriol on IL-22R mRNA expression in vivo.⁴⁴⁹ Our finding that IL-22RA1 is decreased in untreated and non-involved psoriatic skin within 5 h following tape-stripping, adds to the understanding of IL-22 responses, especially following wounding and in psoriasis. The suppressive effects of ustekinumab on the induction of epidermal IL-22RA1 mRNA by tape-stripping in combination with lowered IL-22 serum levels could represent a compensatory feedback mechanism in the skin.⁴⁵⁰

Keratinocyte cultures from non-involved psoriatic skin show ten-fold more NGF production compared to keratinocytes from healthy individuals. The role of NGF in the pathogenesis of psoriasis is further substantiated by the observation that K252a, an NGF receptor antagonist, improved psoriasis.³⁴¹ A similar improvement was achieved by directly inhibiting NGF with a neutralizing antibody.³⁴¹ The reduced upregulation of NGF mRNA following tape-stripping may reflect further stabilization of non-involved skin during ustekinumab treatment.

Tape-stripping enhances epidermal AMP expression, irrespective of the genetic background of the skin disease, such as psoriasis and atopic dermatitis.⁴³⁷ The expression levels of epidermal hBD-2, S100A7, LL-37 and STAT-3 remained unaltered, both in unmanipulated non-involved skin and in triggered non-involved skin, indicating that after a dose of 45 mg ustekinumab, the epidermal antimicrobial response remains intact during ustekinumab-induced clearance of psoriasis.

Previous reports on the treatment of psoriasis showed only limited systemic effects of ustekinumab. However, these studies were limited in the total number of serum proteins

studied. We show that effective ustekinumab treatment reduces the serum expression of hBD-2, paralleled by an increase in TRADD, Macrophage stimulating protein (MSP)- β chain, and osteoactivin. TRADD protein functions as an adaptor in the tumour necrosis factor receptor (TNFR)1 signalling complex, mediating both apoptosis and inflammatory signals.⁴⁵¹ Earlier results based have shown that TNFR1 serum levels correlate to PASI score, however, these results are limited by the included number of patients.⁴⁵² More recent results show that in patients with systemic lupus erythematosus (SLE), TNFR1 expression is negatively correlated with disease activity.⁴⁵³ The kinase macrophage stimulating protein (MSP; also denoted as macrophage stimulating 1) is a 78-kDa disulfide-linked heterodimer belonging to the plasminogen-related kringle protein family. MSP functions together with RAPL, which is a protein that binds the small GTPase Rap1, and is required for the adhesion of lymphocytes.⁴⁵⁴ The transmembrane glycoprotein osteoactivin has been characterized as a negative regulator of T-cell activation and its upregulation mediates the tyrosine kinase inhibitor-mediated inhibition of DC function.⁴⁵⁵

The reduction of serum hBD-2 might be specific for ustekinumab, as results show that successful treatment of psoriasis with fumarates results in increased hBD-2 serum expression.⁴⁵⁶ Increase in serum hBD-2 is not limited to psoriatic skin inflammation, as in AD pa-




Figure 6. Model for the mode of action of ustekinumab in the clearance and prevention of psoriasis. We propose that ustekinumab has a twofold mode of action: first by neutralizing IL-12 and IL-23 in lesional psoriatic skin, the Th1/Th17 inflammatory cascade is interrupted, leading to clinical improvement, assessed by PASI decline and a change in circulating IL-12B-related proteins, including GPNMB, MST1, TRADD, and hBD-2. Second, ustekinumab induces a shift in non-involved skin gene expression towards healthy skin, thereby raising the threshold for skin triggering and new plaque formation.


tients serum hBD-2 is also increased.⁴⁵⁷ In patients with SLE, serum hBD-2 levels positively correlate to the risk of cardiovascular events.⁴⁵⁸ The decline of serum hBD-2 following one injection of ustekinumab might proven to be beneficial to the cardio-vascular co-morbidity of psoriasis.^{173 181-185} Taken together, the effect of ustekinumab is twofold (Figure 6): first by neutralizing IL-12 and IL-23, the Th1/Th17 inflammatory cascade is interrupted in psoriasis plaques, leading to a PASI decline and changes in circulating (probably plaque-derived) inflammatory molecules. Second, ustekinumab induces a shift in non-involved skin gene expression towards patterns of healthy skin, thereby raising the threshold for skin triggering and new plaque formation.

Acknowledgement

The authors thank Ruth Huizinga, PhD, for reviewing the manuscript.

Supplemental Table 1. Patients reporting the prevention of new psoriatic plaques and Koebnerization during ustekinumab treatment.

	PASI Start	PASI-75 at wk 12 ustekinumab	Patient- reported prevention of new plaques	Previously Koebner positive	Prevention of Koebner after accidental provocation during ustekinumab.
♀	11	Yes	Yes	Unaware	Unaware
♀	15	Yes	Yes	Yes	Yes
♀	11	Yes	Yes	Unaware	Yes
♀	15	Yes	Yes	Yes	Yes
♂	18	Yes	Yes	Yes	Yes



Supplemental Figure 1. No significant effect of ustekinumab on general systemic serum markers of inflammation. Before the ustekinumab treatment, general serum inflammatory marker ESR (a), and leucocyte counts (b) were in all patients within normal ranges. No significant alterations were observed in ESR (a; wk 4), or in the leucocyte counts during ustekinumab treatment (b; wk 4).

Chapter 6.2

Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa

Ewout M. Baerveldt^{1,2}, Jasper H. Kappen², H. Bing Thio¹, Jan A.M. van Laar², Martin van Hagen², and Errol P. Prens^{1,2}

Departments of Dermatology¹ and Immunology², Erasmus MC, University Medical Center Rotterdam, The Netherlands

Annals of the Rheumatic Diseases, 2012; 202392

BACKGROUND

During recent years, there has been growing interest in the immunological overlap between diseases. Shared knowledge of clinical cases with overlapping immunological diseases provides important information regarding pathomechanisms and offers insight in therapeutic targets.

OBSERVATIONS

We hereby report a clinical case with two unique features: First it describes a unique patient which has Behçet's disease, hidradenitis suppurativa, and psoriasis vulgaris. Second, all of these three diseases showed prolonged response to treatment with the anti-p40 mAb ustekinumab, which is known to target both IL-12 and IL-23. A broad range of inflammatory serum proteins were analysed to get insight into the systemic alterations. Results show that several proteins involved in IL-23/Th17 axis were upregulated before treatment, and were inhibited following the first injection with ustekinumab.

CONCLUSIONS

This is the first reported patient in which these three diseases were simultaneously present, and who is effectively treated with ustekinumab. The successful treatment with ustekinumab provides a valuable addition to the current therapeutic armamentarium of Behçet's disease.

INTRODUCTION

Behçet's disease (BD) is an auto-inflammatory disorder, characterised by recurrent oral aphthosis, genital ulcers, uveitis and pustular skin lesions.⁴⁵⁹ Associated cutaneous diseases include Sweet's syndrome,⁴⁶⁰ erythema nodosum and pyoderma gangrenosum.⁴⁶¹ Next to BD, both psoriasis and hidradenitis suppurativa (HS) are clear neutrophilic and interleukin (IL)-17-based diseases, suggesting a pathomechanistic overlap.⁴⁶²⁻⁴⁶³ However, these diseases rarely co-occur.⁴⁶² Ustekinumab (anti-p40 mAb), an effective biological treatment for psoriasis, might be effective in BD by interfering with the IL-17 signalling via IL-23 blockade.⁴⁶³ We present a 39-year-old Caucasian woman in whom the combination of BD, psoriasis and HS was successfully treated with ustekinumab.

Case

At the age of 5, the patient developed guttate psoriasis followed by psoriasis vulgaris with severe acne vulgaris since puberty. She started smoking at the age of 13 and periodically developed inflamed and tender boils in both axilla and groins during

puberty. At 35, she was diagnosed with BD according to the guidelines of the international study group on BD based on oro-genital ulcers and uveitis anterior.⁴ Inquiry revealed that she repeatedly developed ulcers at injection sites, highly suggestive of a pathergy reaction. This was complicated by bilateral arthritis of the distal interphalangeal joints and weight loss due to multiple intestinal ulcers at the terminal ileum. Dermatological examination revealed vulvar and multiple circumscribed punched-out vaginal scars and ulcers, and fibrotic and rope-like scarring in the groins, together with HS, Hurley stage 2. The BD-related symptoms prompted immunosuppressive treatment with diclofenac/misoprostol, ocular steroids, colchicine, intra-articular triamcinolone injection and cyclosporin, unfortunately all with only a temporary effect. In the course of the disease she experienced an exacerbation of her psoriasis that was treated with subcutaneous injections of 45 mg ustekinumab at weeks 0, 4 and every 12 weeks thereafter. In all, 50% clinical improvement, as measured by the Psoriasis Activity and Severity Index (PASI 50), was achieved within 4 weeks, followed by PASI 75 within 3 months. Subsequently, both BD and HS skin complaints gradually decreased and remained in complete remission for at least 36 months without adjunctive immunosuppressive treatment.

Before and 4 weeks after first injection of ustekinumab, serum was analysed using a semiquantitative multiplex protein array to monitor changes in circulating cytokines, chemokines and growth factors.⁴⁶⁴ Before treatment, 64 out of 507 proteins showed an increased ≥ 2 -fold expression compared with healthy control serum, including IL-23 and IL-12p70 (Table 1). Four weeks following the first injection of ustekinumab, 18 proteins showed a change of more than 1.5-fold (Table 1), among which the Th1 and Th17-associated proteins

Table 1. Serum proteins compared with healthy controls and change induced by ustekinumab

Protein	Fold change to healthy controls (n=2)	Fold change by ustekinumab	General function
IL-23	21.60	-2.18	Th17
Ciliary neurotrophic factor osteoprotegerin	12.08	-1.82	IL-6 family member
IL-12 p70	12.05	-1.68	Serum biomarker of arthritis
IL-12 p70	7.71	-1.93	Th1
CCL27	7.37	-1.63	Th1/Th17
Glut2	5.56	-2.34	Glucose metabolism
VEGF	4.03	3.33	Angiogenesis
Kininostatin	3.70	-1.61	Angiogenic inhibitor
CCL3 (MIP1 α)	3.45	-1.50	Th1/Th17
TRAIL R4 (TNFRSF10D)	2.82	1.62	Marker of inflammatory DCs
IGFBP-3	2.65	1.85	Growth factor
BMP-8	2.57	1.98	Growth factor
TGF- β 2	2.29	2.06	Growth factor
FGF basic	2.29	1.53	Growth factor
IGFBP-6	2.24	3.27	Growth factor
Inhibin B	2.14	2.51	Endocrine function
Neurturin	2.13	2.06	Neurotrophic factor
IL-24	2.04	2.85	Th17

IL-12p70 and IL-23 were downregulated. These findings support an important role of Th1/Th17 pathways in BD.⁴⁶³

There are only two other cases describing combined occurrence of BD and HS.⁴⁶⁵ This case is the first in which these three diseases were simultaneously present. In addition, our case is the first BD patient reported who was effectively treated with ustekinumab. The successful treatment with ustekinumab provides a valuable addition to the current therapeutic armamentarium.

Chapter 7

Response to treatment with fumaric acid esters in psoriasis patients is linked to suppression of the IL-17 pathway

Armanda J. Onderdijk^{1,2*}, Deepak M.W. Balak^{1*}, Ewout M. Baerveldt^{1,2}, Edwin F. Florencia^{1,2}, Marius Kant^{1,2}, Wilfred FJ van IJcken³, Emöke Racz^{1,2}, Dick de Ridder⁴, H. Bing Thio¹, and Errol P. Prens^{1,2}

Department of Dermatology¹, Immunology², and Center for Biomics, Erasmus MC, University Medical Center Rotterdam, and The Delft Bioinformatics Lab⁴, Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, The Netherlands. *These authors share first authorship.

Submitted for publication

BACKGROUND

Fumaric acid esters (FAE) are an effective oral treatment for psoriasis that is widely used in Europe, but their mechanism of action in psoriasis clearance is largely unknown. We sought to identify pathways and mechanisms affected by FAE treatment, by analyzing Affymetrix gene expression in lesional skin of responders (\geq PASI-75 improvement) and non-responders ($<$ PASI-50 improvement) at baseline and 12 weeks.

MATERIAL AND METHODS

Biopsies were taken from lesional skin of responders and non-responders at baseline and 12 weeks. Gene expression was analyzed using Ingenuity Pathway Analysis and the outcome was compared with gene expression affected by etanercept treatment.

RESULTS

FAE treatment most significantly affected the pathway regulated by IL-17A, reducing the expression of several molecules including CCL20, CXCL1, CXCL6, DEFB4, IL-8, IL-17A, S100A7, S100A8, S100A9 and the transcription factor NF κ BIZ that is important in Th17 cell development. Response to FAE was associated with a significant expression change of 458 genes, whereas an expression change of 320 genes was linked to successful etanercept treatment. The glutathione and Nrf-2 pathway molecules were regulated exclusively by FAE treatment in responders and non-responders.

CONCLUSIONS

Both successful FAE and etanercept treatment were firmly linked to suppression of the IL-17 pathway, which is an evident but novel mechanism of action of FAE in psoriasis clearance.

INTRODUCTION

Psoriasis is a common, chronic, inflammatory skin disease, characterized by hyperproliferation of keratinocytes and an increased dermal infiltration of immune cells. Most patients with moderate to severe disease require long-term systemic treatment to control their psoriasis. Fumaric acid esters (FAE) are small molecules used as oral treatment in psoriasis for more than 25 years, mainly in Western European countries.⁴⁶⁶ Clinical studies have shown that 50 to 70% of FAE treated psoriasis patients show a clinical improvement of at least 75% following 16 weeks of treatment.⁴⁶⁷ Data from long-term observational studies on treatment with FAE indicate a favourable safety profile without evidence of an increased risk of infections or malignancies.⁴⁶⁸⁻⁴⁷⁰ Anti-TNF- α biologics, such as etanercept, are commonly used effective systemic treatments for moderate to severe psoriasis.¹⁹⁶ In recent years, gene expression profiling studies provided insights into the mechanisms of action and the gene expression pathways by which biologics induce improvement of psoriasis.⁴⁷¹⁻⁴⁷² However, the molecular pathways by which FAE improve psoriasis and the comparison to the effects of etanercept remain largely unknown.

In this study we investigated pathways and mechanisms targeted by FAE treatment, and assessed whether successful FAE treatment invoked different molecules and pathways than etanercept. Therefore, gene expression arrays were used for the analysis of gene expression profiles in psoriatic plaques during FAE treatment. Changes in gene expression showed a number of molecules and pathways to be involved, which were then compared to those affected by etanercept treatment.

MATERIAL AND METHODS

Study design and skin biopsies

In a prospective, single-center clinical trial, 50 patients with a psoriasis area and severity index (PASI) score ≥ 10 were treated with oral FAE for 20 weeks. Eligible patients were at least 18 years of age, had a diagnosis of plaque psoriasis for at least 6 months, and were candidates for phototherapy or systemic therapy. Patients were not eligible to participate if they had received biological or other investigational agents within the previous 3 months prior to study enrolment, had received conventional systemic psoriasis therapy or phototherapy within the previous 4 weeks, or had received topical psoriasis treatment within 2 weeks. Other exclusion criteria were concomitant renal, gastrointestinal or haematological disease, a history of any malignancy, pregnancy or breast feeding, and clinically significant abnormal laboratory values in haematology, blood chemistry, or urine analysis. FAE were dosed according to the European S-3 guideline on systemic treatment of psoriasis and consisted of enteric-coated tablets containing 120 mg dimethylfumarate (DMF) and 95 mg

calcium-monoethylfumarate (MEF) (Apotheek de Magistrale Bereider, Oud-Beijerland, The Netherlands). The FAE dose was increased within 9 weeks up to a maximum daily dosage of 6 tablets. During the trial only neutral emollients were allowed. Monthly PASI scoring was performed during the trial. Lesional 3 mm skin biopsies were taken at baseline and after 12 weeks. We defined a significant clinical response as a PASI-improvement $\geq 75\%$ at week 12 compared to baseline, while non-responders were defined as having a PASI-improvement $< 50\%$. The clinical study protocol was approved by the local medical ethical committee (MEC 2005-105), and all patients gave written informed consent prior to study enrollment. The study was conducted according to the principles of the Declaration of Helsinki.

RNA processing and microarray hybridization

RNA was extracted from whole biopsies of 9 selected patients (4 responders and 5 non-responders) before and after 12 weeks of FAE treatment. RNA was extracted using the GeneElute Mammalian Total RNA kit (Sigma-Aldrich, Saint Louis, Missouri). RNA quality was checked with the Agilent RNA 6000 Nano LabChip and the Agilent 2100 Bioanalyzer, before 1 μg of total RNA of individual patients was hybridized to the GeneChip HG-U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Array hybridization and scanning was done as previously described.³⁴⁶

cDNA preparation

cDNA was made using 1 μg of total RNA template, with SuperScript II reverse transcriptase (Invitrogen, Carlsbad, California) and oligo(dT). PCR was performed using the ABI PRISM 7900 sequence-detection system (Applied Biosystems, Foster City, California). The PCR primer sequences and probe numbers are specified in Table 1.

Table 1. Primers and probes for quantitative RT-PCR.

Gene	Forward primer	Reverse primer	Probe
ABL1	TGGAGATAACACTCTAAGCATAACTAAAGGT	GATGTAGTTGCTTGGGACCCA	-
S100A7	CTGCTGACGATGATGAAGGA	CGAGGTAATTTGTGCCCTTT	60
IL-23p19	GTTCCCATATCCAGTGTGG	TCCTTTGCAAGCAGAACTGA	76

Probe numbers; from the Exiqon probe library system (Exiqon, Vedbaek, Denmark).

Statistical analysis

A quality check on the microarray data was performed using the *R* package "affyQCReport". Microarrays were then quantile normalised³⁴⁸ and background was removed using robust multichip analysis.³⁴⁷ Conditions were compared based on the perfect match (PM) probe intensity levels only by performing a per-probeset two-way analysis of variance, with factors "probe" and "condition". This resulted in average expression levels per condition

and a p -value for the difference between conditions. These p -values were adjusted for multiple testing using Šidák step-up adjustment.⁴⁷³ A gene was considered differentially expressed when its adjusted p -value was <0.05 and its fold change were greater than 2.

We utilized Ingenuity Pathway Analysis (IPA) (Ingenuity Systems 2012, Redwood City, California) to identify biological functions and pathways affected by FAE in psoriasis lesions and to more thoroughly understand the roles of the genes uniquely identified in this study as possible targets of FAE treatment.

Comparison material

The gene expression pathways affected by FAE treatment were compared with previously published data⁴⁷² concerning pathways affected by etanercept treatment (NCBI Gene Expression Omnibus GSE11903). In this study GeneChip HG-U133A v2 gene arrays were used to analyze gene expression in lesional skin biopsies (baseline and week 12) from 11 responding patients that were treated with etanercept 50 mg twice a week for 12 weeks. Responders were defined as having histological disease resolution at week 12 marked by decreased epidermal thickening and normalization of Ki67 and K16 expression. For comparison purposes, we selected the 22,277 probesets present both on these microarrays and our HG-U133A Plus 2.0 microarrays and analyzed these using the same methods as used on our full FAE data.


RESULTS

Clinical response to oral FAE treatment

The baseline characteristics of the selected patients (6 male and 3 female patients) with chronic plaque psoriasis are summarized in supplemental Table 2. The median age at the start of FAE treatment was 43 years (interquartile range (IQR) 33-56 years). All patients were treated according to the same scheme for 12 weeks with a daily dose of FAE up to 720 mg DMF and 570 mg MEF (supplemental Table 1). Overall, the median PASI reduction after 12 weeks of FAE treatment in these patients was 44.9% (IQR 39.8%-84.3%), considered statistically significant ($p=0.008$, Wilcoxon Signed Rank Test). The median PASI at baseline was 15.8 (IQR 12.9-20.2), which decreased to 7.2 (IQR 3.2-8.5) following 12 weeks of FAE-treatment. The median (IQR) changes in PASI during the 12-week treatment course with FAE are depicted in Figure 1 separately for responders (at least 75% PASI-improvement at week 12, $n=4$) and non-responders (less than 50% PASI-improvement at week 12, $n=5$). In responders, the median decrease in PASI was 84.3% (IQR 77.5%-89.4%), while among non-responders the median PASI decrease was 40.4% (IQR 34.8%-44.7%). The differ-

Table 2: Top 20 of genes significantly down-regulated in responders following 12 weeks of treatment with FAE, sorted by fold change .

Gene name	Description	Fold change	Adjusted p
SERPINB4	serpin peptidase inhibitor	-70.51	5.44×10^{-10}
DEFB4A/DEFB4B	defensin, beta	-55.43	$< 10^{-12}$
S100A7A	S100 calcium binding protein	-47.66	$< 10^{-12}$
TCN1	transcobalamin I (vit B12 binding protein)	-35.59	$< 10^{-12}$
S100A12	S100 calcium binding protein	-25.51	6.03×10^{-12}
KRT16	keratin 16	-20.06	$< 10^{-12}$
PI3	peptidase inhibitor, skin derived	-19.17	6.03×10^{-12}
IL8	Interleukin 8	-17.02	6.03×10^{-12}
KRT17	keratin 17	-15.71	$< 10^{-12}$
SPRR2C	small proline-rich protein	-15.33	5.91×10^{-9}
IL19	interleukin 19	-14.81	1.14×10^{-10}
LCN2	lipocalin 2	-14.06	$< 10^{-12}$
KLK6	kallikrein-related peptidase	-11.90	6.03×10^{-12}
KRT6A	keratin 6A	-11.26	$< 10^{-12}$
KRT6B	keratin 6B	-10.99	$< 10^{-12}$
MMP1	matrix metallopeptidase	-10.49	$< 10^{-12}$
LTF	lactotransferrin	-9.93	7.62×10^{-9}
RHCG	Rh family C glycoprotein	-9.67	$< 10^{-12}$
CXCL1	chemokine (C-X-C- motif) ligand 1	-8.87	$< 10^{-12}$
ATP12A	ATPase, H+/K+ transporting nongastric alpha polypeptide	-8.61	2.12×10^{-8}

**Figure 1:** (a) Change in PASI in patients during FAE treatment with at least 75% PASI-improvement (responders, n=4) and in patients with less than 50% improvement (non-responders, n=5) *p<0.05 week 0 versus week 12. (b) PASI reduction in responders and non-responders after 12 weeks **p<0.02, Mann-Whitney U test). Bars present median and interquartile range.

ence in PASI reduction between responders and non-responders was significantly different ($p=0.016$, Mann-Whitney U test).

Table 3: Relevant canonical pathways, indicated by Ingenuity Pathway Analysis, affected by FAE in responders (top 10) and non-responders (top 5) following 12 weeks of FAE treatment.

Canonical pathways			
FAE responders	p-value	Up-regulated	Down-regulated
Role of IL-17A in psoriasis	8.98E ⁻¹¹		CCL20, CXCL1, CXCL6, DEFB4A/DEFB4B, IL8, IL17A, S100A8, S100A9
Role of cytokines in mediating communication between cells	3.78E ⁻⁷	IL37	IL8, IL20, IL24, IL12B, IL17A, IL1A, IL1B, IL1RN, IL36A, IL36G, IL36RN
Atherosclerosis signaling	1.75E ⁻⁶	IL37, PLA2R1	ALOX12B, ALOX15B, IL8, IL1A, IL1B, IL1RN, IL36A, IL36G, IL36RN, MMP1, PLA2G3, PLA2G2A, PLA2G4D, S100A8, SERPINA1
Dendritic cell maturation	1.13E ⁻⁴	IL37, LEPR, PIK3C2G, PLCB4	CCR7, FCGR1A, FCGR1B, FCGR3B, IL12B, IL1A, IL1B, IL1RN, IL36A, IL36G, IL36RN, LTBR, STAT1
LXR/RXR activation	1.4E ⁻⁴	IL37	ARG2, CCL7, IL1A, IL1B, IL1RN, IL36A, IL36G, IL36RN, LDLR, NOS2, S100A8, SAA1, SERPINA1
IL-10 signaling	2.16E ⁻⁴	IL37	ARG2, IL1A, IL1B, IL1RN, IL36A, IL36G, IL36RN, IL4R, STAT3
p38 MAPK signaling	2.74E ⁻⁴	EEF2K, HSPB3, IL37	IL1A, IL1B, IL1RN, IL36A, IL36G, IL36RN, PLA2G3, PLA2G2A, PLA2G4D, STAT1
Eicosanoid signaling	3.36E ⁻⁴	AKR1C3, PLA2R1	ALOX12B, ALOX15B, FPR2, LTBR, PLA2G3, PLA2G2A, PLA2G4D
Communication between innate and adaptive immune cells	3.49E ⁻⁴	IL37	CCR7, IL8, IL12B, IL1A, IL1B, IL1RN, IL36A, IL36G, IL36RN
LPS/IL-1 mediated inhibition of RXR function	8.08E ⁻⁴	ABCC3, ALDH3A2, ALDH6A1, GSTM3, HS3ST6, IL37, SULT1E1, UST	ALAS1, ALDH1A3, HMGCS1, HS3ST3A1, IL1A, IL1B, IL1RN, IL36A, IL36G, IL36RN
FAE non-responders	p-value	Up-regulated	Down-regulated
Glutathione redox reactions	7.92E ⁻⁴	GPX2, MGST1	
Putrescine biosynthesis III	5.63E ⁻³	ODC1	
NRF2-mediated oxidative stress response	1.29E ⁻²	GPX2, MGST1, NQO1	
Superoxide radicals degradation	1.68E ⁻²	NQO1	
Xenobiotic metabolism signalling	7.92E ⁻⁴	MGST1, NQO1, PPARGC1A	

Differentially expressed genes in responders to FAE

Successful FAE treatment is linked to the down-regulation of IL-17 pathway genes and the inhibition of Th17 development

The IL-17 pathway was most significantly affected in responders, with a down-regulated expression of CCL20, CXCL1, CXCL6, DEFB4 (β -defensin 2), IL-8, IL-17A, S100A7 (psoriasin), S100A8 (calgranulin-A) and S100A9 (calgranulin-B) (Table 3).

This suggests that inhibition of the IL-17 pathway constitutes a major part of the mechanism of action of FAE. An important transcription factor of the Th17 pathway is STAT3. It is activated by the Th17 cytokine IL-22 and regulates the transcription of many genes specifically associated with psoriasis, such as antimicrobial peptides, chemokines and acute phase proteins.⁴⁷⁴ STAT3 expression was significantly down-regulated at week 12.

The NFKBIZ gene is important for the expression of nuclear protein I κ B ζ , which plays a role in the IL-17 pathway. It has been shown that NFKBIZ $-/-$ mice are not able to produce Th17 cells.⁴⁷⁵⁻⁴⁷⁶ Our data show that FAE down-regulate the expression of the NFKBIZ gene (-2.96 fold), and thereby directly interfere with I κ B ζ expression and subsequent Th17 development.

FAE treatment induces the glutathione and Nrf2-pathway

In vitro data show that FAE can interfere in the glutathione pathway by depleting intracellular glutathione that eventually leads to the induction of heme oxygenase-1 (HO-1) and inactivation of STAT1 and eventually to immunosuppression.⁴⁷⁷ In responders we found several up-regulated genes that are important for this glutathione depletion in the glutathione pathway, including several glutathione transferases and dehydrogenases such as GPX2, NQO1, GSTM3, and GPAM. Interestingly, in non-responding patients 2 genes were down-regulated and 33 were up-regulated including also several glutathione transferases such as GPX2, NQO1 and MGST1. Unexpectedly, during FAE treatment HO-1 was not significantly up-regulated, in contrast STAT1 expression was significantly down-regulated ($p = 0.03E-2$) FAE treatment affected several other pathways involved in immune regulation and inflammation (Figure 3). In addition, FAE treatment significantly affected several molecules that are part of the nuclear factor erythroid 2-related factor (Nrf-2) mediated oxidative stress response pathway including up-regulation of NQO1 and GSTM3. Activation of this pathway has previously been shown to be important in the neuroprotective effect of FAE in MS patients.⁴⁷⁸⁻⁴⁷⁹

FAEs down-regulate antimicrobial peptides and the IL-1 family of cytokines

Antimicrobial peptides are significantly up-regulated in psoriatic skin and are involved in the pathogenesis of the disease.²⁰¹ Effective FAE treatment was associated with a down-




Figure 3: Comparison of gene expression profiles in psoriatic skin of patients achieving $\geq 75\%$ improvement in PASI score following 12 weeks of treatment with either oral FAE or etanercept. (a) Venn-diagram comparing the overlap in genes significantly (> 2 fold change and $p < 0.05$) down- or up-regulated following 12 weeks of treatment. (b) Top 20 of relevant canonical pathways of differentially expressed genes in responders. (c) Canonical pathways affected by both FAE and etanercept.




Figure 2: Down-regulated mRNA expression of S100A7, but no change in IL-23p19 mRNA expression in responding patients after 12 weeks of FAE treatment. Quantitative RT-PCR of n=4 responders (R) and n=5 non-responders (NR) using mRNA extracted from lesional biopsies from psoriatic skin at baseline and after 12 weeks of FAE treatment. The Y axis shows expression relative to that of the housekeeping gene ABL1. *p<0.05

regulation of S100A7 (psoriasin). When validating this finding with quantitative RT-PCR, we confirmed a significant decrease in S100A7 after 12 weeks (Figure 2). The IL-1 family of cytokines is important in psoriasis and it was shown that IL-1F9 (IL36 γ) can induce the expression of AMP⁴¹⁴ and that IL-36 signaling is involved in generalized pustular psoriasis.⁴⁸⁰ In our study, FAE treatment down-regulated IL-36 α (IL-1F6) and IL-36 γ (IL-1F9) expression. Other cytokines that were down-regulated were IL-17A, IL-19 and IL-20.

FAE normalize keratin and epidermal barrier gene expression

Due to epidermal hyperproliferation, psoriatic skin expresses a different mix of keratins than normal healthy skin.⁴⁸¹⁻⁴⁸² In the FAE treated responders several up-regulated keratin genes were detected, including keratin 15 (K15), which is down-regulated in activated keratinocytes and in psoriatic skin.⁴⁸¹⁻⁴⁸² Thus the up-regulation of K15 in FAE treated responding patients was illustrative for the transition to normal skin. Similarly, the expression of keratin 16 and 17, markers of keratinocyte proliferation that are up-regulated in psoriatic skin, were significantly down-regulated in FAE responders after 12 weeks. The epidermal differentiation complex consists of several molecules that are differentially expressed in psoriasis and that are critical for barrier homeostasis.^{223 483} As expected, several of these molecules, such as involucrin (IVL) and late cornified envelope D (LCE3D), were significantly down-regulated after 12 weeks in responders to FAE treatment.

FAE induce T cell inhibitor gene expression

Cyclosporin and tacrolimus are often used for the treatment of psoriasis and these therapies inhibit the activation and differentiation of T cells via the inhibition of calcineurin.⁴⁸⁴ The calcineurin B homologous protein 2 (CHP2) gene is responsible for the inhibition of calcineurin B and thereby affects T cell activation. CHP2 was significantly up-regulated in FAE treated responders (2.4 fold), in line with the inhibitory effect of FAE on T cell activation.⁴⁸⁴ No differences were seen in CD3, CD4, CD8 and FOXP3 expression levels.

FAE do not affect IL-23p19 expression levels

Inflammatory myeloid dendritic cells (CD11C+ and CD1C-) can produce iNOS, IL-20, TNF- α and IL-23 and are important in the pathogenesis of psoriasis.⁴⁸⁵⁻⁴⁸⁷ FAE can modulate the differentiation of dendritic cells *in vitro*, inducing type II dendritic cells that do not produce IL-23p19.⁴⁸⁸ Therefore we assessed the expression levels of iNOS, IL-20 and IL-23 before and after successful FAE treatment, but we did not detect a difference. Because microarrays have been shown to be less reliable for detecting quantitative differences in the expression levels of IL-23, we also checked the mRNA expression levels of IL-23 by RT-PCR.⁴⁸⁹ However, we found no difference in IL-23p19 expression after treatment (Figure 2). The expression level of IL-20 was significantly down-regulated after 12 weeks (-5.5 fold). We also analyzed a possible alteration in expression levels of CD11C and CD1C, but did not observe differences in the expression of these markers.

FAE reduce pentraxin-3 expression; an important atherosclerosis marker

Psoriasis is associated with cardiovascular disease, but it is unclear whether this relationship is causal.⁴⁹⁰ In rheumatoid arthritis there is accumulating data indicating that anti-inflammatory treatment decreases the risk of cardiovascular disease.⁴⁹¹ In psoriasis a similar mechanism has been proposed but not fully elucidated. Interestingly, only in responding patients to FAE treatment the atherosclerosis signaling pathway was clearly affected, by down-regulation of several molecules including ALOX12B (Table 3). In addition, pentraxin-3 (PTX3) has recently been proposed as a marker of atherosclerosis.⁴⁹² The expression of PTX3 was significantly down-regulated after 12 weeks of FAE treatment and only in responding patients.

MMP-1 may predict FAE treatment outcome

We compared responders and non-responders at baseline to see whether it was possible to identify responders or non-responders beforehand. This comparison yielded differentially expressed molecules including the matrix metalloproteinase-1 (MMP1) gene. MMP1 can be induced by IL-22²⁴² and is important in cellular mobility; its expression is up-regulated in psoriasis.⁴¹⁴ In FAE treated patients, MMP1 expression was found to be significantly higher in responders at baseline ($p=0.02$) (Figure 2).

Comparison of gene expression profiles between FAE and etanercept

The list of differentially expressed genes in FAE responders before and after treatment was compared with the list of differentially expressed genes before and after a 12-week treatment with etanercept. When using the same cutoff values (>2 fold change, $p<0.05$) we found 320 changed genes for the responders treated with etanercept of which 112 genes were up-regulated and 208 genes were down-regulated. We compared the change in gene expression of psoriasis related molecules during FAE and etanercept treatment

and found an overlap of 122 significantly down-regulated genes and of 35 significantly up-regulated genes. Overlapping down-regulated genes included CCL20, CXCL1, DEFB4 and several S100 family proteins. All overlapping genes are known markers of the psoriatic transcriptome⁴⁹³⁻⁴⁹⁴ and appear to be important during lesion clearance as they were down-regulated during FAE as well as etanercept treatment.

HBEGF and CD11C are myeloid specific genes that are over expressed in psoriatic skin. Etanercept treatment down-regulates these genes after 12 weeks to non-lesional levels.⁴⁷² FAE treatment reduced HBEGF significantly, however CD11C was not reduced. Etanercept and FAE treatment affected several similar pathways including the IL-17A and atherosclerosis signalling pathway.

DISCUSSION

In this study we assessed the mode of action of FAE and compared microarray analyses of two systemic psoriasis treatments. Our findings show that FAE affect IL-17 pathway genes and that they can regulate the transcription factor NFκBIZ, important in Th17 development.⁴⁷⁵⁻⁴⁷⁶ These are crucial factors in the pathogenesis of psoriasis.⁴⁰¹

Interestingly, in non-responding patients 2 genes were down-regulated and 33 were up-regulated including several glutathione transferases, which were also up-regulated in responders. These transferases are part of the glutathione signalling, which consists of several genes, including glutathione depletion enzymes as MGST1 and GPX2. *In vitro* experiments have shown that FAE deplete intracellular glutathione, which is followed by the induction of the anti-inflammatory stress protein heme oxygenase 1 (HO-1) and the inactivation of the transcription factor STAT1. Induction of HO-1 prevents IL-23p19 transcription and by silencing STAT1 phosphorylation prevents IL-12p35 transcription. Consequently, FAE modulate the IL-17 pathway.⁴⁷⁷ However, HO-1 was not significantly induced and unexpectedly, when investigating IL-23 expression levels in the skin using quantitative RT-PCR, we did not find any significant differences. Therefore it seems that the glutathione mechanism is not the only factor by which FAE induce improvement of psoriasis.

The Nrf-2 plays a role in inflammation. FAE can activate the Nrf-2 pathway and thereby modulate neuroinflammation in MS patients.⁴⁷⁹ The nervous system and neuronal factors promote inflammation in psoriasis lesions, which is characterized by a high density of nerves and an increased expression of neuropeptides in psoriatic lesions such as NGF and SP.⁴²⁸ Interestingly, in our study molecules of the Nrf-2 pathway were up-regulated in responders as well as in non-responders, which suggests that the activation of this pathway is FAE specific, but not crucial for plaque clearance.

FAE are effective in 50-70% of patients and the effect of treatment can be judged after 12-16 weeks.⁴⁶⁷ Prediction of treatment outcome would be convenient and time efficient. MMP1 was significantly up-regulated in responders at baseline compared to non-responders ($p=0.02$). MMP1 could be an interesting molecule to investigate further as a possible marker for failure to FAE treatment .

We compared our findings of FAE treatment with a previously published study that investigated gene expression during etanercept treatment. The comparison shows that FAE and etanercept have an overlap in the affected pathways leading to psoriasis improvement, including the IL-17 pathway.⁴⁷² Another interesting finding is that FAE and etanercept treatment both up-regulated atherosclerosis signalling. Several studies have proposed a relation between psoriasis and the risk of cardiovascular disease.⁴⁹⁰ However, the exact relationship is not yet fully understood. It has been shown that several cardiovascular markers that are overexpressed in psoriatic skin are also increased in the circulation of these patients.⁴⁸⁹ Rheumatoid arthritis patients responding to anti-TNF- α therapy have a decreased risk of cardiovascular disease.⁴⁹⁵ A prospective analysis showed systemic anti-psoriatic therapy to ameliorate biomarkers of cardiovascular risk, the effect also being correlated to clinical treatment response.⁴⁹⁶ In addition, we show that successful FAE treatment in psoriasis patients leads to a reduction of the marker pentraxin-3, a marker of cardiovascular disease.⁴⁹²

In conclusion, FAE modulate crucial components of the immune system that are important in the pathogenesis of psoriasis, such as NF- κ B, pro-inflammatory cytokines, adhesion molecules and dendritic cells. In addition, down-regulation of the IL-17 pathway, the transcription factor NF κ BIZ and consequent inhibition of Th17 development is firmly linked to effective FAE treatment. Glutathione and Nrf2 signalling seem not to be linked to clearance of psoriasis because molecules of these pathways are induced in both responders and non-responders.

Acknowledgements

We thank S. Fallah Arani (MD) for help in collecting patient material.




Figure 4. Model for the mode of action of FAE treatment in psoriasis

In MMP1 + psoriasis plaques, FAE treatment modulates crucial components in the pathogenesis of psoriasis including down-regulation of Th17 development. This results in reduction of pentraxin-3, which is a marker of cardiovascular disease.

SUPPLEMENTARY MATERIAL

Supplementary Table 1: Dosage schedule of fumarates.

Week	Fumarates 105 mg	Fumarate 215 mg
1	1 tablet per day	-
2	2 tablets per day	-
3	3 tablets per day	-
4	-	1 tablet per day
5	-	2 tablets per day
6	-	3 tablets per day
7	-	4 tablets per day
8	-	5 tablets per day
9	-	6 tablets per day
10	-	6 tablets per day
11	-	6 tablets per day
12	-	6 tablets per day

Fumarates 105 mg (Apotheek Magistrale Bereider, Oud-Beijerland, the Netherlands) contains per enteric-coated tablet 30 mg dimethylfumarate and 75 mg calcium-monoethylfumarate.

Fumarates 215 mg (Apotheek Magistrale Bereider, Oud-Beijerland, the Netherlands) contains per enteric-coated tablet 120 mg dimethylfumarate and 95 mg calcium-monoethylfumarate.

Supplementary Table 2: Overview of demographic and clinical characteristics of the study population

No.	Sex	Age at start FAE (in years)	Disease duration (in years)	Previous systemic treatments	PASI at week 0	PASI at week 12	PASI reduction at week 12 (%)
1	Male	68	2	None	19,9	4,7	76
2	Female	43	1	None	21,2	4,1	81
3	Female	27	14	None	16,7	2,0	88
4	Male	71	9	None	21,7	2,2	90
5	Male	44	1	None	13,6	7,5	45
6	Male	43	15	PUVA, UVB phototherapy, methotrexate, cyclosporine, infliximab, adalimumab	12,5	7,6	39
7	Male	35	1	None	13,0	7,2	45
8	Female	30	19	None	15,8	11,0	30
9	Male	37	1	None	15,6	9,3	40

Supplementary Table 3: Top 5 differentially expressed transcriptional regulators following 12 weeks of FAE treatment in responders.

Gene name	Description	fold change	p
NFKBIZ	transcription regulator	-2.96	2.96×10^{-3}
EHF	transcription regulator	-2.53	1.39×10^{-2}
STAT3	transcription regulator	-2.28	4.72×10^{-4}
PTTG1	transcription regulator	-2.22	4.58×10^{-2}
CEBPD	transcription regulator	-2.20	2.12×10^{-2}

Chapter 8

The efficacy of topically applied cyclosporin in nail psoriasis: a prospective, double-blinded, randomized, placebo-controlled study

Ewout M. Baerveldt¹, Lizenka A. Torque¹, Marjon C.H. De Jong¹, Annik M.W. Van Rengen², and Errol P. Prens¹

Department of Dermatology¹, Erasmus University MC, Rotterdam, and MOHS Clinics², Dordrecht, The Netherlands.

F1000 Research, *accepted for publication*

Chapter 9

Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis

Emőke Rácz^{1,2*}, Jaap de Leeuw^{1*}, Ewout M. Baerveldt^{1,2}, Marius Kant^{1,2}, H.A. Martino Neumann¹, Leslie van der Fits^{1,2}, and Errol P. Prens^{1,2}

Department of Dermatology¹, and Immunology,² Erasmus University MC, Rotterdam, The Netherlands. *These authors share first authorship.

Lasers in Surgery and Medicine 2010; 42:201-10

BACKGROUND

Pulsed dye laser (PDL) therapy is effective in clearing psoriasis plaques, but the mechanism of action is only partially understood. Local narrow-band ultraviolet B (NB-UVB), which has a better defined mode of action, is an effective standard treatment for psoriasis. Our aim was to evaluate the cellular and molecular effects of PDL and to compare them with those of local NB-UVB in order to gain further insight into their mechanisms of action in psoriasis.

MATERIAL AND METHODS

Nineteen patients with stable plaque-type psoriasis were treated either with PDL or NB-UVB. Lesional punch biopsies were obtained from all patients before treatment. Additional biopsies were obtained at 3 and 24 hours after PDL treatment in five of these patients. In 14 patients additional biopsies were taken after 7 and 13 weeks of treatment. Samples were histopathologically examined for the level of dermal T cell infiltrate, and the expression of epidermal b-defensin 2, immune cell-derived tumor necrosis factor (TNF)- α , endothelial E-selectin, vascular endothelial growth factor receptor (VEGFR) 2 and 3, and the expression of interleukin (IL)-23 before and after treatment.

RESULTS

The expression of VEGFR2, VEGFR3, and E-selectin was decreased in clinically high responders within 24 hours after PDL treatment. The expression of IL-23, TNF- α mRNA, and E-selectin protein were significantly reduced after two PDL treatments, whereas the expression of all epidermal markers and dermal T cell infiltrates had normalized after four treatments. The expression of epidermal activation markers and E-selectin were significantly reduced after 13 weeks of NB-UVB treatment.

CONCLUSIONS

The expression of epidermal activation markers and the dermal T cell infiltrates were decreased after both treatments. The decreased expression of VEGFR2 and VEGFR3 followed by the down-regulation of TNF- α and IL-23p19 may be contributory factors in the efficacy of PDL in stable plaque-type psoriasis.

INTRODUCTION

The dilation and proliferation of the dermal papillary microvasculature is one of the early changes seen in a new psoriatic plaque.⁵⁰⁶ The increased dermal microvasculature facilitates the traffic of leukocytes from the circulation into the skin and therefore plays an important role in maintaining inflammation in psoriasis.⁵⁰⁷ Interference with leukocyte trafficking via a selective destruction of the dilated capillaries may be an effective therapeutic intervention in psoriasis. Selective targeting of blood vessels may be achieved with the flash-lamp pumped pulsed dye laser (PDL).⁵⁰⁸ The effect of the PDL treatment is based on the selective absorption of short pulses of 585nm light by oxy-hemoglobin inducing photothermolysis of capillaries leaving the other nearby structures in the skin undamaged.⁵⁰⁹ Several studies reported that psoriatic plaques were partly or completely cleared by PDL treatment.⁵¹⁰⁻⁵¹³ In a comparative study, PDL showed a significantly higher efficacy than a class II topically applied corticosteroid.⁵¹³ PDL was also effective in clearing recalcitrant psoriatic plaques,⁵¹⁴ whereas palmoplantar psoriasis responded well to treatment with PDL alone or in combination with topical calcipotriol or salicylic acid.⁵¹⁵

Narrow-band ultraviolet B (NB-UVB) therapy is a standard treatment modality for psoriasis. The mechanism of action of UVB has been investigated more thoroughly than that of PDL. It is known that UVB targets the epidermal compartment, inhibiting the proliferation of keratinocytes, abrogating antigen presentation, migration of Langerhans cells,⁵¹⁶ and inducing apoptosis of activated skin-homing T cells.⁵¹⁷⁻⁵¹⁸ Prolonged exposure to UVB light and a high cumulative dose may result in premature ageing of the skin and lead to a higher risk of skin cancer. However, recent follow-up studies in patients receiving NB-UVB for psoriasis did not report any increase in the incidence of skin cancer as compared to controls.⁵¹⁹⁻⁵²⁰ Long-term side effects of PDL treatment have not yet been reported. No significant differences in the clinical efficacy between PDL and NB-UVB were reported in a single-blind, prospective, paired randomized controlled study,⁵²¹ indicating that PDL is a valid treatment modality for psoriasis. However, to date there is only a poor insight into the cellular and the molecular mechanisms that are affected by PDL explaining its efficacy in psoriasis.

The aim of the present study was to investigate the effects of PDL treatment on the cellular and the molecular markers of disease activity in psoriasis using immunohistochemical and quantitative real-time (RT)-PCR techniques and lesional skin biopsies taken before, during and at the end of treatment and compare them with those of NB-UVB treatment.

MATERIAL AND METHODS

Patients and Biopsies

Nineteen patients with stable plaque type psoriasis were enrolled into the study after they had provided written informed consent. Patient characteristics are summarized in Table 1. In stable plaque type psoriasis, plaques persist on the same anatomical site for at least 6 months despite treatment. The study was approved by the Medical Ethical Committee, Erasmus MC, University Medical Center, Rotterdam (approval number: MEC-2004-154). Patients intolerant to light (toxic or allergic), using drugs with phototoxic or photo-allergic potency, younger than 18 years, were pregnant, or with pre-existing or manifest skin malignancy were excluded. A washout period of 2 weeks was indicated for topical drugs and of 4 weeks for photo (chemo) therapy and systemic drugs. Emollients were allowed. One representative psoriasis plaque was selected for a punch biopsy before treatment (baseline) in each patient. In five patients (two women and three men aged 45–59 years) additional 3-mm punch biopsies were taken at 3 and 24 hours after the first PDL treatment for examining the

Table 1. Patient characteristics and biopsy locations

Patient	Age	Gender (M/F)	Skin phototype	Biopsy body site location		
				Before treatments	PDL	UVB
1	65	M	III	Right ankle	Right ankle	Right wrist
2	20	F	I	Left elbow	Right elbow	Left knee
3	48	F	II	Left leg	Left elbow	Right elbow
4	49	F	III	Left arm	Right knee	Left arm
5	53	M	III	Right leg	Left elbow	Right elbow
6	62	M	III	Left leg	Left leg	Right leg
7	46	F	III	Right elbow	Right elbow	Left knee
8	50	M	III	Left knee	Left elbow	Right elbow
9	57	M	III	Right elbow	Left knee	Right knee
10	35	M	III	Right leg	Right elbow	Left leg
11	48	F	III	Left elbow	Left elbow	Right elbow
12	53	F	III	Right elbow	Right knee	Left elbow
13	56	M	III	Left leg	Right leg	Left knee
14	23	F	III	Right elbow	Left elbow	Right elbow
15	45	M	II	Left elbow	Left elbow	—
16	46	F	II	Left knee	Left knee	—
17	56	F	II	Left elbow	Left elbow	—
18	59	M	II	Left leg	Left leg	—
19	59	M	II	Left knee	Left knee	—

short-term effects. The psoriasis plaques were randomly selected and treated either with PDL or with NB-UVB or left untreated in the remaining 14 patients (7 women and 7 men aged 20–65 years). Treatment schedule of the selected plaques is described in detail by de Leeuw et al.⁵²¹ Two 3-mm punch biopsies, one from a PDL-treated site and one from a NB-UVB-treated site were taken at week 7 (after 2 treatments of PDL and 18 treatments with NB-UVB) and at week 13 (after 4 treatments of PDL and 30–33 treatments of NB-UVB) from each of these 14 patients. Locations of the biopsies are shown in Table 1. The punch biopsies were snap-frozen in Tissue-Tek OCT and stored at -80°C until further processing.

Treatments

The V Star PDL (Cynosure, Inc., Chelmsford, MA), emitting yellow light at a wavelength of 585nm was used for PDL treatment. The skin was air-cooled using a Zimmer Cryo 6 cooler (Zimmer Elektromedizin, Neu-Ulm, Germany) during the treatment. The PDL treatment parameters were fluence between 5.5 and 6.5 J/cm² with pulse duration of 0.50 milliseconds at 7 mm spot size and ~20% overlap. Patients were treated with the PDL every 3 weeks for 10 weeks, a total of four treatments. The UVB-TL01 S (wavelength 311 nm) handheld device (Cosmedico Medizintechnik GmbH, Villingen-Schwenningen, Germany) was used for the NB-UVB treatment. Mean UV-output was 19.4mW/cm². The devices were calibrated with the Optometer P 9710 (Gigahertz Optik, Puchheim, Germany) before treatment. The aperture of the appliance (5.0-10.0 cm²) was held against the skin assuring that the distance between the device and the skin was constant in each patient during the treatment. Minimal erythema dose (MED) was determined in each patient prior to the study. Mean MED of NB-UVB was 0.86 J/cm² (range 0.34–1.2 J/cm²). NB-UVB treatment (three times per week) parameters were: a start dose of 70% of the MED, dose increments of 20% of the previous treatment until persistent erythema appeared or clearing of the lesion was achieved. A total of 30–33 treatments were given during 11 weeks. Mean initial dose was 0.62 J/cm² (range 0.24–0.86 J/cm²), mean cumulative dose 84 J/cm² (range 40–120 J/cm²). Plaques were randomly chosen and treated with PDL, NB-UVB or only with emollient in each patient. Concomitant topical treatment with salicylic acid 5% in petrolatum was permitted for all plaques in between the treatment sessions to reduce reflectance of the PDL and the NB-UVB beam by scales, but was discontinued 2 days before the PDL treatment and directly before the NB-UVB treatment. Clinical efficacy was assessed as described previously.⁵²¹

Immunohistochemistry

Cryostat sections (6 mm) were cut from each punch biopsy, mounted on glass slides, fixed in acetone and stained for markers of psoriasis using antibodies shown in Table 2. Endogenous peroxidase activity was neutralized using 4-chloro-1-naphthol. The slides were washed in phosphate-buffered saline (PBS) containing 0.05% Tween-20 and 0.5% bovine

Table 2. Antibodies used in the study

Antibody	Target molecule	Supplier	Species	Titer
Anti-TGK	Transglutaminase K	Biomedical Technologies, Inc.	Mouse	1:200
Anti-CD3	CD3	Dako	Rabbit	1:100
Anti-vWF	Von Willebrand's factor	Abcam	Rabbit	1:25,000
Anti-E-selectin	E-selectin (CD62E)	R&D systems, Inc.	Mouse	1:20

serum albumin (BSA) and incubated with the appropriate dilution of the primary antibodies (Table 2) for 1 hour at room temperature. They were subsequently incubated with biotinylated secondary antibodies (rabbit-anti-mouse IgG (Dako, High Wycombe, UK, 1:400) or donkey-anti-rabbit IgG (Amersham Biosciences, 1:800)) for 30 minutes and with horseradish peroxidase (HRP)-linked streptavidin (Dako) for 1 h at room temperature. Any non-specific staining was prevented by adding unlabeled (normal) secondary antibody and normal human AB serum. HRP activity was visualized with amino-9-ethylcarbazole (Sigma-Aldrich, St. Louis, MO) as a chromogen, resulting in a bright red staining. Sections were counterstained with hematoxylin and mounted in glycerin–gelatin (Dako).

After initial semi-quantitative scoring, a representative region was selected in each glass slide and photographed at 100x magnification using an AxioCam MRc5 camera (Zeiss, Goettingen, Germany). The acquired images were analyzed by computer-assisted image analysis using the WCIF Vision J (<http://rsb.info.nih.gov/ij>) software. The area occupied by the stained tissue was expressed as a fraction of the total area of interest (i.e., epidermis or dermis).

RNA extraction and RT-PCR

RNA extraction from whole biopsies was performed as follows. Twenty 10 mm cryostat sections were cut under RNAase-free conditions from each punch biopsy, directly placed in RNA lysis buffer (Sigma-Aldrich) followed by mRNA extraction. RNA was transcribed into cDNA and RTPCR was performed using newly designed primers and probes. ABL1 (Abelson murine leukemia viral (v-abl) oncogene homolog 1) was used as a housekeeping control gene. Primer and probe sequences are listed in Table 3.

Statistical Analysis

For statistical analysis of the quantitative data, the Wilcoxon signed ranks test and the Kruskal–Wallis test were used for unpaired and paired sets of data, respectively.

Table 3. Primer sequences

Gene	Forward primer	Reverse primer	Probe no
K17	TTGAGGAGCTGCAGAACAAAG	AGTCATCAGCAGCCAGACG	76
hBD-2	TCAGCCATGAGGGTCTTGTA	GGATCGCCTATACCACCAAA	35
TNF- α	CAGCCTCTTCTCCTCCTGAT	GCCAGAGGGCTGATTAGAGA	29
IL-23p19	GTTCCCCATATCCAGTGTGG	TCCTTTGCAAGCAGAACTGA	76
E-selectin	ACCAGCCCAGGTTGAATG	GGTTGGACAAGGCTGTGC	86
VEGF-A	TGCCCCTGCTGTCTAAT	TCTCCGCTCTGAGCAAGG	1
VEGFR2	GCTCAAGACAGGAAGACCAAG	GGTGCCACACGCTCTAGG	27
VEGFR3	CAAGAAAGCGGCTTCAGGTA	GCAGAGAAGAAAATGCTGACG	8
Bcl2	CAACACGCAGAGAATGTAAGC	GGTAGGAGCTGTGGCGACT	45
ABL1	TGGAGATAAACTCTAAGCATAACTAAAGGT	GATGTAGTTGCTTGGACCCA	-

RESULTS

Clinical Assessment

The Physician's Global Assessment (PGA) score was used to establish clinical improvement. The PGA score is a 5-point scoring system, where score 0 denotes symptom free state, whereas scores 1–5 represent increasing severity. Definition of each score, as well as the clinical outcomes of the study have been reported in more detail by de Leeuw et al. [16]. The results of the present study showed that the mean clinical improvement (mean reduction in the PGA score) at week 13 was 46% for the PDL-treated plaques and 52% for the NB-UVB-treated plaques indicating that the clinical efficacy of both treatments were comparable (data not shown). Six high responders (defined as a PGA reduction >50%) were selected from the 14 patients in order to evaluate the effects of both treatments. Clinical improvement during the treatments as assessed by the PGA score in the whole group and in the six high responders during both treatments is shown in Figure 1. We observed the following adverse effects after PDL treatment: transient purpura (occasionally accompanied by crusts) for 1–2 weeks, moderate discomfort (which is considerably reduced by cooling the skin during treatment), and evident but transient hyperpigmentation.

Regarding side effects of the UVB treatment, most patients observed hyperpigmentation, whereas a small group reported pain and sunburn erythema.

Early effects of the pulsed dye laser

Early changes (within 24 h) in psoriasis plaques upon PDL treatment were investigated in order to elucidate the mechanism of action. No changes were observed in mRNA expression levels of markers of the activated epidermal psoriasis phenotype such as hBD2 and keratin 17 (KRT17), TNF- α , and vascular endothelial growth factor (VEGF)-A in biopsies taken 3 and




Figure 1. Clinical improvement in the psoriatic lesions during PDL and local NB-UVB treatment from baseline to week 13. In each patient, stable psoriatic plaques were randomly selected and treated with PDL or local NB-UVB. Clinical improvement was evaluated using the Physician's Global Assessment (PGA) score. a,b: The average clinical improvement in the 14 patients. c,d: The average clinical improvement in six patients with high clinical response. Error bars represent the standard error of the mean (SEM). Statistically significant changes are marked with asterisks.

24 h after PDL treatment. The expression of the anti-apoptotic, heat-regulated molecule Bcl2 (B cell LL/lymphoma 2) also remained unaltered at the same time points. The expression of the endothelial molecule vascular endothelial growth factor receptor (VEGFR)2 and the lymphatic marker VEGFR3 was significantly decreased to an average of 64% ($p=0.043$) and 47% ($p=0.042$), respectively, in the biopsies taken 3 hours after PDL treatment (Figure 2a,b). Expression of these molecules returned to baseline after 24 h. In the biopsies taken at 24 h, the expression of E-selectin was significantly reduced to an average of 64% ($p= .042$) (Figure 2c). The expression of IL-23p19 mRNA was reduced, although not significantly at 3 and 24 hours after the PDL treatment (Figure 2d). In summary, the PDL treatment reduced the expression of VEGFR2 and VEGFR3 mRNA as early as 3 hours, whereas E-selectin expression was significantly reduced 24 h after treatment. The expression of IL-23p19 mRNA was also inhibited by PDL treatment, although not significantly at 3 and 24 h.

Long-term alterations at the mRNA level

Selected psoriasis plaques were treated either with PDL or with local UVB in 14 patients. The PDL treatment was carried out every 3 weeks for 10 weeks (a total of four treatments), whereas NB-UVB treatment was three times weekly with increasing doses. The mRNA ex-




Figure 2. The effects of the PDL on the expression of the vascular endothelial growth factor receptors, E-selectin and IL-23p19 in psoriatic skin. The expression of (a) VEGFR2, (b) VEGFR3, (c) E-selectin, and (d) IL-23p19 was determined by RT-PCR in punch biopsies taken from psoriatic lesions before, 3 and 24 hours after the PDL treatment in five patients with psoriasis. The figures depict the expression in individual patients relative to the baseline. At each time point, the mean \pm SEM are marked. P-values are shown as calculated with the Wilcoxon signed ranks test.

pression of keratinocyte-, immune cell-, and endothelial cell-associated activation markers was assessed by quantitative RT-PCR in punch biopsies taken before, at weeks 7 and 13 of therapy in the group of clinical responders in order to determine the course of the molecular changes during the treatment. The expression of K17 and hBD-2 decreased significantly to an average of 45% ($p=0.046$) and 30% ($p=0.026$), respectively, in the PDL-treated punch biopsies at week 13, corresponding with the clinical improvement. There were no significant alterations in the expression of K17 and hBD-2 after NB-UVB treatment in responders (Figure 3a–d). The mRNA expression of TNF- α decreased significantly to an average of 60% ($p=0.046$) in the biopsies after the PDL treatment at week 7, but not after the NB-UVB treatment (Figure 3e,f). The expression of IL-23p19 mRNA was suppressed in the punch biopsies at week 7 of the PDL treatment to 56% of the values before treatment ($p=0.046$), but returned to the baseline levels after 13 weeks, whereas there were no significant alterations in the expression of IL-23p19 mRNA in the clinical responders after NB-UVB treatment (Figure 3g,h).

The expression of VEGFR2 mRNA was up-regulated to 145% ($p=0.046$) after 7 weeks of PDL treatment, indicating an activated angiogenesis (Figure 3i,j). In addition, a reduced expression of the anti-apoptotic molecule Bcl2 was observed in the biopsies after the PDL treatment (to an average of 56%, $p=0.028$). In summary, in the six clinical responders the




Figure 3. The effects of PDL and NB-UVB on the expression of the psoriasis markers in lesional psoriatic skin. mRNA expression of (a,b) b-defensin 2 (HBD2), (c,d) keratin 17 (KRT17), (e,f) IL-23p19, (g,h) TNF- α and (i,j) VEGFR2 was determined by quantitative RT-PCR in punch biopsies from six high responder patients. ABL1 was used as a housekeeping control gene. Bars show average expression levels relative to the baseline, error bars represent SEM. Statistically significant changes are marked with asterisks.

PDL treatment resulted in the decreased expression of TNF- α and IL-23p19 at 7 weeks, and reduced hBD-2, KRT17 and Bcl2 at 13 weeks, whereas the expression of the angiogenic molecule VEGFR2 was induced. The mRNA expression of these markers in the punch biopsies varied considerably between patients after NB-UVB treatment.

Immunohistochemical alterations

Punch biopsy samples from all the 14 patients were analyzed by immunohistochemistry. Global improvement of the psoriatic pathology as assessed in the hematoxylin and eosin (H&E)-stained sections was observed in about 50% of the patients, corresponding with the clinical improvement of psoriasis. The expression of transglutaminase K (TGK), an early differentiation marker with strong expression in psoriasis was assessed in order to follow any epidermal alterations. The level of T lymphocyte infiltrates (CD3+) in the dermis was determined to assess the inflammatory components of the disease activity. Changes in blood vessel content were followed by staining for the von Willebrand's factor (vWF) staining, whereas endothelial activation was assessed by the expression of E-selectin. None of these markers showed significant alterations in the PDL-treated biopsies after 13 weeks of treatment in the group of 14 patients (responders and non-responders), whereas the expression of TGK and E-selectin was significantly decreased in the NB-UVB-treated plaques (Figure 4). We analyzed punch biopsies from six clinically high responders (defined as a PGA reduction >50%) for epidermal and dermal markers of psoriasis in order to evaluate the effects of both treatments. The expression of epidermal TGK was significantly reduced to 50% ($p=0.043$) of the baseline value in the PDL-treated plaques and to 40% ($p=0.043$)




Figure 4. Immunohistochemical staining results in the entire study group. Biopsies from 14 patients with psoriasis were taken before and 13 weeks after the start of the study. Immunohistochemical staining for epidermal transglutaminase (TGK), CD3, von Willebrand factor (VWF) and E-selectin (E-sel) was performed. Staining positivity was quantified using digital image analysis. CD3 positivity was quantified separately in the dermis (DCD3). Bars show staining positivity at 13 weeks relative to the baseline. Error bars represent the SEM.




Figure 5. Immunohistochemical staining in punch biopsies from clinical responders. Cryostat sections of punch biopsies from six clinical responders taken before the start of treatment and 7 and 13 weeks later were stained using antibodies against (a,b) transglutaminase K (TGK), (c,d) CD3, (e,f) vWF and (g,h) E-selectin. The level of staining was quantified using digital image analysis. Figures depict the level of expression in individual patients relative to the baseline. At each time point, the mean \pm SEM are marked. P-values are shown as calculated with the Wilcoxon signed ranks test.

in the NB-UVB-treated plaques in these six patients after 13 weeks (Figure 5a,b). Dermal T cell infiltrates were significantly reduced to 30% ($p = 0.027$) of the baseline values at week 13 by NB-UVB treatment, and was not significantly ($p = 0.066$) reduced to 50% by PDL treatment (Figure 5c,d). The expression of vWF was significantly decreased in the NB-UVB-treated plaques to an average of 55% of the baseline expression ($p = 0.046$); a marked, but not significant decrease was also noted after PDL treatment (Figure 5e,f). The expression of E-selectin showed a significant decrease (to 56% of baseline, $p = 0.028$) in the PDL-treated punch biopsies after 7 weeks, but this change did not reach significance at week 13. The expression of E-selectin showed a gradual persistent decrease in the NB-UVB-treated lesional punch biopsies (Figure 5g,h).

DISCUSSION

The results of this study showed that clinical improvement of psoriasis after PDL treatment was accompanied by alterations in certain classical markers of psoriasis disease activity. The observed effects at the mRNA level were comparable in responders to the PDL- and the NB-UVB treatment. The relatively low clinical efficacy (52% improvement vs. minimally 60% reported for Total body irradiation) of NB-UVB in this study may be explained by the fact that local NB-UVB treatment was used instead of total body irradiation. It is assumed that total body NB-UVB irradiation also exerts a systemic effect.⁵²² A hallmark of psoriatic skin is the remarkable transformation of the local microvascular system, characterized by the dilation and the tortuosity of capillaries, increased permeability, and high endothelial venule formation, which is usually observed in lymph nodes.⁵²³ Active angiogenesis in psoriatic lesions evidenced by the upregulation of VEGF and VEGFR2 is accompanied by endothelial cell activation as observed by up-regulation of ICAM-1, vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. During this process, VEGF signalling on endothelial cells represents the major rate-limiting step.⁵²³ VEGF acts by engaging with its tyrosine kinase receptors VEGFR1 and VEGFR2 in endothelial cells. Although VEGF binds to both receptors, it appears that most of its biological functions are mediated via VEGFR2.⁵²³⁻⁵²⁴ Our observation that the early effects of the PDL involve the decreased expression of the endothelial molecules VEGFR2 and E-selectin corresponds with its proposed primary target. However, an additional early effect was also noted on VEGFR3 (FLT4), a lymph-endothelial marker.⁵²⁵ Lymphatics are expanded in psoriasis and the expression of VEGFR3 is increased in both the involved as well as the uninvolved psoriatic skin.⁵²⁴ The decreased expression of VEGFR3 early after PDL treatment may contribute to its efficacy in psoriasis. Interestingly, the expression of VEGFR2 was up-regulated at later time points, indicating re-activation of angiogenesis. This re-activation might be the response of endothelial cells to the vascular damage caused by the PDL. This active angiogenesis may counteract the anti-psoriatic effect of the

PDL treatment and may explain the insufficient clinical response in some patients. Another possibility might be that the main source of VEGF in psoriatic lesions, the activated keratinocyte, is not targeted by the PDL treatment. Therefore, activated lesional keratinocytes therefore, are less inhibited and may continue to stimulate the lesional microvasculature. The up-regulation of VEGFR2 may explain the enhanced efficacy of the PDL treatment when combined with calcipotriol ointment, which targets activated keratinocytes.⁵¹⁵

TNF- α and IL-23 mainly produced by inflammatory dendritic cells (DC) in the dermis are critical cytokines in the pathogenesis of psoriasis.⁴⁸⁶⁻⁴⁸⁷ Their importance is underlined by the fact that biologics targeting TNF- α and IL12/IL23p40 are effective in treating psoriasis.⁵²⁶ Both TNF- α and IL-23 are down-regulated during the treatment with other effective modalities.⁵²⁷ The results of the present study showed that after 7 weeks of PDL treatment, TNF- α and IL-23 mRNA were downregulated in psoriatic skin, whereas IL-23 was already observed to be down-regulated within 3 h after the PDL treatment. In combination with the observed decreased number of dermal CD3+ T cells, it may indicate that the vascular damage induced by PDL treatment, may also affect the peri-vascular immune cells.

Markers of keratinocyte activation and of the psoriasis phenotype were only significantly reduced at the end of the series of the PDL and the NB-UVB treatment sessions. KRT17 expression is high in the psoriatic epidermis correlating with the clinical severity.³⁹⁸ KRT17 is considered to be a candidate auto-antigen in psoriasis.⁵²⁸ hBD-2 is a molecule with antimicrobial activity, expressed by epidermal keratinocytes under inflammatory conditions such as psoriasis.⁴³⁴ Patients with psoriasis have higher genomic copy numbers of DEFB4, the gene encoding hBD-2 and have higher serum hBD-2 levels than healthy controls.^{263 265} Serum hBD-2 levels were shown to correlate positively with the disease severity.²⁶⁵ Since the PDL treatment does not target the epidermis primarily, it is conceivable that the PDL associated decrease in the expression of epidermal KRT17 and hBD-2 is secondary to the dermal blood vessel damage and to the subsequent reduction in the inflammatory infiltrate and their mediators. Our finding that PDL treatment is effective in approximately 50% (a subgroup) of patients has also been reported by others.⁵²⁹ In our study, the group of PDL responders could not be distinguished from the non-responders in terms of specific baseline expression patterns (results not shown) or immunohistochemical alterations induced by the treatment. Further studies are essential for identifying the prognostic markers of PDL responsiveness in psoriasis.

In conclusion, PDL and local NB-UVB treatment are clinically equally effective in stable plaque-type psoriasis. At the end of the treatment period, both the treatments resulted in the decreased expression of epidermal markers of keratinocyte activation as well as decreased dermal T cell infiltrates. This indicated that alterations in the expression of markers

of psoriasis activity do not clearly disclose the clinical treatment modality used and may just reflect the clinical improvement of the disease. We observed early effects of the PDL treatment on VEGFR2, VEGFR3 and the down-regulation of TNF- α and IL-23p19. These are previously unrecognized factors for the efficacy of PDL treatment in psoriasis.

Acknowledgements

The authors thank Hilde Both (MD) and Anne-Moon van Thuyll van Serooskerken (MD) for their help in recruiting the patients and taking the punch biopsies, and Tar van Os for the preparation of the figures.

Chapter 10

Summary of results, general discussion, and future perspectives

SUMMARY OF RESULTS AND GENERAL DISCUSSION

The role of peripheral sensory nerves in psoriasis has intrigued investigators during the last decades.^{1-2 300 310 312-313 320-321 351 359 530} However, the mode of action of peripheral nerves and associated mediators in psoriasis is incompletely understood and most current knowledge is based on *in vitro* studies and studies in mice.^{294 331 335} In general, it is thought that in psoriasis peripheral nerves and neuropeptides exert their effect mainly via: 1) vasoactive properties,¹¹¹ facilitating the influx of immune cells,^{111 351} 2) modulation of keratinocyte activation and proliferation,^{351 530} 3) function and migration of LC,³⁰⁸ and 4) the degranulation of mast cells.¹⁵⁷ It has become clear that peripheral nerves actively participate in innate skin defence utilising mechanisms such as signalling via PRR,^{111 114} and the rapid production and precise delivery of antimicrobial peptides.¹²⁹

Expanding scientific evidence points towards aberrancies in innate defence mechanisms in psoriasis, which are involved in the transition of uninvolved skin into psoriatic plaques.^{79 96 259} A therapeutic option of our observation that sensory denervation results in disappearance of psoriatic plaques, could be selective denervation of psoriatic plaques, which is currently not feasible. Therefore, we used the imiquimod-induced psoriasiform mouse model to investigate the function of peripheral sensory nerves and their mediators in the pathophysiology of psoriasis. Gaining in depth information about the role of neuromediators involved in psoriasis could yield realistic potential therapeutic targets.

In this thesis global transcriptomic effects of denervation were analyzed in unique cases in which local unilateral resolution of psoriasis occurred following surgical denervation (chapter 2). To identify pivotal mediators and pathways involved in the observed clinical resolution of human psoriatic plaques, we performed *in vivo* experiments using mice, *in vitro* experiments using keratinocytes in culture and *ex vivo* experiments using human skin explants. We analysed global transcriptomic effects of surgical denervation in a murine psoriasiform model (chapter 3). Because the contribution of neuromediators to innate defence is mostly unknown, we investigated the effects of SP, CGRP, and VIP on the epidermal expression of TLR and AMP in an *ex vivo* skin explant model (chapter 4). The molecular epidermal targets of recombinant IL-4 in *ex vivo* stimulated biopsies from psoriatic plaques and healthy skin were investigated in a wound healing model (chapter 5). Furthermore, the effect of the biologic ustekinumab (anti IL-12/IL-23) on epidermal molecular markers of innate defence in uninvolved skin of patients with psoriasis was investigated (chapter 6).

In our studies, we focused on the epidermis, as this forms the main innate defence barrier of the skin.

In general, the following main conclusions were drawn (see also box 1):

- 1) In patients with psoriasis, loss of cutaneous sensory innervation affected genes involved in epidermal barrier function that are important in the pathophysiology of psoriasis.
- 2) Peripheral nerves modify cutaneous TLR function, as the inflammatory response to the TLR7 ligand imiquimod is prevented in denervated skin, paralleled by an upregulation of negative TLR regulators in murine denervated skin. Denervation inhibited cutaneous CGRP expression and prevented the enhanced expression of CGRP by imiquimod. In human skin, *ex vivo* stimulation with CGRP results in enhanced expression of epidermal TLR9 expression.
- 3) Established treatments reach beyond the dermal inflammatory infiltrate and also target keratinocytes: *ex vivo* IL-4 treatment and *in vivo* ustekinumab therapy increase epidermal GATA3, which is a transcription factor critical for epidermal homeostasis, and down-regulate NGF expression, which is known to be induced during inflammatory conditions.
- 4) In addition, we demonstrated that topical application of cyclosporin is not superior to corn oil in the treatment of nail psoriasis.
- 5) Effective treatment with FAE (fumaric acid esters) targets molecules involved in the IL-17 pathway, corresponding to but not identical to that of effective anti-TNF- α treatment.
- 6) Finally, we show that pulsed dye laser (PDL) treatment downregulates IL-23p19.

Below, the results on the molecular targets of denervation in human psoriasis and in murine psoriasiform inflammation are summarized and discussed. Our results are positioned in the perspective of the current pathophysiology of psoriasis, and future prospects in this field of research are discussed.

Denervation renders the skin less susceptible to psoriasis plaque formation

The investigations described in **chapter 2** revealed three major features. First, epidermal gene expression profiles differ between denervated and normal, innervated skin. Loss of peripheral nerves inhibits the expression of genes involved in epidermal differentiation, innate barrier function, and type I IFN signalling. Bioinformatics analysis predicts a malfunction of TLR7 signalling upstream of the differentially expressed transcripts in denervated skin. Second, loss of nerves resulted in a diminished histamine-induced axon reflex response. Denervated skin showed no Koebner response upon tape-stripping in contrast to the normal, innervated skin. Evidence supporting a strong role for TLR in the pathogenesis of psoriasis is based on the exacerbation of disease induced by the TLR7 agonist imiquimod.^{79 273-275} Additional important factors are the roles of TLR7, TLR8 and TLR9 in detecting nucleic acids in complex with LL-37, resulting in activation of pDC and myeloid DC and production of

type I IFN.⁹⁶⁻⁹⁷ Disruption of TLR7 signalling through denervation supports the importance of peripheral sensory nerves in setting the stage for psoriatic plaque formation.¹

Experiments in the imiquimod-induced psoriasiform mouse model show that TLR7 ligation results in psoriasiform inflammation including upregulation of the cytokines IL-17A and IL-22.²⁷⁷ This model is currently extensively investigated worldwide.^{353-354 531-532} Our own results show that the induced inflammation is not solely depending on immune cells.²⁷⁷ A role for keratinocytes in the inflammatory response to imiquimod is suggested by the slight expression of TLR7 by keratinocytes,⁵³³ and their production of IL-17C, which enables an imiquimod response similar to IL-17A.⁵³¹ Studies in **chapter 3** describe the effects of surgical denervation of murine skin on TLR regulation in the skin and the response to imiquimod. The major finding of this study is that during the acute phase following denervation and loss of CGRP mRNA, the inflammatory response to imiquimod is prevented, including ongoing repression of CGRP mRNA in contrast to an upregulation of CGRP mRNA by imiquimod painting.

Excessive activation of TLR could result in a disruption of cutaneous innate barrier and disturbance of immune homeostasis. Studies have revealed an inappropriate activation of TLR7, TLR8, and TLR9 in autoimmune disease such as systemic lupus erythematosus.⁵³⁴ To avoid excessive inflammation, TLR functioning is negatively regulated by multiple mechanisms, including cell-intrinsic and cell-extrinsic mechanisms.³⁶³ Cell-intrinsic proteins collaborate to inhibit TLR signalling. Cytoplasmic regulatory proteins include IRAK-M, A20, ABIN1, I κ B α , and DAP12. Cell-extrinsic negative regulators include IL-10 and TGF- β , which suppress many TLR-activated pro-inflammatory genes. In general, these intrinsic and extrinsic negative regulators are induced by TLR ligands and their integration controls the cellular response to TLR activation.^{63 363} For excellent reviews on this topic, we refer to Kondo, Kawai and Akira 2012, and Murray and Smale, 2012.

Three days following cutaneous denervation, we observed the differential expression of genes involved in negative TLR regulation. Skin denervation in C57BL/6 mice induced several known negative TLR regulators, such as CD11b, TRIM30a, SOCS3, and STAT-1.⁶³ These results add to the role of peripheral sensory nerves in TLR regulation and function.

Our results show that in denervated skin the expression of the proinflammatory cytokines IL-1 β , IL-17A, IL-22, and IL-23p19 remains inducible by imiquimod. However, as in denervation in the KC-Tie2 psoriasiform model,³³¹ an inhibition of CGRP expression was observed in denervated skin after 7 days of imiquimod painting. The strong induction of IL-22 mRNA by topical imiquimod in denervated skin may derive from Th22 cells producing IL-22 and fibroblast growth factors (FGF5), which are both involved in neuronal differ-

entiation.²⁴⁰ We hypothesize that, similar to the central nervous system, peripheral nerve damage demands the involvement of IL-22.⁵³⁵ Because in denervated skin the inflammatory effects of imiquimod are not translated into visible skin inflammation, it seems that expression of IL-23p19, IL-17A, IL-22 in the case of underlying denervation is not sufficient to induce full scale clinical psoriasiform inflammation. Overall, this indicates that the initial sensing of imiquimod is maintained in denervated skin, but that peripheral nerves form a crucial connection between the initial sensing and the recruitment of immune cells capable of initiating inflammation.

Mice that are unable to express TLR7 (TLR7^{-/-}) still respond in a modest way to imiquimod, exhibiting TLR7-independent keratinocyte hyperproliferation by imiquimod.³⁵³ An important study showed that imiquimod exerts additional TLR7-independent effects via adenosine receptor signalling in keratinocytes.⁵³⁶ Recent studies show that peripheral nerves sense imiquimod resulting in DRG-activation followed by the onset of itch and modification of their pain sensation.¹¹⁴ Imiquimod also activates DRG in TLR7^{-/-} mice causing depolarization and action potential firing.³⁵⁶ These results show that imiquimod requires the presence of a subset of TRPV1-expressing sensory nerves that contain different intracellular receptors responding to histamine, chloroquine, and imiquimod.³⁵⁶ We therefore postulate that sensory nerves are important imiquimod sensors in both TLR7+ and TLR7-independent micro-environments, resulting in epidermal changes, pruritis, and influx of immune cells. The exact contribution of TLR7 requires further investigation.

In peripheral tissues, neuropeptides are particularly enriched in sensory nerves and play an important role in pain sensation and neurogenic inflammation. Multiple neuropeptides interact within the epidermis as keratinocytes express the appropriate receptors such as CGRP receptors and NK1R.³⁵¹ Neuropeptides display pro- and anti-inflammatory properties, and induce secretion of adenosine 3', 5'-cyclic monophosphate (cAMP).^{351 392} CGRP potentiates LPS-induced IL-6 release in macrophages via the cAMP pathway,³⁷² and acts as a negative TLR regulator via the transcriptional repressor ICER.³⁷³ In **chapter 4**, we used exogenous CGRP, SP, and VIP to identify their role in the epidermal expression of antimicrobial peptides and TLR7, 8 and 9. We show that CGRP enhances the epidermal expression of both LL-37 and TLR9. CGRP8-37 binds to both CGRP receptors (CLR/RAMP1) and adrenomedullin (AM)2 receptors (CLR/RAMP3).⁵³⁷ The facilitating effects of CGRP were inhibited by CGRP8-37, suggesting that CGRP receptors mediate the effect.⁵³⁸ CGRP induces TLR9 expression in astrocytes and microglia via ERK and p38 MAPK signalling pathways.³⁷¹

The suprabasal epidermal expression of TLR9 and LL-37 co-localizes with the epidermal distribution of CGRP receptors in pruritic psoriasis.³⁵² TLR9 expression in keratinocytes is also induced by LL-37, and LL-37 and TLR9 are expressed in the same epidermal layers with-

in psoriatic plaques.⁹⁸ Our results suggest that CGRP primes keratinocytes to respond to TLR9 ligands *in vivo*, which is a critical mechanism in the pathogenesis of psoriasis. Psoriasis patients that improve on etanercept (anti-TNF- α) therapy showed a decrease in epidermal TLR9 expression.⁵³⁹ Interestingly, the TLR7/TLR9 antagonist IMO-3100 is being developed and is currently in a phase II clinical trial in psoriasis.

The ability of the peripheral nerves to reinforce cutaneous defences can be considered as a highly conserved mechanism, showing similarities with the strong neuronal influence in epithelial defences in amphibians.⁵⁴⁰

Treatment reaching beyond the dermal infiltrate, and targeting of epidermal aberrancies.

Ustekinumab is a human mAb against the shared p40 subunit of IL-12 and IL-23. In clinical trials, ustekinumab treatment resulted in a PASI75 improvement in 60% of patients with moderate-to-severe psoriasis after 8 weeks of therapy. Some patients showed a prolonged clinical PASI-75 response following three injections of ustekinumab. The mechanisms underlying this prolonged clinical response remained unclear. It is currently thought that the main therapeutical focus of ustekinumab lies within the dermis, targeting the cross-talk between pro-inflammatory DC and Th-cells. The clinical effects of ustekinumab were preceded by earlier reports on the therapeutical effects of IL-4 in psoriasis. Treatment with recombinant human IL-4 showed clear clinical improvement of up to 68 % PASI improvement in 6 weeks.⁴¹⁰ This improvement were initially ascribed to the effects of IL-4 on the dermal pro-inflammatory infiltrate, inducing a shift from Th1/Th17 towards Th2 signature. Despite cumulating insight into epidermal aberrancies in both uninvolved and involved psoriatic skin, the direct effects of ustekinumab and IL-4 on epidermal targets remained unknown. The results of our study described in **chapter 5** show that IL-4 targets the psoriatic epidermis, by inhibiting the expression of IL-1 β and IL-6. This is accompanied by an increase in epidermal GATA3.²⁹¹ Established plaques show hardly any IL-4 expression.⁵⁴¹ It is conceivable that the low level of IL-4 in psoriatic lesions contributes to the reduction of GATA3 in the epidermis, and to the upregulation of the IL-4 receptor on psoriatic keratinocytes.⁴²⁵ Polymorphisms in the gene encoding for IL-4 have been reported in psoriasis.⁵⁴² *In vitro* stimulation of keratinocytes with IL-4 directly inhibits the induction of hBD-2 expression by TNF- α and IFN- γ .⁴³⁵ Overall, the ability of IL-4 to regulate epidermal barrier function, suggests that topical application of IL-4 offers an effective psoriatic treatment.

In **chapter 6.1**, we analyzed the effects of ustekinumab on genes involved in epidermal barrier function. In the uninvolved epidermis of patients who respond successfully to ustekinumab, GATA3 mRNA and protein expression is induced, whereas NGF mRNA expression is reduced. The epidermal innate barrier response to skin injury was not altered by ustekinumab, as the molecular expression of AMP hBD-2, LL-37 and S100A7 was not

affected by treatment. In contrast, patients who responded to treatment showed a decline in serum levels of hBD-2. These results might be specific for ustekinumab, since successful treatment of psoriasis with FAE results in increased hBD-2 serum expression.⁴⁵⁶ Increase in serum hBD-2 is not limited to psoriatic skin inflammation, as in atopic dermatitis patients serum hBD-2 is also increased.⁴⁵⁷ Recent results show that patients with systemic lupus erythematosus, serum hBD-2 levels positively correlate to the risk of cardiovascular events.⁴⁵⁸ The decline of serum hBD-2 following one injection of ustekinumab might prove to be beneficial to the cardio-vascular co-morbidity of psoriasis.^{173 181-185} It would be worthwhile doing a comprehensive study on the effects of ustekinumab on serum proteins such as hBD-2 during long lasting remission of psoriasis. Our observations indicate that the effects of ustekinumab might go beyond the clinical resolution of psoriatic plaques. This is demonstrated by the patient described in **chapter 6.2**, who has psoriasis vulgaris, hidradenitis suppurativa, and Behçet's disease including uveitis and IBD. Successful treatment of the psoriasis with ustekinumab additionally also improved the two other diseases. Recently, a phase III trial showed positive results in patients with Crohn's disease treated with ustekinumab.⁵⁴³

Chapter 7 shows that clinical successful treatment of psoriatic plaques with FAE is paralleled by reduced gene-expression of CCL20, CXCL1, DEFB4, S100A8, S100A9 and the transcription factor NFκB1, all important components of the IL-23/IL-17 axis. The down-regulation of DEFB4, the gene encoding for hBD-2, seems to contradict results claiming that treatment with FAE results in an increase of hBD-2 serum levels.⁴⁵⁶ As we have not investigated serum hBD-2 levels in parallel, the question remains whether the resolution of psoriatic plaques by FAE treatment results in responses of serum hBD-2 levels.

The lack of clinical efficacy of topical cyclosporine in psoriasis nails is described in **chapter 8**. In contrast to the beneficial effects of standard topical treatments in psoriatic plaques such as corticosteroids, these therapies show disappointing and variable results in nail psoriasis.^{497 500} Several studies have demonstrated the response of nail psoriasis to systemic treatments such as cyclosporin and anti-TNF-α biologics.⁵⁰⁰ We show that the beneficial aspects observed are similar to that of twice daily application of corn oil. This may point toward epidermal barrier defects contributing to the aberrancies in psoriasis nails.

Psoriasis patients responding to pulsed dye laser therapy (PDL) showed comparable effects at the mRNA level as NB-UVB treatment (**chapter 9**). Skin biopsies taken at 3 and 24 h following PDL therapy showed reduced expression of the endothelial markers VEGFR2 and E-selectin. This response is in agreement with the theoretically proposed cutaneous target. Furthermore, following 2 PDL treatments, TNF-α and IL-23p19 mRNA expression were suppressed in psoriatic plaques. Biopsies taken after 1 month showed upregulation of VEGFR2. This result suggests that re-angiogenesis takes place following the initial thermal

destruction of the vasculature. However, the increase of VEGFR2 did not correlate with the therapeutical response. Additionally, PDL treatment reduced cutaneous mRNA expression of VEGFR3, also denoted as FLT4, which is a lymph-endothelial marker. In psoriatic plaques, the production of the lymphoid-organizing chemokine CCL19 occurs selectively within perivascular T-cell and DC aggregates. It is suggested that CCL19 recruits CCR7+ (self-antigen-specific) T cells and DC into this focus, suggestive of a microenvironment suitable for the expansion of Tem from Tcm cells.²⁹³ This concept of lymphoid organization in psoriatic lesions is supported by the ability of CCL19 to organize functional lymphoid structures within the pancreas of mice.⁵⁴⁴ The effects of PDL on lymphoid organization is potentially a novel therapeutical effect of PDL.

Box 1. Main conclusions

Aim 1. To determine to what extent functional peripheral sensory nerves and their neuromediators control the onset and maintenance of psoriasis.

- Clearance of psoriasis by denervation is paralleled by alterations in steady state epidermal mRNA expression involved in innate defence such as TLR regulation and interferon signalling, which are important in the initiation phase of psoriasis.
- Cutaneous surgical denervation in C57BL/6 mice results in diminished inflammatory response to the TLR7-agonist imiquimod and absence of CGRP mRNA expression.
- CGRP stimulation enhances TLR9 expression within 24 h in healthy human skin explants. Thus, in addition to its vasodilatory, chemotactic and antimicrobial properties, CGRP acts as an innate defence regulator.

Aim 2. To assess the clinical efficacy of selected treatments of psoriasis, and to delineate their molecular mode of action.

- The Th2 cytokine IL-4 directly affects epidermal aberrancies observed in psoriasis: IL-4 upregulates GATA3 and downregulates the neurotrophic factor NGF.
- Ustekinumab therapy not only clears psoriatic plaques, it also induces GATA3 expression in uninvolved skin. Innate defence seems to be unharmed as PRR expression and AMP responses remain stable during therapy. These changes indicate that the pre-psoriatic epidermal state of uninvolved skin can be shifted to a more healthy state.
- Treatment of nail psoriasis by topical cyclosporine is not superior to treatment with corn oil.
- Improvement of psoriasis by fumaric acid esters is accompanied by molecular changes reflecting suppression of the IL-17A pathway.
- Treatment with PDL of the vascular dimension of psoriasis is a therapeutical option. Within 3 h following PDL treatment, the vascular markers VEGFR2, VEGFR3 together with IL-23p19 are inhibited. The alteration in vascular markers suggests a decrease in vascular density. Diminished IL-23p19 may reflect reduced activity or presence of TIP-DC.

Limitations

The studies met with the following limitations. First of all, during the last 5 years it turned out that the described unique clinical cases in which psoriasis disappears due to denervation are hard to recruit. Collaborating partners mentioned several encounters with this phenomenon; however, they had difficulty retrieving these cases from their archives. From our own efforts, we identified 8 cases, of which 2 could be analyzed as described in this thesis.

Second, there are no elegant techniques suitable for inducing selective peripheral sensory denervation in humans. Therefore we used the imiquimod-induced psoriasiform mice model to experimentally assess the effects of surgical denervation.

Third, the use of mice limits the time-window in which the effects of denervation can be studied, as cutaneous nerves are known to reappear within 10 days following surgery.¹⁵⁷³³¹ This implies that there is a difference between our human data and the results obtained from denervation in mice. Our patient displayed chronic long lasting denervation. Since mice are known for having strong regenerative capabilities of their peripheral nerves, we were forced to investigate the effects of denervation only in an acute model.

Fourth, as discussed in the introduction, within hours to days following surgical denervation, an immunologic cascade is unleashed, including the influx of immune cells and the functional transition of injured Schwann cells into regenerative forms. As such, changes induced by surgical denervation are accompanied by inflammatory and regenerative responses. Recent findings show that the expression of functional TLR9 in spleen and antigen-presenting cells is regulated by circadian rhythms.⁶⁶ The strongest peak in TLR9 expression is displayed at night, when the mice are the most active.⁶⁶ In order to partly exclude time-point depending differences in TLR expression, our observations have been performed at fixed time-points during working days.

Finally, we used barrier disruption by tape-stripping to investigate the effects of ustekinumab on epidermal barrier function. It was not easy, in terms of kinetics, to determine the optimal time point to assess effects of mechanical injury and of ustekinumab. The initial experimental design was to collect biopsies of each patient at weeks 0, 4 and 12. Unfortunately we did not succeed in collecting sufficient biopsies at week 12. This means that it remains unclear whether our short term 4 week results are also valid in the long term. However, extrapolating from results regarding a limited number of patients, we expect that the effects of ustekinumab reach beyond the first 4 weeks.

The pathophysiology of psoriasis in light of the results

By using various experimental approaches to investigate the role of peripheral nerves and neuronal mediators in the onset of psoriasis, we have learned that peripheral nerves are crucial for epidermal barrier homeostasis, interferon signalling and TLR regulation (chapters

2, 3 and 4). Stimulation with IL-4 and blocking p40 with ustekinumab therapy results in increased expression of epidermal GATA3 and inhibited expression of NGF (chapters 5 and 6). Epidermal GATA3 is involved in the expression of anti-inflammatory and pro-apoptotic proteins, and induces epidermal differentiation and homeostasis. In contrast, NGF is involved in both pro-inflammatory and anti-apoptotic processes. Overall, our results support the concept that psoriasis is not only a disease defined by the interaction between immune cells and keratinocytes in psoriatic plaques. Psoriasis is a disease of the total skin, in which all functional components of the skin are important, including peripheral nerves and the vasculature.

Below, we incorporate our findings into a viewpoint on the pathophysiology of psoriasis (Figure 1). For comprehensive recent overviews on genetic aspects and the immunobiology of psoriasis, we refer to reviews on this subject, e.g. Răcz & Prens 2009,⁵⁴⁵ Perera et al 2012,⁴⁰¹ and Bergboer et al 2012.⁶




Figure 1. Viewpoint on psoriasis based on our results in the perspective of current genetic and molecular data.

Genetic aberrancies involved in skin barrier and immune function will cooperatively determine the response to environmental stimuli (trauma, infection), and facilitate penetration of antigens. Nociceptor activation and release of neuropeptide enhance the low-grade inflammation caused by keratinocyte and ILC activation, followed by activation of endothelium and chemotaxis of immunocompetent cells. Ultimately, this could lead to activation of adaptive immunity in genetically predisposed individuals, e.g. HLA-Cw6, IL-12B, IL-23, who respond to unidentified external antigens or autoantigens through molecular mimicry. The ensuing immune response, which includes secretion of Th1 and Th17 cytokines, will in turn cause activation of keratinocytes, resulting in a vicious cycle and chronicity of inflammation.

Phase I: Pre-psoriatic aberrancies and initiating factors set the stage

The onset of psoriasis is based on multifactor aetiology. The actual manifestation of psoriasis represents an interaction between a genetically predisposed individual⁵⁵⁹ (Table 1) and exogenous factors. Pre-psoriatic aberrancies in skin barrier function, innate immune response, and growth factors such as NGF set the stage for the psoriatic cascade.^{5-6 229 263 294} GATA3 is strongly involved in the maintenance of homeostasis via regulation of epidermal growth, antimicrobial defence and homeostasis.¹³ Our results show that uninvolved skin of psoriatic skin displays reduced epidermal expression of GATA3.²⁹¹ Together with genetic predisposing factors,^{6 253} these epidermal aberrancies cooperatively determine the degree of exposure, handling, and response to physical trauma and environmental stimuli (such as PAMP).⁶ Triggering factors such as mechanical injury start a cascade of events that include stimulation of peripheral sensory nerves,³¹² and the formation of RNA/DNA–LL-37 complexes.⁹⁶⁻⁹⁷ The latter are able to activate DC, especially pDC, resulting in secretion of IFN- α .⁹⁶⁻⁹⁷ In parallel, innate lymphoid cells (ILC) play a role in the onset as these cells produce IL-17A and IL-17C upon triggering. Upon activation of mast cells via their PRR or by sensory nerve endings, they degranulate and release IL-17A, neuropeptides and antimicrobial peptides.^{157 312 546} Together with the release of neuropeptides such as SP and CGRP by sensory nerve endings, the local vascular endothelium is stimulated and dilates.¹¹¹ This vasodilatation is clinically visible as erythema and facilitates the influx of immune cells.¹¹¹ In addition, both CGRP (chapter 4) and LL-37 will enhance epidermal expression of TLR9 expression, ligation of which by self-DNA or exogenous DNA promotes the production of type I IFN.⁹⁸

Phase II: Activation of adaptive immune cells resulting in ongoing inflammation

Activated myeloid DC migrate into draining lymph nodes and induce the differentiation of naive T-cells into Th1 and Th17 cells. These cells recirculate and slow down in skin capillaries guided by interactions of cutaneous lymphocyte-associated antigen (CLA), selectin- and integrin receptor–ligand interactions. Lymphocytes expressing the chemokine receptors CCR6, CCR4, and CXCR3 emigrate into skin tissue along chemokine gradients.

Based on genetically predisposition, currently unidentified superantigens or skin-derived autoantigens, may further activate the adaptive immune response via molecular mimicry.⁵⁴⁷ The ongoing production of the Th1 and Th17 cytokines IL-17A, IL-17C, IL-17E,²³⁷ and IL-22 disturb the differentiation and activation program of keratinocytes, promoting epidermal hyperplasia, especially when they are simultaneously stimulated with TNF- α .³⁶⁸ The increased pool of proliferating keratinocytes produces an array of proinflammatory cytokines, such as IL-1 family members,⁴¹⁴ IL-6, IL-19, IL-20, IL-22, IL-24,⁵⁴⁸ TNF- α , adhesion molecules, growth factors VEGF and NGF,²⁹⁴ AMP and neuropeptides.^{259 323}

The clinically visible white scales are a result of this hyperproliferative epidermis with premature maturation of keratinocytes and incomplete cornification with retention of nuclei in the stratum corneum (parakeratosis), together with thinning or absence of the granular

Table 1. Table with short list genes known to be risk factor for psoriasis

SNP	Chr.	Position (bp)	Notable genes	Number of genes \pm 500 kb
rs7552167	1	24518643	<i>IL28RA</i>	26
rs9988642	1	67726104	<i>IL23R</i>	17
rs6677595	1	152590187	<i>LCE3B, LCE3D</i>	43
rs11121129	1	8268095	<i>SLC45A1, TNFRSF9</i>	15
rs7536201	1	25293084	<i>RUNX3</i>	18
rs62149416	2	61083506	<i>FLJ16341, REL</i>	9
rs17716942	2	163260691	<i>KCNH7, IFIH1</i>	7
rs10865331	2	62551472	<i>B3GNT2</i>	6
rs27432	5	96119273	<i>ERAP1</i>	7
rs1295685	5	131996445	<i>IL13, IL4</i>	21
rs2233278	5	150467189	<i>TNIP1</i>	17
rs12188300	5	158829527	<i>IL12B</i>	5
rs4406273	6	31266090	<i>HLA-B, HLA-C</i>	56
rs33980500	6	111913262	<i>TRAF3IP2</i>	8
rs582757	6	138197824	<i>TNFAIP3</i>	5
rs9504361	6	577820	<i>EXOC2, IRF4</i>	5
rs2451258	6	159506600	<i>TAGAP</i>	8
rs2700987	7	37386237	<i>ELMO1</i>	3
rs11795343	9	32523737	<i>DDX58</i>	7
rs10979182	9	110817020	<i>KLF4</i>	0
rs1250546	10	81032532	<i>ZMIZ1</i>	9
rs645078	11	64135298	<i>RPS6KA4, PRDX5</i>	36
rs4561177	11	109962432	<i>ZC3H12C</i>	4
rs3802826	11	128406438	<i>ETS1</i>	7
rs2066819	12	56750204	<i>STAT2, IL23A</i>	40
rs8016947	14	35832666	<i>NFKBIA</i>	11
rs12445568	16	31004812	<i>PRSS53, FBXL19</i>	46
rs367569	16	11365500	<i>PRM3, SOCS1</i>	14
rs28998802	17	26124908	<i>NOS2</i>	9
rs963986	17	40561579	<i>PTRF, STAT3, STAT5A/B</i>	42
rs11652075	17	78178893	<i>CARD14</i>	16
rs545979	18	51819750	<i>POL1, STARD6, MBD2</i>	6
rs892085	19	10818092	<i>ILF3, CARM1</i>	37
rs34536443	19	10463118	<i>TYK2</i>	42
rs1056198	20	48556229	<i>RNF114</i>	11
rs4821124	22	21979289	<i>UBE2L3</i>	16

layer. The parakeratosis may be confluent or may alternate with orthokeratosis, and is inversely correlated with presence of the granular layer.^{506 549} Collections of neutrophils are seen in different epidermal layers, for example in the parakeratotic stratum corneum where they are called Munro's microabscesses,^{506 549} and in the spinous layer, forming the spongiform pustules of Kogoj.⁵⁵⁰ Acanthosis occurs, with elongation of rete ridges with thinning of the suprapapillary epidermis. This is paralleled by enhanced PRR expression across epidermal layers.²⁵⁸ In the established plaque, the tips of the rete ridges are often clubbed or fused with adjacent ridges with somewhat edematous dermal papillae containing dilated, tortuous capillaries, without clear spongiosis.^{506 549} The combination of increased numbers of tortuous capillaries and local epidermal thinning explains the observed redness of the psoriatic lesions.²⁰² This increase in vasculature is accompanied by a marked increase of terminal C fibers.³¹³

Within the established plaque, continuous interaction and positive feedback between PRR, DC, lymphocytes including ILC, $\gamma\delta$ T cells,⁵⁵¹ Th1 and Th17 cells²³⁸, keratinocytes and skin appendages such as peripheral nerves, perpetuate the inflammation. The production of the lymphoid-organizing chemokine CCL19 occurs selectively within perivascular T-cell and DC aggregates. It has been suggested that CCL19 may recruits CCR7+ (self-antigen-specific) T cells and DC into this focus, suggestive of the development of a lymphoid micro-environment suitable for the expansion of Tem from Tcm cells.²⁹³

FUTURE PERSPECTIVES

Molecular knowledge regarding the role of psychological stress in psoriasis is warranted

Our data support the view that peripheral nerves are a critical component of the micro-environment needed to ignite the onset of psoriasis and maintain plaque activity. Psychological stress is one of the most common initiating factors in the onset and exacerbation of this disease. Further unravelling of the mechanisms by which stress modifies the skin to become more prone to develop psoriasis is urgently needed. Identification of the pivotal neuronal mediators could provide pharmacological targets to treat established plaques but also to prevent the development of new lesions. Changes in cutaneous PRR signalling due to psychological stress could provide novel insights into the influence of stress on microbial colonization of the skin and the risk of infections.³⁷⁶⁻³⁷⁷ Indirect evidence of a regulatory role of peripheral nerves in microbial colonization, is the observation that peritoneal denervation results in changes in microbial colonization of peritoneal epithelia.⁵⁵ PET-scan results have shown abnormal microglia activation in brains of patients with psoriasis, indicating an involvement of the central nervous system in psoriasis, in addition to peripheral nerves.

(Griffiths & Kleyn, personal communication) Further exploration of the skin-brain axis could provide clues regarding the interaction between psyche, life style and psoriasis.

The effects of denervation resulting in resolution of disease phenomenon is not unique to psoriasis, as illustrated in a patient with arthritis in which accidental surgical denervation of the affected joint resulted in resolution of inflammation. In animal models of arthritis, for example, Levine and colleagues have shown that denervation of the joint leads to a striking attenuation of inflammation.⁵⁵³ An imbalanced autonomic nervous system, with a reduced parasympathetic and increased sympathetic tone, has been a consistent finding in rheumatoid arthritis patients.⁵⁵⁴ Moreover, promising results show that electrically stimulating the vagus nerve could have beneficial effects on inflammation markers and arthritis.⁵⁵⁴

Reintroduction of surgical treatment of recalcitrant psoriatic plaques

Before the introduction of effective pharmacological treatments, several attempts have been made in order to develop surgical treatment options for psoriatic plaques. Several studies showed that complete surgical removal of psoriatic epidermis results in prolonged (up to 16 months) and long-term remission of treated plaques.⁵⁵⁵ On the basis of our results, we propose that these surgical effects may in fact resemble an effective approach of skin denervation, as all peripheral nerve endings are removed alongside the removed skin. A re-introduction of surgical removal by dermatome of the superficial skin in psoriasis could provide an interesting therapeutical option in recalcitrant plaques, with low economical costs compared to biologics such as ustekinumab.

Therapeutical targeting of neuromediator signalling

Accumulating data shows that in the skin, neuropeptides are released from neuronal and non-neuronal sources such as mast cells. Neuropeptide signalling is controlled at the level of release, receptor expression, and by proteolytic peptidases. Unbalanced signalling of neuropeptides due to an increase in sensory nerve endings, and enhanced interaction with mast, keratinocytes, Langerhans cells, will deregulate cutaneous homeostasis and trigger or exacerbate atopic dermatitis and psoriasis. Neuropeptide signalling results from activating and inhibitory functions and interventions herein require careful dose-finding and timing. Nonetheless, some therapeutic options derived from our present understanding of the topic, such as CGRP inhibitors, NGF-R antagonists and the NK-1R antagonist aprepitant may be regarded as guidance for future investigations. Optimal use of these pharmaceuticals may prove profitable at beginning of stressful period in order to prevent onset or further development of psoriasis.

The uninvolved psoriatic skin should be further investigated.

Many pharmacological studies of psoriasis take a retrograde view on the disease, e.g. following the regression from plaque to healthy skin. However, defining the exact sequence

of events taking place during initiation could also provide therapeutical options for early intervention in pro-inflammatory signalling. Early interruption in psoriasis may prevent further escalation of psoriatic inflammation and its co-morbidities. Hence, we argue that the retrograde approach should be replaced by a prospective one: following the transition of uninvolved, healthy appearing skin into an established plaque.

Concluding remarks

In conclusion, peripheral nerves and derived neuromediators are essential factors in cutaneous homeostasis and in the pathophysiology of psoriasis. Our results confirm their roles in the initiating phase of psoriasis inflammation by stimulating and regulating innate defence and immune responses. Loss of innervation makes the affected skin less prone to the development of psoriasis. Following up on our data regarding the effect of ustekinumab on epidermal NGF expression, it will be valuable to investigate whether biologics currently in use as psoriatic treatment also interfere with the function of peripheral nerves and keratinocytes. Currently a range of pharmaceutical compounds is available for scientific and clinical studies on the function of peripheral nerves. In addition to resolution of established plaques, studies should aim at controlling the initiation of psoriasis before the escalation to established plaques takes place.

Chapter 11

Samenvatting

SAMENVATTING

Het proefschrift beslaat twee pathogenetische aspecten van psoriasis, een van de meest voorkomende chronische huidaandoeningen. Psoriasis komt bij 2% van de Westerse bevolking voor, en wordt gekenmerkt door schilferende rode plekken, meestal aan de ellebogen en knieën. Hiernaast hebben patiënten vaak last van forse schilfering van de behaarde hoofdhuid, pijnlijke afwijkingen van de nagels, en van gewrichtsontstekingen (psoriasis artritidis). Het verkrijgen van ernstige psoriasis op jeugdige leeftijd gaat gepaard met een sterk verhoogd risico op hart en vaatziekten. Psoriasis heeft naast deze geassocieerde ziekten een forse negatieve invloed op de kwaliteit van leven. In de afgelopen decennia hebben snelle ontwikkelingen plaatsgevonden op het gebied van dure biotechnologische middelen, de zogeheten biologics, anti-inflammatoire monoklonale antilichamen zoals anti-TNF- α en anti-p40 (anti-IL-12/IL-23). Deze therapieën zijn voortgekomen uit de vooruitgang in het immunologisch onderzoek naar de oorzaak van psoriasis. De laatste jaren staan de epidermale afwijkingen weer in toenemende mate in de belangstelling van psoriasis-onderzoekers. Dit komt vooral door het toenemend aantal resultaten uit genetisch onderzoek die wijzen op psoriasis-gerelateerde epidermale barrière afwijkingen. Ondanks de toegenomen genetische kennis en het succes biologics, ligt permanente genezing of het voorkomen van de psoriasis nog lang niet binnen ons bereik. Daarnaast hebben deze biologics soms vervelende bijwerkingen. Een betere therapie is dus meer dan welkom.

Enkele casus tonen aan dat psoriasis plekken verdwijnen na schade aan perifere sensibele zenuwen (ook wel denervatie genoemd) in dat huidgebied. Er is relatief weinig bekend over de rol van perifere zenuwen in de huid van psoriasis patiënten. Omdat het aantal patiënten met accidentele denervatie schaars bleek te zijn, was verrichten van onderzoek naar de effecten van cutane denervatie op psoriasis niet eenvoudig. Een beperkt aantal patiënten kon getraceerd worden waarbij chirurgisch geïnduceerde denervatie van de huid heeft geleid tot lokaal verdwijnen van de psoriasis.

Het doel van dit proefschrift was om meer inzicht te verkrijgen in de moleculaire aangrijpingspunten van perifere zenuw innervatie en hun functie in de pathogenese van psoriasis.

Ten eerste zijn in bovengenoemde casus, de klinische en moleculaire verschillen tussen gedenerveerde en de contralaterale (symmetrisch aan andere zijde gelegen) niet-aangedane huid in kaart gebracht. De resultaten hiervan worden besproken in **hoofdstukken 2 en 3**. Ons onderzoek toont dat de cutane denervatie klinisch gepaard gaat met een veranderde basale huidtemperatuur en thermoregulatie en een verminderde axon-reflex afhankelijke histamine respons. Bovendien blijkt dat in de aangedane huid geen uitlokking van psoriasis meer mogelijk is.

Met epidermaal RNA afgenomen doormiddel van huidbiopten van zowel gedenerveerde en niet aangedane huid werd globale genexpressie met behulp van microarrays verricht. De verschillen tussen gedenerveerde en niet-aangedane huid betrof vooral genen betrokken bij epidermale differentiatie en proliferatie zoals GATA3, LCE, en SPRR, en interferon-signalering, waaronder IFI-27. Met behulp van bioinformatica werd vast gesteld dat denervatie ingrijpt op genen die een rol spelen bij het op gang brengen van de zogeheten aangeboren afweer (innate immuniteit). In het bijzonder op genen, die geclassificeerd kunnen worden als respondenten op imiquimod, een therapeutisch TLR7 ligand. Imiquimod is een afweer activerend middel dat klinisch toegepast in de bestrijding van ondermeer genitale wratten, actinische keratose en superficiele basaalcelcarcinomen.

Wij hebben een muis model ontwikkeld waarbij het op de huid aanbrengen van imiquimod resulteert in een psoriasis-gelijkende huidontsteking. In **hoofdstuk 3** staat beschreven of de klinische respons op imiquimod daadwerkelijk verstoord wordt door denervatie van de huid. Het blijkt dat zenuwinnervatie in dit model cruciaal is voor het opwekken van zichtbare huidontsteking. Het effect van denervatie bleek uit het verdwijnen van PGP+ zenuwen in de huid en de verminderde expressie van de neuropeptide CGRP. Zowel klinisch als op immunohistochemisch blijkt dat denervatie ingrijpt op de reactie van de huid op imiquimod. Moleculaire analyse toont aan dat denervatie factoren activeert die bekend staan als remmers van TLR en dus de innate immuunrespons van de huid. Dit laatste bied een verklaring biedt voor het falen van imiquimod in gedenerveerde huid.

De verminderde expressie van CGRP deed ons vermoeden dat dit neuropeptide een belangrijke functie vervult in de cutane innate afweer. Uit de literatuur blijkt dat psoriasis plaques een verhoogde expressie vertonen van CGRP. In **hoofdstuk 4** beschrijven we de effecten van dit neuropeptide op de epidermale expressie van TLR7, TLR8 en TLR9, en op de antimicrobiële eiwitten hBD-2 en LL-37 in gekweekte normale humane huidbiopten. Resultaten werden vergeleken met de die van acetylcholine. CGRP verhoogde de epidermale expressie van TLR9 en LL-37. Uit recent onderzoek blijken zowel TLR9 als LL-37 een cruciale rol te spelen in de vroege fase van het ontstaan van psoriasis. Dit resultaat toont een functionele rol aan van neuropeptiden en perifere zenuwen in de vroege fase van psoriasis.

In **hoofdstuk 5** onderzochten we de effecten van IL-4 op epidermaal GATA3 en nerve growth factor (NGF). Interleukine-4 staat immunologisch bekend om het sturen van T helper (Th) cellen richting het zogeheten Th2 type, welke cellen belangrijk zijn bij ziekten zoals astma en eczeem. Eczeem wordt qua immunologisch mechanisme als een tegenpool van psoriasis beschouwd, en daarom is in het verleden onderzocht of het toedienen van IL-4 klinisch effectief zou zijn bij psoriasis. Inderdaad bleek IL-4 zeer effectief, wat werd toegeschreven aan de mogelijke verandering van de Th1 populatie naar een Th2 type. Een direct effect op keratinocyten werd echter niet onderzocht. Vandaar dat wij de moleculaire

effecten van IL-4 op epidermale cellen van psoriasis plekken onderzocht hebben. Keratinocyten uit psoriasis plaques vertonen een sterk verlaagde expressie van de transcriptiefactor GATA3, en een versterkte expressie van de epidermale- en neuronale groeifactor NGF. Beide spelen een rol in de uitrijping van keratinocyten, alsmede uitgroei van zenuwcellen. IL-4 verhoogde de epidermale expressie van GATA3 wat gepaard ging met een verlaagde expressie van NGF. Op basis van deze resultaten concluderen wij dat IL-4 naast het belang voor Th2 cellen, ook een belangrijke anti-psoriasis functie vervult via een direct effect op de epidermis.

Enkele psoriasis patiënten die behandeld werden met het anti-p40 mAb ustekinumab, bemerkten dat, naast het verdwijnen van de plaques, hun niet-aangedane huid minder snel nieuwe plekken ontwikkelden. Deze observaties van patiënten heeft ertoe geleid dat wij, zoals beschreven in **hoofdstuk 6.1**, onderzocht hebben hoe ogenschijnlijk niet-aangedane huid reageert op succesvolle ustekinumab therapie. Dit is getest door voorafgaand aan therapie en 4 weken na de eerste injectie van ustekinumab, huidbiopten af te nemen. Tevens werd er op dezelfde tijdstippen op dezelfde huidlocatie tape-stripping toegepast, gevolgd door het afnemen van huidbiopten 5 uur later. Van elk biopt werd de epidermis gescheiden van het dermale deel, waarna epidermaal RNA werd geïsoleerd. Onderzoek toonde aan dat de expressie van GATA3 in niet-aangedane huid onder succesvolle therapie toenam. Bovendien bleek dat ustekinumab de versterkte expressie van NGF door tape-stripping sterk verminderde. De basale expressie en respons op tape-stripping van de antimicrobiële eiwitten hBD-2, psoriasin, en LL-37 bleef onverstoord. Dit toont aan dat niet-aangedane huid reeds epidermale afwijkingen vertoont die reageren op therapie. Daarnaast blijkt succesvolle therapie gericht tegen zowel IL-12 als IL-23 niet noodzakelijk te leiden tot een verminderde antibacteriële respons.

In **hoofdstuk 6.2** beschrijven wij een patiënte met de zeldzame doch ongelukkige combinatie van de ziekte van Behçet, hidradenitis suppurativa (HS), en psoriasis vulgaris. Alle drie betreffen aandoeningen die gepaard gaan met huidafwijkingen waarbij neutrofiële granulocyten prominent betrokken zijn. Uit de literatuur blijkt dat in al deze aandoeningen mogelijk een rol is weggelegd voor Th1 en Th17 cellen. Patiënte werd in het kader van psoriasis succesvol behandeld met ustekinumab. Gedurende de behandelingsperiode van 36 maanden bleek dat ook de klachten passend bij Behçet en HS geleidelijk tot rust kwamen.

Deze casus toont aan dat deze ziekten mogelijk een gemeenschappelijke deler hebben in hun afzonderlijke pathogenese. Het therapeutisch richten op zowel IL-12 als IL-23 kan een belangrijke welkome therapeutische aanvulling betekenen voor zowel Behçet als HS.

In Europa is fumaarzuur therapie een veel voorkomende behandeling van psoriasis. Deze vorm van therapie wordt verondersteld een breed effect te hebben op immunologische ver-

anderingen in psoriasis, maar precieze kennis omtrent de effecten van fumaarzuur therapie in psoriasis ontbreekt. In **hoofdstuk 7** hebben wij met moleculaire technieken onderzocht welke veranderingen op RNA niveau plaats vinden in met fumaarzuur therapie succesvol behandelde psoriasis plaques. De verkregen resultaten zijn geplaatst in het kader van reeds bestaande kennis omtrent RNA veranderingen die optreden tijdens anti-TNF- α therapie.

Nagelafwijkingen komen voor bij 25-50% van de psoriasis patiënten. Ondanks de sterke groei qua therapeutische opties voor cutane psoriasis, blijft het aantal opties voor nagelpsoriasis gering. Kleinere non-placebo gecontroleerde studies meldden gunstige resultaten van topicale cyclosporine (CsA) bij nagelpsoriasis. Wij beschrijven in **hoofdstuk 8** de resultaten van een prospectieve, dubbel geblindeerde, gerandomiseerde, placebo-gecontroleerde onderzoek naar het effect van topicale toepassing van CsA in 70% maisolie versus maisolie (placebo) in patiënten met matige tot ernstige nagelpsoriasis. Op basis van dubbel-geblindeerde randomisatie werd de linker of rechter hand voor 16 weken 2 maal daags behandeld met CsA of placebo. Ter evaluatie van het klinisch effect werd de Nail Severity Index (NAPSI) bepaald. De resultaten van 30 patiënten konden worden gebruikt voor statistische analyse. Gedurende beide behandelingen bleef de NAPSI onveranderd. Echter, bij controle bezoek na 3 maanden bleek dat bij beide behandelingen een significante verbetering was opgetreden. Met deze studie is aangetoond dat het toepassen van topicale CsA geen meerwaarde heeft op nagelpsoriasis dan simpele maisolie.

Psoriasis wordt gekenmerkt door een sterke toename van bloedvaten in de hogere (papillaire) delen van de dermis. Verondersteld wordt dat veranderingen van het vaatendotheel het transport van afweercellen naar de huid faciliteert. Dit speelt mogelijk een belangrijke rol in het tot stand houden van de huidontsteking. Onderzoek heeft aangetoond dat reductie van deze bloedvaten doormiddel van selective photothermolysis met de pulsed dye laser (PDL), een gunstig therapeutisch effect heeft. In **Hoofdstuk 9** zijn de cellulaire en moleculaire effecten van PDL onderzocht door deze te vergelijken met de bekende effecten van small band-UVB. VEGFR2 en E-selectine staan beide bekend om de vaatwand (endotheel) specifieke expressie. Reeds na 1 PDL behandeling werd de expressie van VEGFR2 verlaagd wat gevolgd werd door een verlaging van E-selectine na 2 behandelingen. Dit laatste ging tevens gepaard met verminderde expressie van IL-23p19 en TNF- α mRNA. Gecombineerd dragen deze effecten bij aan de klinische effectiviteit van PDL in het behandelen van psoriasis.

Concluderend: Dit proefschrift dankt zijn oorsprong aan een belangrijke klinische observatie waarin het belang van perifere zenuwen in psoriasis werd opgemerkt. Dit onderzoek toont aan dat perifere zenuwen een cruciale rol spelen in de epidermale innate afweer en barrière, en in de pathogenese van psoriasis. Mogelijk dat de effecten van CGRP op zowel LL-37 als TLR9 hierbij een belangrijke rol spelen. Het aangetoonde effect van ustekinumab op zowel GATA3 als NGF in niet-aangedane huid toont indirect de verbondenheid van pe-

rifere zenuwen met het immuunsysteem. Op dit moment zijn er therapeutische middelen in aantocht die succesvol psoriasis bestrijden via het ingrijpen op de effecten van NGF. Toekomstig onderzoek moet uitwijzen of ingrijpen in neuropeptiden en TLR signalering therapeutisch effectief is in psoriasis.

Chapter 12

Dankwoord

List of publications

Curriculum vitae

PhD portfolio

Abbreviations

References

DANKWOORD

Na 5 jaar zit het er dan (bijna) op. En ondanks dat het bij tijd en wijle flink aanpoten was, zal deze periode mij bijblijven als een zeer leerzame en plezierige ervaring die de leergierige ik niet had willen missen. Terugkijkend durf ik te stellen dat het werk vertegenwoordigd door dit proefschrift, het resultaat is van samenwerking tussen een keur van mensen, teveel om op te noemen. Echter, aan een aantal wil ik in het bijzonder mijn dank betuigen.

Beste Errol, onze gezamenlijke wetenschappelijke inspanningen lijken te zijn gestart met het vallen van de naam Jose. Niet alleen op wetenschappelijk, maar ook op persoonlijk gebied stond je deur altijd open, wat ik als zeer plezierig heb mogen ervaren. Jouw rijke en brede wetenschappelijke en klinische kennis was de reden om dit traject te starten, maar ook uitermate belangrijk in het afronden van het project. Moge er nog vele komen.

Beste Jon, tezamen met Errol vormde je een zeer effectief promotoren-duo. Bedankt voor alle mogelijkheden, flexibiliteit, kritische blik, geduld en kennisoverdracht die je de afgelopen jaren hebt geboden.

Beste Jurr, zie hier alweer een project gebaseerd op jou klinische blik. Dank voor je luisterend oor, je creatieve ingevingen en het delen van je persoonlijk archief.

Geachte prof. Hovius, dank voor het kritisch willen beschouwen van dit proefschrift.

Beste professor Neumann, dank voor het gestelde vertrouwen om dit onderzoek te laten verrichten in de vorm van een AGIKO-constructie. Ik ben het helemaal met u eens: het proefschrift draait, linksom of rechtsom, om wetenschappelijke vorming.

Geachte prof. Schalkwijk, beste Joost, ik kan me de eerste ontmoeting te Gleneden Beach nog goed herinneren. Ik wil je bedanken voor de goede samenwerking, heldere uitleg, en voor je inzet als lid van de leescommissie.

Dear Johann, I am constantly amazed by the unique scientific approach of your work in the field of psoriasis. I would like to thank you for the collaboration and your swift acceptance of the invitation to take part in the thesis defence committee.

Dear prof Pincelli, we share certainly the scientific interest in the interaction of nerves and skin, and I feel honoured by your visit to our department and taking part in the defence committee.

Geachte prof. De Rie, beste Menno, jou inzet op het gebied van huidinflammatie en in het bijzonder psoriasis geldt voor mij als goed voorbeeld. Dank voor de getoonde interesse en de deelname aan de grote commissie.

Beste Eddy, jou positieve manier van denken en inzet waardeer ik enorm. Bedankt voor je hulp. Masha masha danki pa bo apoyo i bo koloborashon.

Beste Armanda, Emöke en Hessel, jullie raad en steun zorgde ervoor dat er een effectieve vaart gehandhaafd werd. Ik hoop dat wij nog lang onderzoeks-sparring partners kunnen zijn.

Anne, Lizenka, Chris, Robin, Erik Walbeehm, Ineke, Leslie, Karin, Marie-Jose, Ann, Marjan, Jeroen, Karim, Ruth, Erik Iubberts, Patrick, Björn, Dorota, Prof. Benner, Prof. Van Hagen, Prof. Hooijkaas, Tanja, Hilly, Peter en vele andere collega's: er is altijd wel een moment geweest dat ik een beroep op jullie heb gedaan in het kader van dit proefschrift. Dank voor jullie interesse, medewerking en steun.

Beste Marjon, Deborah, Deepak, Martijn, Jaap en Bing, dank voor jullie inzet en steun, met name tijdens de roerige maar bijzondere dagen van enkele klinische trials, maar ook voor het gezelschap in Lunteren en ver daarbuiten.

Alle arts-assistenten van de afdeling Dermatologie wil ik bedanken voor hun flexibiliteit tijdens het 'aanpoten', maar ook voor de broodnodige afleiding, vooral in de vorm van 'culturele' weekeinden te Brugge, Bergen, het pittoreske Rijssel, Gerlos en Mayrhofen. In het bijzonder wil ik Leon, Tom, Hilde, Willemijn, Oded, Patrick, Tim, en Wendy bedanken voor de afgelopen mooie jaren.

Edmée Crombag, Monique van den Bergh en Daniel Monasso, bedankt voor jullie inzet gedurende de afgelopen jaren en ik zie uit naar onze verdere samenwerking.

Veel dank gaat uit naar alle patiënten die onbaatzuchtig letterlijk deel uitmaken van dit proefschrift.

Alle vrienden wil ik bedanken voor hun interesse en het aanhoren van ellendelange verhalen over onderzoek. In het bijzonder wil ik Carla Offerhaus en Bender danken voor hun inzet en hulp om de cover een 'smoel' te geven.

Beste Rene, mede door jou zijn we de rol van zenuwen gaan verkennen. Dank voor al je inzet, de mooie tijd in de Alpen en voor het bieden van een luisterend oor en de duidelijke taal tussen ons beiden.

Tja, Evert-Jan, wat kan ik zeggen. Over lij- en loefzijde kunnen we twisten, maar jou gedrevenheid voor onderzoek en kliniek mag zeker als leidraad gelden.

Waar ook ter wereld, niets gaat zonder de aanhoudende steun en interesse van familie, schoonfamilie en aanhang, dank voor al jullie hulp. Lieve oma Muis en opa Kip, speciale dank gaat zeker uit naar jullie inzet.

Lieve ouders, zie hier het resultaat van al jullie inzet, ouderavonden, geduld, stimuleren van breed wetenschappelijke denkwijze en vergaren van kennis, beslommingen, bezorgdheid, en bovenal onvoorwaardelijke liefde en steun.

Lieve Louke, lieve Mijntje en lieve Floor. Jullie komst maakte het uitslapen tot een uitdaging maar bovenal het leven een waar feest vol verwondering!

Lieve schat, zonder enige twijfel ben ik dit avontuur in 2007 gestart wetende dat ik op jou, je geduld, perspectief, ondersteuning, relativeringsvermogen en bovenal liefde kon rekenen. Je verdient het om net zo trots te zijn als ikzelf op dit werk.

Bo a mi!

LIST OF PUBLICATIONS

Baerveldt EM, Onderdijk AJ, Kant M, Boer J and Prens EP. Resolution of psoriatic plaques due to skin denervation: Molecular exploration of a forgotten phenomenon. Submitted

Baerveldt EM, Onderdijk AJ, Wohn CT, Kant M, Florencia EF, Hekking-Weijma IJ, Laman JD, Swindell WR, Gudjonsson JE, Clausen BE, Walbeehm ET, and Prens EP. Surgical denervation of mouse skin prevents imiquimod induced psoriasiform inflammation. Submitted

Baerveldt EM, Florencia EF, Kant M, Kurek DM, Neumann HAM, Laman JD, and Prens EP. CGRP and acetylcholine promote epidermal TLR9 and LL-37 expression in human healthy skin explants. Submitted

Onderdijk AJ, Balak DMW, **Baerveldt EM**, Florencia EF, Kant M, Rácz E, De Ridder D, Thio HB, and Prens EP. Fumaric acid esters and etanercept target different gene signalling pathways in psoriasis. Submitted

Baerveldt EM, Onderdijk AJ, Kurek DM, Kant M, Florencia EF, Bastiaans J, Jansen PA, Van Kilsdonk JWJ, Ijpm AS, Laman JD and Prens EP. Ustekinumab improves psoriasis-related gene expression in non-involved psoriatic skin without inhibition of the antimicrobial response. *British Journal of Dermatology* 2012; 12175

Onderdijk AJ, **Baerveldt EM**, Kurek DM, Kant M, Florencia EF, Debets R and Prens EP. IL-4 down-regulates IL-1 β and IL-6 and induces GATA-3 in psoriatic epidermal cells: a cell type-restricted route of action of a Th2 cytokine. Submitted

Baerveldt EM, Torcque LA, De Jong MCH, Neumann HAM, Van Rengen AMW and Prens EP. The efficacy of topically applied cyclosporin in nail psoriasis: a prospective, double-blinded, randomized, placebo-controlled study. *F1000 research* 2012; accepted for publication

Baerveldt EM, Kappen J, Thio HB, Laar van J, Van Hagen PM and Prens EP. Successful ustekinumab treatment in a patient with combined psoriasis, behçet's disease, and hidradenitis suppurativa. *Annals of the Rheumatic Diseases* 2012; 202392

Van Der Flier M, **Baerveldt EM**, Miedema A, Hazelzet JA, Emonts M, Hartwig NG, Prens EP, Van Vught AJ, De Groot R and Jansen NJ. Decreased expression of microvascular endothelial VEGF receptor-2 in meningococcal sepsis. *Pediatric Critical Care Medicine* 2012. Submitted

Rácz E, Prens EP, Kurek D, Kant M, de Ridder D, Mourits S, **Baerveldt EM**, Ozgur Z, van IJcken WF, Laman JD, Staal FJ and van der Fits L. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. *Journal of Investigative Dermatology* 2011; 131:1547-58.

Van Hagen PM, Prens EP, Hooijkaas HH, **Baerveldt EM**, Dik WA, van der Velden VHJ. Monoclonal antibodies: The immune system and haematological malignancies. *European Journal of Hospital Pharmacists Practice*. 2011; 17:16-9.

Rácz E, Kurek D, Kant M, **Baerveldt EM**, Florencia E, Mourits S, de Ridder D, Laman JD, van der Fits L and Prens EP. GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4. *PLoS ONE* 2011; 6:e19806.

Rácz E, de Leeuw J, **Baerveldt EM**, Kant M, Neumann HA, van der Fits L and Prens EP. Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis. *Lasers in Surgery and Medicine* 2010; 42:201-10.

Baerveldt EM, Thio HB and Prens EP. Effecten van ustekinumab op niet-aangedane psoriasis-huid: Reductie van psoriasis gerelateerde genexpressie zonder verstoring van de antimicrobiële respons. *Nederlands Tijdschrift voor Dermatologie en Venereologie* 2012; 22:115-117.

Prens EP, Torque LA, Onderdijk AJ, **Baerveldt EM**. Psoriasis: A disease caused by our innate immunity? – Psoriasis: Een ziekte veroorzaakt door onze innate immuniteit? *Nederlands Tijdschrift voor Dermatologie en Venereologie*. 2011; 21:79-81.

Baerveldt EM and Thio HB. Het antimicrobiële peptide LL-37: vriend of vijand? *Nederlands Tijdschrift voor Dermatologie en Venereologie* 2011; 21: 336-39.

Baerveldt EM and Prens EP. Is er een verband tussen ‘erosive pustular dermatosis’ en interne medicatie? *Spreekuur Dermatologie* 2010; 1

Baerveldt EM and Diekman MJ. Strange stripe. *Netherlands Journal of Medicine* 2007; 65: 309-10.

CURRICULUM VITAE

Ewout Marinus Baerveldt

- 8th April 1979 Born in Zwolle, The Netherlands
- 2012 Residency, Dept. Dermatology, supervised by H.B. Thio, MD, PhD, Erasmus MC, Rotterdam
- 2011 Residency, Dept. Dermatology, supervised by M.C.G. Van Praag, MD, PhD, Sint Franciscus Gasthuis, Rotterdam
- 2010 Spring Research internship, supervised by N.L. Ward, PhD, Depts. Dermatology and Neuroscience, Case Western Reserve University, Cleveland, OH, USA
- 2007 – 2010 Local subinvestigator in pharmacy initiated clinical phase III trials
- 2007 – 2012 PhD research project: “Neurogenic inflammation in the pathogenesis of psoriasis” Supervised by Prof. E.P. Prens, MD, PhD, and Prof. J.D. Laman, PhD, Depts. Dermatology and Immunology, Erasmus MC, Rotterdam
- 2007 Residency, Dept. Dermatology, supervised by Prof. H.A.M. Neumann, MD, PhD, Erasmus MC, Rotterdam, The Netherlands
- 2007 MD degree, (Arts-examen), Faculty of Medicine, University of Groningen
- 2006 –2007 Research internship: “The effects of pulsed dye laser treatment on psoriatic plaques: an immunohistochemical study”, supervisors Prof. E.P. Prens, MD, PhD, Dept. Dermatology, Erasmus MC and J. Boer, MD, PhD, Dept. Dermatology, Deventer Hospital
- 2005 Spring Extra-curricular internship Dermatology, supervisor L.W. Barkema, MD, PhD, Dept. Dermatology, Antonius Hospital, Sneek
- 2005 – 2006 Internship; Deventer Hospital, The Netherlands
- 1999 – 2002 Extra-curricular courses, Faculty of Law, University of Groningen
- 1997 – 2004 Faculty of Medicine, University of Groningen, The Netherlands
- 1991 – 1997 Atheneum (Science High School), Sneek, the Netherlands

PHD PORTFOLIO

Summary of PhD training and teaching activities

Name PhD student:	Ewout Baerveldt	PhD period:	2007 – 2012
Erasmus MC Department:	Dermatology	Promotors:	Prof. E.P. Prens, MD, PhD Prof. J.D. Laman, PhD
Research School:	Moleculuar Medicine		

	Year	Workload Hours/ECTS
1. PhD Training		
General academic skills		
- Cursus Management voor promovendi en postdocs (NIBI)	2010	24 h
- English Biomedical Writing and Communication	2010	4 ECTS
Research skills		
- Biostatistics for clinicians (Nihes)	2009	1 ECTS
- Introduction to clinical research (Nihes)	2009	1 ECTS
In-depth seminars, workshop and courses		
- 12 th NVED meeting, Lunteren, The Netherlands	2011	1 ECTS
- Training Implementatie Medische Vervolgopleidingen (Desiderius)	2010	8 h
- 11 th NVED meeting, Lunteren, The Netherlands	2010	1 ECTS
- Medische Ethiek (Desiderius)	2009	8 h
- Infectieziekten en immunologie nascholingscursus	2009	16 h
- 10 th NVED meeting, Lunteren, The Netherlands	2009	1 ECTS
- Minisymposium: Autoimmunity to neural antigens in MS Dept. Immunology, Erasmus MC, Rotterdam, The Netherlands	2009	0.5 ECTS
- Cursus medische immunologie (Hogeschool Avans)	2008	16 h
- Good Clinical Practice Course Medical Trials	2008	4 h
- 12 th Molecular Medicine Day, Rotterdam, The Netherlands	2008	0.7 ECTS
- 9 th NVED meeting, Lunteren, The Netherlands	2008	1 ECTS
- Seminar: GATA3 in T cell development and effector function. Dept. Immunology, Erasmus MC, Rotterdam, The Netherlands	2008	0.5 ECTS
- Minisymposium: Dendritic cells in the immune response Dept. Immunology, Erasmus MC, Rotterdam, The Netherlands	2008	0.5 ECTS
- Minisymposium: Cardiovascular risk factors in psoriasis Dept. Dermatology, Erasmus MC, Rotterdam, The Netherlands	2008	0.5 ECTS

(Inter)national scientific presentations (oral)

- Progress report, Dept. Immunology	2007-2012	5 ECTS
- Skin denervation prevents imiquimod-induced psoriasiform inflammation. 12 th NVED meeting, Lunteren, The Netherlands	2011	1 ECTS
- Topical cyclosporin in nail psoriasis. 11 th NVED meeting, Lunteren, The Netherlands	2010	1 ECTS
- Neuroinflammation of the skin. Brugge Dagen, Valkenburg a/d Geul, The Netherlands	2009	1 ECTS
- Neuropeptides and acetylcholine promote epidermal expression of TLR9, LL-37 and IL-22 receptor in human skin. 10 th NVED meeting, Lunteren, The Netherlands	2009	1 ECTS
- The role of the peripheral nervous system in the development of psoriasis. Research collaboration meeting. Dept. Dermatology, University of Manchester, UK	2009	1 ECTS
- Neuronal activation of innate skin immunity: Stress-mediators enhance antimicrobial barrier. Montagna Symposium on the Biology of Skin, Gleneden Beach, OR, USA	2008	1 ECTS

(Inter)national scientific presentations (Poster)

- Clinically effective ustekinumab reduces plaque-derived serum β -defensin-2 without impairing the epidermal antimicrobial response in uninvolved psoriatic skin. 16 th Molecular Medicine Day, Rotterdam, The Netherlands	2012	1 ECTS
- Determining effects clinically effective ustekinumab outside psoriatic plaques: Selectively improving epidermal barrier and suppressing serum β -Defensin-2. 6th International congress Psoriasis: From Gene to Clinic, London, UK	2011	1 ECTS
- Anti-p40 therapy protects against epidermal barrier disruption 11 th NVED annual meeting, Lunteren, The Netherlands	2010	1 ECTS
- Nerve growth factor regulation by Th17/IL23 in murine psoriasis-like model and human uninvolved psoriatic skin. Montagna Symposium on the Biology of Skin, Gleneden Beach, OR, USA	2010	1 ECTS
- Anti IL-12/IL-23 p40 therapy inhibits epidermal activation in uninvolved psoriatic skin. 40 th ESDR meeting, Helsinki, Finland	2010	1 ECTS
- CGRP induces ex vivo upregulation of epidermal TLR9 expression and LL-37 gene-expression. 39th ESDR meeting, Budapest, Hungary	2009	1 ECTS
- Neuronal activation of innate skin immunity: Stress-mediators enhance antimicrobial barrier. Montagna Symposium on the Biology of Skin, Gleneden Beach, OR, USA	2008	1 ECTS

(Inter)national conferences

- 42th ESDR Meeting, Venice, Italy	2012	1 ECTS
- 41th ESDR Meeting, Barcelona, Spain	2011	1 ECTS
- 6th International congress Psoriasis: From Gene to Clinic, London, UK	2011	1 ECTS
- 40th ESDR Meeting, Helsinki, Finland	2010	1 ECTS
- Montagna Symposium on the Biology of Skin, Gleneden Beach, OR, USA	2010	1 ECTS
- 39th ESDR Meeting, Budapest, Hungary	2009	1 ECTS
- International Investigative Dermatology meeting Kyoto, Japan	2008	1 ECTS
- Montagna Symposium on the Biology of Skin, Gleneden Beach, OR, USA	2008	1 ECTS
- 38th ESDR Meeting, Zürich, Switzerland	2007	1 ECTS

Other

- Bruggedagen, Valkenburg a/d Geul, The Netherlands	2009	1 ECTS
- Research meeting 'pearls' Brussels, Belgium	2009	8 h
- Psoriasis & PDT (DIS; Dermatologie Immunologie Stichting)	2008	16 h
- Drug research investigator's meetings, Europe	2007-2009	56 h
- Immunology PhD retreat (Organizing committee 2009)	2007-2010	70 h

Occasional reviewer for

- Journal of Investigative Dermatology	2010	4 h
- Nederlands Tijdschrift voor Geneeskunde	2010	4 h
- International Journal of Dermatology	2007	4 h

2. Student coaching and teaching

- Immunological case discussions for 2 nd year medical students	2007-2012	100 h
- Supervising and assisting research projects medical students	2007-2011	
- Teach the teacher (Desiderius)	2008	16 h

ABBREVIATIONS

ACh	Acetylcholine
AD	Atopic Dermatitis
AhR	Aryl hydrocarbon receptor
AMP	Antimicrobial peptide
APC	Antigen presenting cell
CGRP	Calcitonin gene related peptide
CLA	cutaneous lymphocyte-associated antigen
CLR	C-type lectins
CsA	Cyclosporin
DAMP	Danger-associated molecular pattern molecules
DC	Dendritic cell
DCD	Dermcidin
DN	Denervation
DRG	Dorsal root ganglia
EDC	Epidermal differentiation complex
EGF	Epidermal growth factor
GWAS	Genome-wide association studies
hBD	Human β -defensin
HLA	Human leukocyte antigen
HS	Hidradenitis suppurativa
IBD	Inflammatory bowel disease
IFN	Interferon
IGF	Insulin-like growth factor
IL	Interleukin
IMDM	Iscove's modified Dulbecco's medium
IMQ	Imiquimod
IPA	Ingenuity Pathway Analysis
IRAK	IL-1R-associated kinases
KC	Keratinocyte
LC	Langerhans cells
LCE	Late cornified envelopes
LPS	Lipopolysaccharide
MAPK	MAP kinase
MC	Mast cell
MMP	Matrix metalloproteinase
mAb	Monoclonal antibodies
MyD88	Myeloid differentiation factor

Neu	Neutrophil
NGF	Nerve growth factor
NK	Natural killer
NKA	Neurokinin A
NK-1R	Neurokinin receptor
NLR	NOD-like receptor
NPY	Neuropeptide Y
NRF	Nuclear factor erythroid derived 2, like 2
P75-NTR	p75 Neurotrophin receptor
PAMP	Pathogen-associated molecular patterns
PASI	Psoriasis area and severity index
PDL	Pulsed dye laser
PGP9.5	Protein gene product 9.5
PP	Plaque psoriasis
PRR	Pattern recognition receptors
RA	Rheumatoid arthritis
RMA	Robust multichip analysis
RNase7	Ribonuclease 7
SFRP	Secreted frizzled related protein
SKALP	Skin-derived antileukoproteinase
SNP	Single nucleotide polymorphism
SP	Substance P
SPP1	Secreted phosphoprotein 1
SPRR	Small proline rich proteins
TA	Transiently amplifying
Tcm	Central memory T cells
TGF	Transforming growth factor
Th	T helper
TIRAP	TIR-associated protein
TLR	Toll like receptor
TNC	Tenascin C
TNF	Tumor necrosis factor
TRAF	TNFR-associated factor 6
TRAM	TRIF-related adaptor molecule
TRIF	TIR-domain-containing adaptor protein-inducing IFN-
TRPV	Transient receptor potential vanilloid
VEGF	Vascular endothelial growth factor
VIP	Vasoactive intestinal peptide

REFERENCES

1. Farber EM, Nickoloff BJ, Recht B, Fraki JE. Stress, symmetry, and psoriasis: possible role of neuropeptides. *J Am Acad Dermatol* 1986;14(2 Pt 1):305-11.
2. Farber EM, Lanigan SW, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis. *Int J Dermatol* 1990;29(6):418-20.
3. Raychaudhuri SP, Farber EM. Are sensory nerves essential for the development of psoriatic lesions? *J Am Acad Dermatol* 1993;28(3):488-9.
4. Prens EP, Benne K, van Joost T, Benner R. The autologous mixed epidermal cell-T lymphocyte reaction is elevated in psoriasis: a crucial role for epidermal HLA-DR+/CD1a- antigen-presenting cells. *J Invest Dermatol* 1991;96(6):880-7.
5. Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS, et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. *J Invest Dermatol* 2009;129(12):2795-804.
6. Bergboer JG, Zeeuwen PL, Schalkwijk J. Genetics of Psoriasis: Evidence for Epistatic Interaction between Skin Barrier Abnormalities and Immune Deviation. *J Invest Dermatol* 2012.
7. Grice EA, Segre JA. The skin microbiome. *Nat Rev Microbiol* 2011;9(4):244-53.
8. Fuchs E, Horsley V. More than one way to skin. *Genes Dev* 2008;22(8):976-85.
9. Chiodino C, Cesinaro AM, Ottani D, Fantini F, Giannetti A, Trentini GP, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. *J Invest Dermatol* 1999;113(3):415-8.
10. Li F. Survivin study: what is the next wave? *J Cell Physiol* 2003;197(1):8-29.
11. Marconi A, Dallaglio K, Lotti R, Vaschieri C, Truzzi F, Fantini F, et al. Survivin identifies keratinocyte stem cells and is downregulated by anti-beta1 integrin during anoikis. *Stem Cells* 2007;25(1):149-55.
12. Jones PH, Simons BD, Watt FM. Sic transit gloria: farewell to the epidermal transit amplifying cell? *Cell Stem Cell* 2007;1(4):371-81.
13. de Guzman Strong C, Wertz PW, Wang C, Yang F, Meltzer PS, Andl T, et al. Lipid defect underlies selective skin barrier impairment of an epidermal-specific deletion of Gata-3. *J Cell Biol* 2006;175(4):661-70.
14. Hohl D, de Viragh PA, Amiguet-Barras F, Gibbs S, Backendorf C, Huber M. The small proline-rich proteins constitute a multigene family of differentially regulated cornified cell envelope precursor proteins. *J Invest Dermatol* 1995;104(6):902-9.
15. Schafer M, Farwanah H, Willrodt AH, Huebner AJ, Sandhoff K, Roop D, et al. Nrf2 links epidermal barrier function with antioxidant defense. *EMBO Mol Med* 2012;4(5):364-79.
16. Truzzi F, Marconi A, Atzei P, Panza MC, Lotti R, Dallaglio K, et al. p75 neurotrophin receptor mediates apoptosis in transit-amplifying cells and its overexpression restores cell death in psoriatic keratinocytes. *Cell Death Differ* 2011;18(6):948-58.
17. Hoste E, Denecker G, Gilbert B, Van Nieuwerburgh F, van der Fits L, Asselbergh B, et al. Caspase-14-Deficient Mice Are More Prone to the Development of Parakeratosis. *J Invest Dermatol* 2012.
18. Lin TK, Crumrine D, Ackerman LD, Santiago JL, Roelandt T, Uchida Y, et al. Cellular Changes that Accompany Shedding of Human Corneocytes. *J Invest Dermatol* 2012;132(10):2430-9.
19. Tam C, Mun JJ, Evans DJ, Fleiszig SM. Cytokeratins mediate epithelial innate defense through their antimicrobial properties. *J Clin Invest* 2012;122(10):3665-77.
20. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. *Nat Rev Immunol* 2009;9(10):679-91.
21. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, et al. The vast majority of CLA+ T cells are resident in normal skin. *J Immunol* 2006;176(7):4431-9.

22. Barohn RJ. Intraepidermal nerve fiber assessment: a new window on peripheral neuropathy. *Arch Neurol* 1998;55(12):1505-6.
23. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. *Immunity* 2011;35(6):857-69.
24. Nestle FO, Nickoloff BJ. Deepening our understanding of immune sentinels in the skin. *J Clin Invest* 2007;117(9):2382-5.
25. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* 2008;8(12):958-69.
26. Dupasquier M, Stoitzner P, van Oudenaren A, Romani N, Leenen PJ. Macrophages and dendritic cells constitute a major subpopulation of cells in the mouse dermis. *J Invest Dermatol* 2004;123(5):876-9.
27. Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. *J Clin Immunol* 2009;29(3):247-56.
28. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIa+ macrophages. *J Clin Invest* 2007;117(9):2517-25.
29. Bursch LS, Wang L, Igyarto B, Kissenpfennig A, Malissen B, Kaplan DH, et al. Identification of a novel population of Langerin+ dendritic cells. *J Exp Med* 2007;204(13):3147-56.
30. Ginhoux F, Collin MP, Bogunovic M, Abel M, Leboeuf M, Helft J, et al. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. *J Exp Med* 2007;204(13):3133-46.
31. Poulin LF, Henri S, de Bovis B, Devilard E, Kissenpfennig A, Malissen B. The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. *J Exp Med* 2007;204(13):3119-31.
32. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. *Nat Immunol* 2009;10(5):488-95.
33. Mathers AR, Janelsins BM, Rubin JP, Tkacheva OA, Shufesky WJ, Watkins SC, et al. Differential capability of human cutaneous dendritic cell subsets to initiate Th17 responses. *J Immunol* 2009;182(2):921-33.
34. Morelli AE, Rubin JP, Erdos G, Tkacheva OA, Mathers AR, Zahorchak AF, et al. CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. *J Immunol* 2005;175(12):7905-15.
35. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. *Nat Immunol* 2004;5(10):987-95.
36. Fuentes-Duculan J, Suarez-Farinas M, Zaba LC, Nograles KE, Pierson KC, Mitsui H, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. *J Invest Dermatol* 2010;130(10):2412-22.
37. Oliphant CJ, Barlow JL, McKenzie AN. Insights into the initiation of type 2 immune responses. *Immunology* 2011;134(4):378-85.
38. Djemadji-Oudjiel N, Goerdts S, Kodelja V, Schmutz M, Orfanos CE. Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis. *Arch Dermatol Res* 1996;288(12):757-64.
39. Clark RA. Skin-resident T cells: the ups and downs of on site immunity. *J Invest Dermatol* 2010;130(2):362-70.
40. Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. *Sci Transl Med* 2012;4(117):117ra7.
41. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 1999;401(6754):708-12.
42. Mackay CR, Marston WL, Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. *J Exp Med* 1990;171(3):801-17.

43. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. *Nat Rev Immunol* 2009;9(3):153-61.
44. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. *Annu Rev Immunol* 2000;18:975-1026.
45. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. *Science* 2001;294(5542):605-9.
46. Jameson J, Havran WL. Skin gammadelta T-cell functions in homeostasis and wound healing. *Immunol Rev* 2007;215:114-22.
47. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. *Nat Immunol* 2011;12(1):21-7.
48. Di Santo JP. Natural killer cells: diversity in search of a niche. *Nat Immunol* 2008;9(5):473-5.
49. Lanier LL. NK cell recognition. *Annu Rev Immunol* 2005;23:225-74.
50. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. *J Exp Med* 2005;202(2):203-7.
51. Shrestha N, Ida JA, Lubinski AS, Pallin M, Kaplan G, Haslett PA. Regulation of acquired immunity by gamma delta T-cell/dendritic-cell interactions. *Ann N Y Acad Sci* 2005;1062:79-94.
52. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol* 2007;81(1):1-5.
53. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell* 2010;140(6):805-20.
54. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. *J Biol Chem* 2001;276(13):10229-33.
55. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. *J Immunol* 2001;167(5):2887-94.
56. Savage CD, Lopez-Castejon G, Denes A, Brough D. NLRP3-Inflammasome Activating DAMPs Stimulate an Inflammatory Response in Glia in the Absence of Priming Which Contributes to Brain Inflammation after Injury. *Front Immunol* 2012;3:288.
57. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat Immunol* 2001;2(8):675-80.
58. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol* 2010;11(5):373-84.
59. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. *J Immunol* 2003;170(3):1517-23.
60. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. *Nature* 2009;458(7237):514-8.
61. Karpala AJ, Doran TJ, Bean AG. Immune responses to dsRNA: implications for gene silencing technologies. *Immunol Cell Biol* 2005;83(3):211-6.
62. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-like receptors and their function. *Nat Rev Immunol* 2012;12(3):168-79.
63. Kondo T, Kawai T, Akira S. Dissecting negative regulation of Toll-like receptor signaling. *Trends Immunol* 2012;33(9):449-58.
64. Merlo A, Calcaterra C, Menard S, Balsari A. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses. *J Leukoc Biol* 2007;82(3):509-18.
65. Wang J, Shao Y, Bennett TA, Shankar RA, Wightman PD, Reddy LG. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. *J Biol Chem* 2006;281(49):37427-34.
66. Silver AC, Arjona A, Walker WE, Fikrig E. The circadian clock controls toll-like receptor 9-mediated innate and adaptive immunity. *Immunity* 2012;36(2):251-61.
67. Mempel M, Voelcker V, Kollisch G, Plank C, Rad R, Gerhard M, et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus

- aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. *J Invest Dermatol* 2003;121(6):1389-96.
68. Miller LS, Sorensen OE, Liu PT, Jalian HR, Eshtiaghpour D, Behmanesh BE, et al. TGF-alpha regulates TLR expression and function on epidermal keratinocytes. *J Immunol* 2005;174(10):6137-43.
 69. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. *J Invest Dermatol* 2007;127(2):331-41.
 70. Harder J, Nunez G. Functional expression of the intracellular pattern recognition receptor NOD1 in human keratinocytes. *J Invest Dermatol* 2009;129(5):1299-302.
 71. Sandig H, Bulfone-Paus S. TLR signaling in mast cells: common and unique features. *Front Immunol* 2012;3:185.
 72. Kalali BN, Kollisch G, Mages J, Muller T, Bauer S, Wagner H, et al. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. *J Immunol* 2008;181(4):2694-704.
 73. Prens EP, Kant M, van Dijk G, van der Wel LI, Mourits S, van der Fits L. IFN-alpha enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: relevance for psoriasis. *J Invest Dermatol* 2008;128(4):932-8.
 74. Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. *Nat Rev Immunol* 2012;12(7):503-16.
 75. Barton GM, Medzhitov R. Linking Toll-like receptors to IFN-alpha/beta expression. *Nat Immunol* 2003;4(5):432-3.
 76. Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial peptides. *J Invest Dermatol* 2005;125(1):9-13.
 77. Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol* 2002;20:197-216.
 78. Kadowaki N, Liu YJ. Natural type I interferon-producing cells as a link between innate and adaptive immunity. *Hum Immunol* 2002;63(12):1126-32.
 79. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. *Arch Dermatol* 2004;140(12):1490-5.
 80. Zucchini N, Bessou G, Traub S, Robbins SH, Uematsu S, Akira S, et al. Cutting edge: Overlapping functions of TLR7 and TLR9 for innate defense against a herpesvirus infection. *J Immunol* 2008;180(9):5799-803.
 81. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. *Nature* 1997;387(6636):861.
 82. Schaubert J, Svanholm C, Termen S, Iffland K, Menzel T, Scheppach W, et al. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. *Gut* 2003;52(5):735-41.
 83. Braff MH, Di Nardo A, Gallo RL. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. *J Invest Dermatol* 2005;124(2):394-400.
 84. Lai Y, Li D, Li C, Muehleisen B, Radek KA, Park HJ, et al. The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. *Immunity* 2012;37(1):74-84.
 85. Di Nardo A, Yamasaki K, Dorschner RA, Lai Y, Gallo RL. Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. *J Immunol* 2008;180(11):7565-73.
 86. Kanda N, Watanabe S. IL-12, IL-23, and IL-27 enhance human beta-defensin-2 production in human keratinocytes. *Eur J Immunol* 2008;38(5):1287-96.
 87. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. *Nat Immunol* 2011;12(5):383-90.

88. Kobayashi M, Yoshiki R, Sakabe J, Kabashima K, Nakamura M, Tokura Y. Expression of toll-like receptor 2, NOD2 and dectin-1 and stimulatory effects of their ligands and histamine in normal human keratinocytes. *Br J Dermatol* 2009;160(2):297-304.
89. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. *J Immunol* 2004;172(5):3070-7.
90. Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S, et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. *Nat Immunol* 2001;2(12):1133-7.
91. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. *Trends Immunol* 2002;23(6):291-6.
92. Niyonsaba F, Suzuki A, Ushio H, Nagaoka I, Ogawa H, Okumura K. The human antimicrobial peptide dermcidin activates normal human keratinocytes. *Br J Dermatol* 2009;160(2):243-9.
93. Kopfnagel V, Wittmann M, Werfel T. Human keratinocytes express AIM2 and respond to dsDNA with IL-1beta secretion. *Exp Dermatol* 2011;20(12):1027-9.
94. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. *Circ Res* 2012;110(6):875-88.
95. Park HJ, Cho DH, Kim HJ, Lee JY, Cho BK, Bang SI, et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. *J Invest Dermatol* 2009;129(4):843-50.
96. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. *Nature* 2007;449(7162):564-9.
97. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. *J Exp Med* 2009;206(9):1983-94.
98. Morizane S, Yamasaki K, Muhleisen B, Kotel PF, Murakami M, Aoyama Y, et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. *J Invest Dermatol* 2012;132(1):135-43.
99. Johansson O. The innervation of the human epidermis. *J Neurol Sci* 1995;130(2):228.
100. Fuchs E. Scratching the surface of skin development. *Nature* 2007;445(7130):834-42.
101. Martinez-Martinez E, Galvan-Hernandez CI, Toscano-Marquez B, Gutierrez-Ospina G. Modulatory role of sensory innervation on hair follicle stem cell progeny during wound healing of the rat skin. *PLoS One* 2012;7(5):e36421.
102. Dale HH, Feldberg W. The chemical transmission of secretory impulses to the sweat glands of the cat. *J Physiol* 1934;82(1):121-8.
103. Hilliges M, Wang L, Johansson O. Ultrastructural evidence for nerve fibers within all vital layers of the human epidermis. *J Invest Dermatol* 1995;104(1):134-7.
104. McArthur JC, Griffin JW. Another tool for the neurologist's toolbox. *Ann Neurol* 2005;57(2):163-7.
105. Grando SA. Cholinergic control of epidermal cohesion. *Exp Dermatol* 2006;15(4):265-82.
106. Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. *J Invest Dermatol* 2006;126(9):1948-65.
107. Tracey KJ. The inflammatory reflex. *Nature* 2002;420(6917):853-9.
108. Andersson U, Tracey KJ. Neural reflexes in inflammation and immunity. *J Exp Med* 2012;209(6):1057-68.
109. Barajon I, Serrao G, Arnaboldi F, Opizzi E, Ripamonti G, Balsari A, et al. Toll-like receptors 3, 4, and 7 are expressed in the enteric nervous system and dorsal root ganglia. *J Histochem Cytochem* 2009;57(11):1013-23.
110. Goethals S, Ydens E, Timmerman V, Janssens S. Toll-like receptor expression in the peripheral nerve. *Glia* 2010;58(14):1701-9.
111. Chiu IM, von Hehn CA, Woolf CJ. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. *Nat Neurosci* 2012;15(8):1063-7.

112. Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. *J Virol* 2005;79(20):12893-904.
113. Zhou Y, Ye L, Wan Q, Zhou L, Wang X, Li J, et al. Activation of Toll-like receptors inhibits herpes simplex virus-1 infection of human neuronal cells. *J Neurosci Res* 2009;87(13):2916-25.
114. Lee J, Kim T, Hong J, Woo J, Min H, Hwang E, et al. Imiquimod enhances excitability of dorsal root ganglion neurons by inhibiting background (K(2P)) and voltage-gated (K(v)1.1 and K(v)1.2) potassium channels. *Mol Pain* 2012;8:2.
115. Boivin A, Pineau I, Barrette B, Filali M, Vallieres N, Rivest S, et al. Toll-like receptor signaling is critical for Wallerian degeneration and functional recovery after peripheral nerve injury. *J Neurosci* 2007;27(46):12565-76.
116. Peters EM, Ericson ME, Hosoi J, Seiffert K, Hordinsky MK, Ansel JC, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. *J Invest Dermatol* 2006;126(9):1937-47.
117. Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. *J Immunol* 1993;150(10):4478-85.
118. Mikami N, Matsushita H, Kato T, Kawasaki R, Sawazaki T, Kishimoto T, et al. Calcitonin gene-related peptide is an important regulator of cutaneous immunity: effect on dendritic cell and T cell functions. *J Immunol* 2011;186(12):6886-93.
119. Shi X, Wang L, Li X, Sahbaie P, Kingery WS, Clark JD. Neuropeptides contribute to peripheral nociceptive sensitization by regulating interleukin-1beta production in keratinocytes. *Anesth Analg* 2011;113(1):175-83.
120. McCormack DG, Mak JC, Coupe MO, Barnes PJ. Calcitonin gene-related peptide vasodilation of human pulmonary vessels. *J Appl Physiol* 1989;67(3):1265-70.
121. Saria A. Substance P in sensory nerve fibres contributes to the development of oedema in the rat hind paw after thermal injury. *Br J Pharmacol* 1984;82(1):217-22.
122. Bull HA, Hothersall J, Chowdhury N, Cohen J, Dowd PM. Neuropeptides induce release of nitric oxide from human dermal microvascular endothelial cells. *J Invest Dermatol* 1996;106(4):655-60.
123. Quinlan KL, Song IS, Bunnett NW, Letran E, Steinhoff M, Harten B, et al. Neuropeptide regulation of human dermal microvascular endothelial cell ICAM-1 expression and function. *Am J Physiol* 1998;275(6 Pt 1):C1580-90.
124. Quinlan KL, Song IS, Naik SM, Letran EL, Olerud JE, Bunnett NW, et al. VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. *J Immunol* 1999;162(3):1656-61.
125. Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E. Preferential expression and function of Toll-like receptor 3 in human astrocytes. *J Neuroimmunol* 2005;159(1-2):12-9.
126. Bsibi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. *J Neuropathol Exp Neurol* 2002;61(11):1013-21.
127. Hao HN, Zhao J, Lotoczky G, Grever WE, Lyman WD. Induction of human beta-defensin-2 expression in human astrocytes by lipopolysaccharide and cytokines. *J Neurochem* 2001;77(4):1027-35.
128. Brandenburg LO, Varoga D, Nicolaeva N, Leib SL, Wilms H, Podschun R, et al. Role of glial cells in the functional expression of LL-37/rat cathelin-related antimicrobial peptide in meningitis. *J Neuropathol Exp Neurol* 2008;67(11):1041-54.
129. Brogden KA, Guthmiller JM, Salzet M, Zasloff M. The nervous system and innate immunity: the neuropeptide connection. *Nat Immunol* 2005;6(6):558-64.
130. El Karim IA, Linden GJ, Orr DF, Lundy FT. Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. *J Neuroimmunol* 2008;200(1-2):11-6.

131. Staff NP, Engelstad J, Klein CJ, Amrami KK, Spinner RJ, Dyck PJ, et al. Post-surgical inflammatory neuropathy. *Brain* 2010;133(10):2866-80.
132. Muller SA, Winkelmann RK. Cutaneous nerve changes in zoster. *J Invest Dermatol* 1969;52(1):71-7.
133. Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. *Pain* 2001;92(1-2):139-45.
134. Ruocco V, Sangiuliano S, Brunetti G, Ruocco E. Beyond zoster: sensory and immune changes in zoster-affected dermatomes: a review*. *Acta Derm Venereol* 2012;92(4):378-82.
135. Luo L, O'Leary DD. Axon retraction and degeneration in development and disease. *Annu Rev Neurosci* 2005;28:127-56.
136. Guertin AD, Zhang DP, Mak KS, Alberta JA, Kim HA. Microanatomy of axon/glia signaling during Wallerian degeneration. *J Neurosci* 2005;25(13):3478-87.
137. Mueller M, Wacker K, Ringelstein EB, Hickey WF, Imai Y, Kiefer R. Rapid response of identified resident endoneurial macrophages to nerve injury. *Am J Pathol* 2001;159(6):2187-97.
138. Toews AD, Barrett C, Morell P. Monocyte chemoattractant protein 1 is responsible for macrophage recruitment following injury to sciatic nerve. *J Neurosci Res* 1998;53(2):260-7.
139. Shamash S, Reichert F, Rotshenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. *J Neurosci* 2002;22(8):3052-60.
140. Esper RM, Loeb JA. Rapid axoglia signaling mediated by neuregulin and neurotrophic factors. *J Neurosci* 2004;24(27):6218-27.
141. Kim D, You B, Lim H, Lee SJ. Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury. *Mol Pain* 2011;7:74.
142. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. *Nat Neurosci* 2007;10(11):1361-8.
143. Kleinschnitz C, Hofstetter HH, Meuth SG, Braeuninger S, Sommer C, Stoll G. T cell infiltration after chronic constriction injury of mouse sciatic nerve is associated with interleukin-17 expression. *Exp Neurol* 2006;200(2):480-5.
144. Zochodne DW, Levy D, Zwiers H, Sun H, Rubin I, Cheng C, et al. Evidence for nitric oxide and nitric oxide synthase activity in proximal stumps of transected peripheral nerves. *Neuroscience* 1999;91(4):1515-27.
145. Stoll G, Jander S, Myers RR. Degeneration and regeneration of the peripheral nervous system: from Augustus Waller's observations to neuroinflammation. *J Peripher Nerv Syst* 2002;7(1):13-27.
146. Vargas ME, Barres BA. Why is Wallerian degeneration in the CNS so slow? *Annu Rev Neurosci* 2007;30:153-79.
147. Barker AR, Rosson GD, Dellon AL. Wound healing in denervated tissue. *Ann Plast Surg* 2006;57(3):339-42.
148. Carr RW, Delaney CA, Westerman RA, Roberts RG. Denervation impairs cutaneous microvascular function and blister healing in the rat hindlimb. *Neuroreport* 1993;4(5):467-70.
149. Maggi CA, Borsini F, Santicoli P, Geppetti P, Abelli L, Evangelista S, et al. Cutaneous lesions in capsaicin-pretreated rats. A trophic role of capsaicin-sensitive afferents? *Naunyn Schmiedeberg Arch Pharmacol* 1987;336(5):538-45.
150. Smith PG, Liu M. Impaired cutaneous wound healing after sensory denervation in developing rats: effects on cell proliferation and apoptosis. *Cell Tissue Res* 2002;307(3):281-91.
151. Engin C. Effects of calcitonin gene-related peptide on wound contraction in denervated and normal rat skin: a preliminary report. *Plast Reconstr Surg* 1998;101(7):1887-90.
152. Delgado AV, McManus AT, Chambers JP. Exogenous administration of Substance P enhances wound healing in a novel skin-injury model. *Exp Biol Med (Maywood)* 2005;230(4):271-80.

153. Peters EM, Botchkarev VA, Botchkareva NV, Tobin DJ, Paus R. Hair-cycle-associated remodeling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides. *J Invest Dermatol* 2001;116(2):236-45.
154. Dong J, He Y, Zhang X, Wang L, Sun T, Zhang M, et al. Calcitonin gene-related peptide regulates the growth of epidermal stem cells in vitro. *Peptides* 2010;31(10):1860-5.
155. Silver A, Montagna W, Versaci A. The Effect of Denervation on Sweat Glands and Meissner Corpuscles of Human Hands. *J Invest Dermatol* 1964;42:307-24.
156. Botchkarev VA, Eichmuller S, Peters EM, Pietsch P, Johansson O, Maurer M, et al. A simple immunofluorescence technique for simultaneous visualization of mast cells and nerve fibers reveals selectivity and hair cycle--dependent changes in mast cell--nerve fiber contacts in murine skin. *Arch Dermatol Res* 1997;289(5):292-302.
157. Siebenhaar F, Magerl M, Peters EM, Hendrix S, Metz M, Maurer M. Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. *J Allergy Clin Immunol* 2008;121(4):955-61.
158. Isogai N, Fukunishi K, Kamiishi H. Patterns of thermoregulation associated with cold intolerance after digital replantation. *Microsurgery* 1995;16(8):556-65.
159. Ruijs AC, Niehof SP, Selles RW, Jaquet JB, Daanen HA, Hovius SE. Digital rewarming patterns after median and ulnar nerve injury. *J Hand Surg Am* 2009;34(1):54-64.
160. Hikawa N, Ishikawa Y, Takenaka T. Interleukin-12 p40-homodimer production in sensory dorsal root ganglion neurons. *Neuroscience* 2004;129(1):75-83.
161. Lotti T, Bianchi B, Panconesi E. Neuropeptides and skin disorders. The new frontiers of neuro-endocrine-cutaneous immunology. *Int J Dermatol* 1999;38(9):673-5.
162. Wyburn-Mason R. Malignant change arising in tissues affected by herpes. *Br Med J* 1955;2(4948):1106-9.
163. Hudson CP, Hanno R, Callen JP. Cutaneous angiosarcoma in a site of healed herpes zoster. *Int J Dermatol* 1984;23(6):404-7.
164. Zalaudek I, Leinweber B, Richtig E, Smolle J, Hofmann-Wellenhof R. Cutaneous zosteriform melanoma metastases arising after herpes zoster infection: a case report and review of the literature. *Melanoma Res* 2003;13(6):635-9.
165. Hasson J. The effect of methylcholanthrene on the denervated skin of strain A mice. *Cancer Res* 1958;18(3):267-73.
166. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. *J Invest Dermatol Symp Proc* 2004;9(2):136-9.
167. Christophers E. Psoriasis--epidemiology and clinical spectrum. *Clin Exp Dermatol* 2001;26(4):314-20.
168. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. *Br J Dermatol* 1996;135(4):533-7.
169. Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. *Hum Mol Genet* 1998;7(10):1537-45.
170. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. *Arch Dermatol* 1994;130(2):216-24.
171. Elder JT, Nair RP, Voorhees JJ. Epidemiology and the genetics of psoriasis. *J Invest Dermatol* 1994;102(6):245-275.
172. Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *J Invest Dermatol* 2010;130(7):1785-96.
173. Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased

- understanding across the medical community. *J Eur Acad Dermatol Venereol* 2010;24(12):1371-7.
174. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. *J Invest Dermatol* 2009;129(7):1601-3.
 175. Hajdarbegovic E, Nijsten T, Westgeest A, Habraken F, Hollestein L, Thio B. Decreased prevalence of atopic features in patients with psoriatic arthritis, but not in psoriasis vulgaris. *J Am Acad Dermatol* 2012.
 176. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol* 2010;62(1):114-35.
 177. Rehal B, Modjtahedi BS, Morse LS, Schwab IR, Maibach HI. Ocular psoriasis. *J Am Acad Dermatol* 2011;65(6):1202-12.
 178. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. *Arch Dermatol* 2011;147(4):419-24.
 179. Gelfand JM, Abuabara K. Diet and weight loss as a treatment for psoriasis. *Arch Dermatol* 2010;146(5):544-6.
 180. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. *J Am Acad Dermatol* 2012.
 181. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. *J Invest Dermatol* 2010;130(4):962-7.
 182. Wakkee M, Meijer W, Neumann HA, Herings RM, Nijsten T. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. *Acta Derm Venereol* 2009;89(5):476-83.
 183. Stern RS, Nijsten T. Going beyond associative studies of psoriasis and cardiovascular disease. *J Invest Dermatol* 2012;132(3 Pt 1):499-501.
 184. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. *J Invest Dermatol* 2010;130(4):919-22.
 185. Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. *BMC Neurol* 2012;12:41.
 186. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Arch Dermatol* 2010;146(8):891-5.
 187. Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. *J Invest Dermatol* 2006;126(7):1480-9.
 188. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. *J Am Acad Dermatol* 2004;51(5):704-8.
 189. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. *Br J Dermatol* 1995;132(2):236-44.
 190. Sampogna F, Tabolli S, Abeni D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. *Acta Derm Venereol* 2012;92(3):299-303.
 191. Lindelof B, Eklund G, Liden S, Stern RS. The prevalence of malignant tumors in patients with psoriasis. *J Am Acad Dermatol* 1990;22(6 Pt 1):1056-60.
 192. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. *J Natl Cancer Inst* 1998;90(17):1278-84.

193. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. *J Invest Dermatol* 2009;129(11):2604-12.
194. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Association of patient-reported psoriasis severity with income and employment. *J Am Acad Dermatol* 2007;57(6):963-71.
195. Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. *Ann N Y Acad Sci* 2009;1182:97-110.
196. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med* 2010;362(2):118-28.
197. Bosch X, Saiz A, Ramos-Casals M. Monoclonal antibody therapy-associated neurological disorders. *Nat Rev Neurol* 2011;7(3):165-72.
198. Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. *Arch Dermatol* 2012;148(4):463-70.
199. Huggett B, Lahteenmaki R. Public biotech 2011-the numbers. *Nat Biotechnol* 2012;30(8):751-7.
200. Melnikova I. Psoriasis market. *Nat Rev Drug Discov* 2009;8(10):767-8.
201. Nestle FO, Kaplan DH, Barker J. Psoriasis. *N Engl J Med* 2009;361(5):496-509.
202. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet* 2007;370(9583):263-71.
203. Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. *J Invest Dermatol* 2003;120(4):627-32.
204. Holubar K. The man behind the eponym. Remembering Heinrich Auspitz. *Am J Dermatopathol* 1986;8(1):83-5.
205. Holubar K, Fatovic-Ferencic S. Papillary tip bleeding or the Auspitz phenomenon: a hero wrongly credited and a misnomer resolved. *J Am Acad Dermatol* 2003;48(2):263-4.
206. Quekenborn-Trinquet V, Fogel P, Aldana-Jammayrac O, Ancian P, Demarchez M, Rossio P, et al. Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity. *Br J Dermatol* 2005;152(3):489-504.
207. Augustin M, Reich K, Blome C, Schafer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. *Br J Dermatol* 2010;163(3):580-5.
208. Shai A, Vardy D, Zvulunov A. [Psoriasis, biblical afflictions and patients' dignity]. *Harefuah* 2002;141(5):479-82, 96.
209. Glickman FS. Lepra, psora, psoriasis. *J Am Acad Dermatol* 1986;14(5 Pt 1):863-6.
210. Köbner H. Zur Aetiologie Psoriasis. *Vjschr Dermatol* 1876;3.
211. Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. *J Eur Acad Dermatol Venereol* 2002;16(3):241-8.
212. Boyd AS, Neldner KH. The isomorphic response of Koebner. *Int J Dermatol* 1990;29(6):401-10.
213. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. *J Invest Dermatol* 2010;130(4):933-43.
214. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. *J Am Acad Dermatol* 2004;51(4):563-9.
215. Nickoloff BJ, Schroder JM, von den Driesch P, Raychaudhuri SP, Farber EM, Boehncke WH, et al. Is psoriasis a T-cell disease? *Exp Dermatol* 2000;9(5):359-75.
216. Mueller W, Herrmann B. Cyclosporin A for psoriasis. *N Engl J Med* 1979;301(10):555.

217. Prens E, Debets R, Hegmans J. T lymphocytes in psoriasis. *Clin Dermatol* 1995;13(2):115-29.
218. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? *Immunol Today* 1995;16(3):145-9.
219. Nickoloff BJ, Wrono-Smith T. Superantigens, autoantigens, and pathogenic T cells in psoriasis. *J Invest Dermatol* 1998;110(4):459-60.
220. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. *Adv Immunol* 1993;54:99-166.
221. Leung DY, Walsh P, Giorno R, Norris DA. A potential role for superantigens in the pathogenesis of psoriasis. *J Invest Dermatol* 1993;100(3):225-8.
222. Leung DY, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production. *J Exp Med* 1995;181(2):747-53.
223. Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet* 2010;42(11):985-90.
224. Picard C, Dogniaux S, Chemin K, Maciorowski Z, Lim A, Mazerolles F, et al. Hypomorphic mutation of ZAP70 in human results in a late onset immunodeficiency and no autoimmunity. *Eur J Immunol* 2009;39(7):1966-76.
225. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. *Arch Dermatol* 1992;128(1):39-42.
226. Diluvio L, Vollmer S, Besgen P, Ellwart JW, Chimenti S, Prinz JC. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. *J Immunol* 2006;176(11):7104-11.
227. Besgen P, Trommler P, Vollmer S, Prinz JC. Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis. *J Immunol* 2010;184(9):5392-402.
228. Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? *Arch Dermatol* 1996;132(6):717-8.
229. Riveira-Munoz E, He SM, Escaramis G, Stuart PE, Huffmeier U, Lee C, et al. Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. *J Invest Dermatol* 2011;131(5):1105-9.
230. Barker JN. The pathophysiology of psoriasis. *Lancet* 1991;338(8761):227-30.
231. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. *J Invest Dermatol* 1999;113(5):752-9.
232. Landgren E, Braback L, Hedlin G, Hjern A, Rasmussen F. Psoriasis in Swedish conscripts: time trend and association with T-helper 2-mediated disorders. *Br J Dermatol* 2006;154(2):332-6.
233. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. *Annu Rev Immunol* 2007;25:821-52.
234. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. *J Immunol* 2006;176(3):1908-15.
235. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. *J Invest Dermatol* 1998;111(4):645-9.
236. Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. *Arch Dermatol Res* 2012;304(6):465-9.

237. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings. *J Invest Dermatol* 2012.
238. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. *J Invest Dermatol* 2009;129(6):1339-50.
239. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. *J Allergy Clin Immunol* 2009;123(6):1244-52 e2.
240. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. *J Clin Invest* 2009;119(12):3573-85.
241. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. *Cytokine Growth Factor Rev* 2006;17(5):367-80.
242. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. *Eur J Immunol* 2006;36(5):1309-23.
243. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. *Semin Cutan Med Surg* 2010;29(1):3-9.
244. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. *Nat Rev Immunol* 2005;5(9):699-711.
245. Sansseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide association studies for drug repositioning. *Nat Biotechnol* 2012;30(4):317-20.
246. Zhang XJ, Huang W, Yang S, Sun LD, Zhang FY, Zhu QX, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. *Nat Genet* 2009;41(2):205-10.
247. Feng BJ, Sun LD, Soltani-Arabshahi R, Bowcock AM, Nair RP, Stuart P, et al. Multiple Loci within the major histocompatibility complex confer risk of psoriasis. *PLoS Genet* 2009;5(8):e1000606.
248. Cargill M, Schrodri SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* 2007;80(2):273-90.
249. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H, et al. Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. *J Dermatol Sci* 2002;30(2):161-6.
250. Capon F, Novelli G, Semprini S, Clementi M, Nudo M, Vultaggio P, et al. Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. *J Invest Dermatol* 1999;112(1):32-5.
251. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. *J Invest Dermatol* 1996;106(5):989-92.
252. de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, Dannhauser EN, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. *Nat Genet* 2009;41(2):211-5.
253. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nat Genet* 2012.
254. Racz E, Prens EP, Kurek D, Kant M, de Ridder D, Mourits S, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. *J Invest Dermatol* 2011;131(7):1547-58.
255. Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. *Br J Dermatol* 2003;148(4):670-9.

256. Curry JL, Qin JZ, Bonish B, Carrick R, Bacon P, Panella J, et al. Innate immune-related receptors in normal and psoriatic skin. *Arch Pathol Lab Med* 2003;127(2):178-86.
257. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. *Arterioscler Thromb Vasc Biol* 2005;25(6):1213-9.
258. de Koning HD, Rodijk-Olthuis D, van Vlijmen-Willems IM, Joosten LA, Netea MG, Schalkwijk J, et al. A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: upregulation of dectin-1 in psoriasis. *J Invest Dermatol* 2010;130(11):2611-20.
259. de Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk PG, Blokkx W, et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. *J Invest Dermatol* 2005;125(6):1163-73.
260. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. *PLoS One* 2008;3(7):e2719.
261. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? *J Clin Invest* 1999;104(9):1161-4.
262. Harder J, Siebert R, Zhang Y, Matthiesen P, Christophers E, Schlegelberger B, et al. Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. *Genomics* 1997;46(3):472-5.
263. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, et al. Psoriasis is associated with increased beta-defensin genomic copy number. *Nat Genet* 2008;40(1):23-5.
264. Stuart PE, Huffmeier U, Nair RP, Palla R, Tejasvi T, Schalkwijk J, et al. Association of beta-Defensin Copy Number and Psoriasis in Three Cohorts of European Origin. *J Invest Dermatol* 2012;132(10):2407-13.
265. Jansen PA, Rodijk-Olthuis D, Hollox EJ, Kamsteeg M, Tjabringa GS, de Jongh GJ, et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. *PLoS One* 2009;4(3):e4725.
266. Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. *J Invest Dermatol* 2002;119(5):1096-102.
267. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. *J Am Acad Dermatol* 2000;42(5 Pt 1):829-30.
268. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. *Arch Dermatol* 2001;137(7):930-3.
269. Garber K. Psoriasis: from bed to bench and back. *Nat Biotechnol* 2011;29(7):563-6.
270. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. *Lancet* 1986;1(8496):1466-8.
271. van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. *J Invest Dermatol* 2004;122(1):51-60.
272. Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, et al. Type I interferon: potential therapeutic target for psoriasis? *PLoS One* 2008;3(7):e2737.
273. Wu JK, Siller G, Strutton G. Psoriasis induced by topical imiquimod. *Australas J Dermatol* 2004;45(1):47-50.
274. Fanti PA, Dika E, Vaccari S, Miscial C, Varotti C. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. *Int J Dermatol* 2006;45(12):1464-5.
275. Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. *Clin Exp Dermatol* 2006;31(1):140-1.

276. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. *J Exp Med* 2005;202(1):135-43.
277. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. *J Immunol* 2009;182(9):5836-45.
278. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. *Clin Dermatol* 2007;25(6):606-15.
279. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. *Am J Med* 2007;120(11):953-9.
280. Fortes C, Mastroeni S, Leffondre K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. *Arch Dermatol* 2005;141(12):1580-4.
281. Gupta MA, Gupta AK, Watteel GN. Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. *Br J Dermatol* 1996;135(5):859-60.
282. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. *J Am Acad Dermatol* 1986;15(5 Pt 1):1007-22.
283. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. *Am J Clin Dermatol* 2000;1(3):159-65.
284. Melski JW, Bernhard JD, Stern RS. The Koebner (isomorphic) response in psoriasis. Associations with early age at onset and multiple previous therapies. *Arch Dermatol* 1983;119(8):655-9.
285. Bergboer JG, Oostveen AM, de Jager ME, Zeeuwen PL, Joosten I, Seyger MM, et al. Koebner phenomenon in psoriasis is not associated with deletion of late cornified envelope genes LCE3B and LCE3C. *J Invest Dermatol* 2012;132(2):475-6.
286. Farber EM, Roth RJ, Aschheim E, Eddy DD, Epinette WW. Role of Trauma in Isomorphic Response in Psoriasis. *Arch Dermatol* 1965;91:246-51.
287. Jablonska S, Chowaniec O, Beutner EH, Maciejowska E, Jarzabek-Chorzelska M, Rzeska G. Stripping of the stratum corneum in patients with psoriasis: production of prepinpoint papules and psoriatic lesions. *Arch Dermatol* 1982;118(9):652-7.
288. Verschoore M, Kowalewski C, Chorzelska MJ, Bernard BA, Darmon YM. Intraepidermal leakage of plasma proteins after tape stripping of normal skin and uninvolved psoriatic skin. *Br J Dermatol* 1990;122(3):391-7.
289. Oren A, Ganz T, Liu L, Meerloo T. In human epidermis, beta-defensin 2 is packaged in lamellar bodies. *Exp Mol Pathol* 2003;74(2):180-2.
290. Aberg KM, Man MQ, Gallo RL, Ganz T, Crumrine D, Brown BE, et al. Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. *J Invest Dermatol* 2008;128(4):917-25.
291. Racz E, Kurek D, Kant M, Baerveldt EM, Florencia E, Mourits S, et al. GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4. *PLoS One* 2011;6(5):e19806.
292. Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. *Nat Rev Immunol* 2009;9(2):125-35.
293. Mitsui H, Suarez-Farinas M, Belkin DA, Levenkova N, Fuentes-Duculan J, Coats I, et al. Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. *J Invest Dermatol* 2012;132(6):1615-26.
294. Raychaudhuri SP, Jiang WY, Raychaudhuri SK. Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. *Am J Pathol* 2008;172(4):961-71.
295. de Mare S, van Erp PE, Ramaekers FC, van de Kerkhof PC. Flow cytometric quantification of human epidermal cells expressing keratin 16 in vivo after standardized trauma. *Arch Dermatol Res* 1990;282(2):126-30.

296. Castelijns FA, Gerritsen MJ, van Vlijmen-Willems IM, van Erp PE, van de Kerkhof PC. The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis. *J Am Acad Dermatol* 1999;40(6 Pt 1):901-9.
297. Komine M, Karakawa M, Takekoshi T, Sakurai N, Minatani Y, Mitsui H, et al. Early inflammatory changes in the "perilesional skin" of psoriatic plaques: is there interaction between dendritic cells and keratinocytes? *J Invest Dermatol* 2007;127(8):1915-22.
298. Maytin EV, Habener JF. Transcription factors C/EBP alpha, C/EBP beta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo. *J Invest Dermatol* 1998;110(3):238-46.
299. Alshenawy HA, Hasby EA. Immunophenotyping of dendritic cells in lesional, perilesional and distant skin of chronic plaque psoriasis. *Cell Immunol* 2011;269(2):115-9.
300. Dewing SB. Remission of psoriasis associated with cutaneous nerve section. *Arch Dermatol* 1971;104(2):220-1.
301. Joseph T, Kurian J, Warwick DJ, Friedmann PS. Unilateral remission of psoriasis following traumatic nerve palsy. *Br J Dermatol* 2005;152(1):185-6.
302. Stratigos AJ, Katoulis AK, Stavrianeas NG. Spontaneous clearing of psoriasis after stroke. *J Am Acad Dermatol* 1998;38(5 Pt 1):768-70.
303. Cacioppo JT, Berntson GG, Malarkey WB, Kiecolt-Glaser JK, Sheridan JF, Poehlmann KM, et al. Autonomic, neuroendocrine, and immune responses to psychological stress: the reactivity hypothesis. *Ann N Y Acad Sci* 1998;840:664-73.
304. Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. *J Invest Dermatol* 2006;126(8):1697-704.
305. Evers AW, Verhoeven EW, Kraaimaat FW, de Jong EM, de Brouwer SJ, Schalkwijk J, et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis. *Br J Dermatol* 2010;163(5):986-91.
306. Verhoeven EW, Kraaimaat FW, de Jong EM, Schalkwijk J, van de Kerkhof PC, Evers AW. Individual differences in the effect of daily stressors on psoriasis: a prospective study. *Br J Dermatol* 2009;161(2):295-9.
307. Verhoeven EW, Kraaimaat FW, Jong EM, Schalkwijk J, van de Kerkhof PC, Evers AW. Effect of daily stressors on psoriasis: a prospective study. *J Invest Dermatol* 2009;129(8):2075-7.
308. Kleyn CE, Schneider L, Saraceno R, Mantovani C, Richards HL, Fortune DG, et al. The effects of acute social stress on epidermal Langerhans' cell frequency and expression of cutaneous neuropeptides. *J Invest Dermatol* 2008;128(5):1273-9.
309. El-Nour H, Santos A, Nordin M, Jonsson P, Svensson M, Nordlind K, et al. Neuronal changes in psoriasis exacerbation. *J Eur Acad Dermatol Venereol* 2009;23(11):1240-5.
310. Harvima IT, Viinamaki H, Naukkarinen A, Paukkonen K, Neittaanmaki H, Harvima RJ, et al. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. *Psychother Psychosom* 1993;60(3-4):168-76.
311. Garg A, Chren MM, Sands LP, Matsui MS, Marenus KD, Feingold KR, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. *Arch Dermatol* 2001;137(1):53-9.
312. Naukkarinen A, Harvima I, Paukkonen K, Aalto ML, Horsmanheimo M. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. *Arch Dermatol Res* 1993;285(6):341-6.
313. Naukkarinen A, Nickoloff BJ, Farber EM. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. *J Invest Dermatol* 1989;92(1):126-9.
314. Jiang WY, Raychaudhuri SP, Farber EM. Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. *Int J Dermatol* 1998;37(8):572-4.

315. Anand P, Springall DR, Blank MA, Sellu D, Polak JM, Bloom SR. Neuropeptides in skin disease: increased VIP in eczema and psoriasis but not axillary hyperhidrosis. *Br J Dermatol* 1991;124(6):547-9.
316. Brody I. Mast cell degranulation in the evolution of acute eruptive guttate psoriasis vulgaris. *J Invest Dermatol* 1984;82(5):460-4.
317. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. *Arch Dermatol Res* 1985;277(5):352-8.
318. Harvima IT, Naukkarinen A, Harvima RJ, Horsmanheimo M. Enzyme- and immunohistochemical localization of mast cell tryptase in psoriatic skin. *Arch Dermatol Res* 1989;281(6):387-91.
319. Toyry S, Fraki J, Tammi R. Mast cell density in psoriatic skin. The effect of PUVA and corticosteroid therapy. *Arch Dermatol Res* 1988;280(5):282-5.
320. Naukkarinen A, Harvima IT, Aalto ML, Harvima RJ, Horsmanheimo M. Quantitative analysis of contact sites between mast cells and sensory nerves in cutaneous psoriasis and lichen planus based on a histochemical double staining technique. *Arch Dermatol Res* 1991;283(7):433-7.
321. Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. *Arch Dermatol* 1988;124(7):1052-7.
322. Reich A, Szepletowski JC. Mediators of pruritus in psoriasis. *Mediators Inflamm* 2007;2007:64727.
323. Reich A, Orda A, Wisnicka B, Szepletowski JC. Plasma neuropeptides and perception of pruritus in psoriasis. *Acta Derm Venereol* 2007;87(4):299-304.
324. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 1997;389(6653):816-24.
325. Geppetti P, Nassini R, Materazzi S, Benemei S. The concept of neurogenic inflammation. *BJU Int* 2008;101 Suppl 3:2-6.
326. Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. *J Am Acad Dermatol* 1993;29(3):438-42.
327. Kikwai L, Babu RJ, Kanikkannan N, Singh M. Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. *J Pharm Pharmacol* 2004;56(1):19-25.
328. Xu XJ, Hao JX, Wiesenfeld-Hallin Z, Hakanson R, Folkers K, Hokfelt T. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. *Neuroscience* 1991;42(3):731-7.
329. Andoh T, Nagasawa T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. *J Pharmacol Exp Ther* 1998;286(3):1140-5.
330. Shah PP, Desai PR, Patel AR, Singh MS. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. *Biomaterials* 2012;33(5):1607-17.
331. Ostrowski SM, Belkadi A, Loyd CM, Diaconu D, Ward NL. Cutaneous denervation of psoriasis-form mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner. *J Invest Dermatol* 2011;131(7):1530-8.
332. Marriott I, Bost KL. Substance P receptor mediated macrophage responses. *Adv Exp Med Biol* 2001;493:247-54.
333. Marriott I, Bost KL. Expression of authentic substance P receptors in murine and human dendritic cells. *J Neuroimmunol* 2001;114(1-2):131-41.
334. Lambrecht BN. Immunologists getting nervous: neuropeptides, dendritic cells and T cell activation. *Respir Res* 2001;2(3):133-8.
335. Ward NL, Kavlick KD, Diaconu D, Dawes SM, Michaels KA, Gilbert E. Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acanthosis in the KC-Tie2 mouse model. *J Invest Dermatol* 2012;132(7):1927-30.

336. Botchkarev VA, Yaar M, Peters EM, Raychaudhuri SP, Botchkareva NV, Marconi A, et al. Neurotrophins in skin biology and pathology. *J Invest Dermatol* 2006;126(8):1719-27.
337. Raychaudhuri SP, Jiang WY, Smoller BR, Farber EM. Nerve growth factor and its receptor system in psoriasis. *Br J Dermatol* 2000;143(1):198-200.
338. Raychaudhuri SP, Farber EM, Raychaudhuri SK. Role of nerve growth factor in RANTES expression by keratinocytes. *Acta Derm Venereol* 2000;80(4):247-50.
339. Pincelli C, Sevigiani C, Manfredini R, Grande A, Fantini F, Bracci-Laudiero L, et al. Expression and function of nerve growth factor and nerve growth factor receptor on cultured keratinocytes. *J Invest Dermatol* 1994;103(1):13-8.
340. Pincelli C, Fantini F, Giannetti A. Nerve growth factor and the skin. *Int J Dermatol* 1994;33(5):308-12.
341. Raychaudhuri SP, Sanyal M, Weltman H, Kundu-Raychaudhuri S. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. *J Invest Dermatol* 2004;122(3):812-9.
342. Caroleo MC, Costa N, Bracci-Laudiero L, Aloe L. Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors. *J Neuroimmunol* 2001;113(2):193-201.
343. Lambiase A, Bracci-Laudiero L, Bonini S, Starace G, D'Elia MM, De Carli M, et al. Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. *J Allergy Clin Immunol* 1997;100(3):408-14.
344. Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, et al. Mast cells synthesize, store, and release nerve growth factor. *Proc Natl Acad Sci U S A* 1994;91(9):3739-43.
345. Jiang Y, Chen G, Zheng Y, Lu L, Wu C, Zhang Y, et al. TLR4 signaling induces functional nerve growth factor receptor p75NTR on mouse dendritic cells via p38MAPK and NF-kappa B pathways. *Mol Immunol* 2008;45(6):1557-66.
346. Staal FJ. Gene expression profiling in acute lymphoblastic leukemia (ALL). *Lab Hematol* 2004;10(3):178-81.
347. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* 2003;4(2):249-64.
348. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics* 2003;19(2):185-93.
349. Roberson ED, Liu Y, Ryan C, Joyce CE, Duan S, Cao L, et al. A subset of methylated CpG sites differentiate psoriatic from normal skin. *J Invest Dermatol* 2012;132(3 Pt 1):583-92.
350. Liu JY, Hu JH, Zhu QG, Li FQ, Sun HJ. Substance P receptor expression in human skin keratinocytes and fibroblasts. *Br J Dermatol* 2006;155(4):657-62.
351. Saraceno R, Kleyn CE, Terenghi G, Griffiths CE. The role of neuropeptides in psoriasis. *Br J Dermatol* 2006;155(5):876-82.
352. Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. *Br J Dermatol* 2007;156(6):1272-7.
353. Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasisform plaque formation in mice. *J Clin Invest* 2012;122(6):2252-6.
354. El Malki K, Karbach SH, Huppert J, Zayoud M, Reissig S, Schuler R, et al. An Alternative Pathway of Imiquimod-Induced Psoriasis-Like Skin Inflammation in the Absence of Interleukin-17 Receptor A Signaling. *J Invest Dermatol* 2012.
355. Liu T, Xu ZZ, Park CK, Berta T, Ji RR. Toll-like receptor 7 mediates pruritus. *Nat Neurosci* 2010;13(12):1460-2.

356. Kim SJ, Park GH, Kim D, Lee J, Min H, Wall E, et al. Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons. *Proc Natl Acad Sci U S A* 2011;108(8):3371-6.
357. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. *Physiol Rev* 2006;86(4):1309-79.
358. Nickoloff BJ, Bonish BK, Marble DJ, Schriedel KA, DiPietro LA, Gordon KB, et al. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. *J Invest Dermatol Symp Proc* 2006;11(1):16-29.
359. Perlman HH. Remission of psoriasis vulgaris from the use of nerve-blocking agents. *Arch Dermatol* 1972;105(1):128-9.
360. Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. *PLoS One* 2011;6(4):e18266.
361. Kim Y, Remacle AG, Chernov AV, Liu H, Shubayev I, Lai C, et al. The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration. *PLoS One* 2012;7(3):e33664.
362. Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS, Fares C. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. *Micron* 2004;35(7):503-42.
363. Murray PJ, Smale ST. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. *Nat Immunol* 2012;13(10):916-24.
364. Swindell WR, Johnston A, Gudjonsson JE. Transcriptional profiles of leukocyte populations provide a tool for interpreting gene expression patterns associated with high fat diet in mice. *PLoS One* 2010;5(7):e11861.
365. Jander S, Bussini S, Neuen-Jacob E, Bosse F, Menge T, Muller HW, et al. Osteopontin: a novel axon-regulated Schwann cell gene. *J Neurosci Res* 2002;67(2):156-66.
366. Kury P, Zickler P, Stoll G, Hartung HP, Jander S. Osteopontin, a macrophage-derived matricellular glycoprotein, inhibits axon outgrowth. *FASEB J* 2005;19(3):398-400.
367. Czopka T, Von Holst A, Schmidt G, Ffrench-Constant C, Faissner A. Tenascin C and tenascin R similarly prevent the formation of myelin membranes in a RhoA-dependent manner, but antagonistically regulate the expression of myelin basic protein via a separate pathway. *Glia* 2009;57(16):1790-801.
368. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nogales KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. *J Invest Dermatol* 2011;131(3):677-87.
369. An H, Yu Y, Zhang M, Xu H, Qi R, Yan X, et al. Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. *Immunology* 2002;106(1):38-45.
370. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. *Science* 2003;300(5625):1524-5.
371. Wang Z, Ma W, Chabot JG, Quirion R. Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia. *FASEB J* 2009;23(8):2576-86.
372. Tang Y, Feng Y, Wang X. Calcitonin gene-related peptide potentiates LPS-induced IL-6 release from mouse peritoneal macrophages. *J Neuroimmunol* 1998;84(2):207-12.
373. Harzenetter MD, Novotny AR, Gais P, Molina CA, Altmayr F, Holzmann B. Negative regulation of TLR responses by the neuropeptide CGRP is mediated by the transcriptional repressor ICER. *J Immunol* 2007;179(1):607-15.
374. Amura CR, Marek L, Winn RA, Heasley LE. Inhibited neurogenesis in JNK1-deficient embryonic stem cells. *Mol Cell Biol* 2005;25(24):10791-802.

375. Gudjonsson JE, Johnston A, Stoll SW, Riblett MB, Xing X, Kochkodan JJ, et al. Evidence for altered Wnt signaling in psoriatic skin. *J Invest Dermatol* 2010;130(7):1849-59.
376. Radek KA, Elias PM, Taupenot L, Mahata SK, O'Connor DT, Gallo RL. Neuroendocrine nicotinic receptor activation increases susceptibility to bacterial infections by suppressing antimicrobial peptide production. *Cell Host Microbe* 2010;7(4):277-89.
377. Aberg KM, Radek KA, Choi EH, Kim DK, Demerjian M, Hupe M, et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. *J Clin Invest* 2007;117(11):3339-49.
378. Giebelen IA, Leendertse M, Florquin S, van der Poll T. Stimulation of acetylcholine receptors impairs host defence during pneumococcal pneumonia. *Eur Respir J* 2009;33(2):375-81.
379. Armstrong AW, Armstrong EJ, Fuller EN, Sockolov ME, Voyles SV. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. *Br J Dermatol* 2011;165(6):1162-8.
380. Radosa J, Dyck W, Goerd S, Kurzen H. The cholinergic system in guttate psoriasis with special reference to mast cells. *Exp Dermatol* 2011;20(8):677-9.
381. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. *Immunity* 2009;31(6):965-73.
382. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. *Nat Rev Immunol* 2011;11(3):163-75.
383. Rossi SG, Dickerson IM, Rotundo RL. Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression. *J Biol Chem* 2003;278(27):24994-5000.
384. Kawasaki H, Eguchi S, Miyashita S, Chan S, Hirai K, Hobarra N, et al. Proton acts as a neurotransmitter for nicotine-induced adrenergic and calcitonin gene-related peptide-containing nerve-mediated vasodilation in the rat mesenteric artery. *J Pharmacol Exp Ther* 2009;330(3):745-55.
385. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. *J Cell Sci* 2007;120(Pt 16):2864-74.
386. Carmichael NM, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. *Pain* 2010;149(2):316-24.
387. Zanchi M, Favot F, Bizzarini M, Piai M, Donini M, Sedona P. Botulinum toxin type-A for the treatment of inverse psoriasis. *J Eur Acad Dermatol Venereol* 2008;22(4):431-6.
388. Companjen AR, van der Wel LI, Wei L, Laman JD, Prens EP. A modified ex vivo skin organ culture system for functional studies. *Arch Dermatol Res* 2001;293(4):184-90.
389. Nhu QM, Cuesta N, Vogel SN. Transcriptional regulation of lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 (IRF-2). *J Endotoxin Res* 2006;12(5):285-95.
390. Petrasek J, Dolganiuc A, Csak T, Kurt-Jones EA, Szabo G. Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. *Gastroenterology* 2011;140(2):697-708 e4.
391. Schmitz F, Heit A, Guggemoos S, Krug A, Mages J, Schiemann M, et al. Interferon-regulatory-factor 1 controls Toll-like receptor 9-mediated IFN-beta production in myeloid dendritic cells. *Eur J Immunol* 2007;37(2):315-27.
392. Chiba T, Yamaguchi A, Yamatani T, Nakamura A, Morishita T, Inui T, et al. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). *Am J Physiol* 1989;256(2 Pt 1):E331-5.
393. Chakraborty K, Maity PC, Sil AK, Takeda Y, Das S. cAMP stringently regulates human cathelicidin antimicrobial peptide expression in the mucosal epithelial cells by activating cAMP-response element-binding protein, AP-1, and inducible cAMP early repressor. *J Biol Chem* 2009;284(33):21810-27.

394. Takeshita F, Suzuki K, Sasaki S, Ishii N, Klinman DM, Ishii KJ. Transcriptional regulation of the human TLR9 gene. *J Immunol* 2004;173(4):2552-61.
395. Anderson K, Robinson PJ, Marley PD. Cholinoceptor regulation of cyclic AMP levels in bovine adrenal medullary cells. *Br J Pharmacol* 1992;106(2):360-6.
396. Kim BE, Howell MD, Guttman-Yassky E, Gilleaudeau PM, Cardinale IR, Boguniewicz M, et al. TNF-alpha downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-alpha antagonists to improve skin barrier. *J Invest Dermatol* 2011;131(6):1272-9.
397. van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2). *J Pathol* 2003;199(1):107-14.
398. de Jong EM, van Vlijmen IM, van Erp PE, Ramaekers FC, Troyanovski SM, van de Kerkhof PC. Keratin 17: a useful marker in anti-psoriatic therapies. *Arch Dermatol Res* 1991;283(7):480-2.
399. Debets R, Hegmans JP, Croughs P, Troost RJ, Prins JB, Benner R, et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. *J Immunol* 1997;158(6):2955-63.
400. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. *J Invest Dermatol* 2008;128(5):1207-11.
401. Perera GK, Di Meglio P, Nestle FO. Psoriasis. *Annu Rev Pathol* 2012;7:385-422.
402. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. *J Immunol* 2008;180(11):7423-30.
403. Zhu K, Ye J, Wu M, Cheng H. Expression of Th1 and Th2 cytokine-associated transcription factors, T-bet and GATA-3, in peripheral blood mononuclear cells and skin lesions of patients with psoriasis vulgaris. *Arch Dermatol Res* 2010;302(7):517-23.
404. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. *J Exp Med* 1994;180(5):1961-6.
405. Hart PH, Cooper RL, Finlay-Jones JJ. IL-4 suppresses IL-1 beta, TNF-alpha and PGE2 production by human peritoneal macrophages. *Immunology* 1991;72(3):344-9.
406. Wong HL, Costa GL, Lotze MT, Wahl SM. Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. *J Exp Med* 1993;177(3):775-81.
407. Guenova E, Volz T, Sauer K, Kaesler S, Muller MR, Wolbing F, et al. IL-4-mediated fine tuning of IL-12p70 production by human DC. *Eur J Immunol* 2008;38(11):3138-49.
408. Li J, Li X, Zhang Y, Zhou XK, Yang HS, Chen XC, et al. Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. *J Gene Med* 2010;12(6):481-90.
409. Biedermann T, Mailhammer R, Mai A, Sander C, Ogilvie A, Brombacher F, et al. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. *Eur J Immunol* 2001;31(5):1582-91.
410. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. *Nat Med* 2003;9(1):40-6.
411. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet* 2008;371(9625):1665-74.
412. Companjen A, van der Wel L, van der Fits L, Laman J, Prens E. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. *Eur Cytokine Netw* 2004;15(3):210-6.

413. Takeda K, Kishimoto T, Akira S. STAT6: its role in interleukin 4-mediated biological functions. *J Mol Med (Berl)* 1997;75(5):317-26.
414. Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. *J Immunol* 2011;186(4):2613-22.
415. Debets R, Hegmans JP, Troost RJ, Benner R, Prens EP. Enhanced production of biologically active interleukin-1 alpha and interleukin-1 beta by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1 beta levels and facilitated interleukin-1 release. *Eur J Immunol* 1995;25(6):1624-30.
416. Wei L, Debets R, Hegmans JJ, Benner R, Prens EP. IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. *J Pathol* 1999;187(3):358-64.
417. Debets R, Timans JC, Homey B, Zurawski S, Sana TR, Lo S, et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. *J Immunol* 2001;167(3):1440-6.
418. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. *Immunity* 2011;35(4):596-610.
419. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. *J Immunol* 2009;183(5):3170-6.
420. Lindroos J, Svensson L, Norsgaard H, Lovato P, Moller K, Hagedorn PH, et al. IL-23-mediated epidermal hyperplasia is dependent on IL-6. *J Invest Dermatol* 2011;131(5):1110-8.
421. Kaufman CK, Zhou P, Pasolli HA, Rendl M, Bolotin D, Lim KC, et al. GATA-3: an unexpected regulator of cell lineage determination in skin. *Genes Dev* 2003;17(17):2108-22.
422. Kurek D, Garinis GA, van Doorninck JH, van der Wees J, Grosveld FG. Transcriptome and phenotypic analysis reveals Gata3-dependent signalling pathways in murine hair follicles. *Development* 2007;134(2):261-72.
423. Albanesi C, De Pita O, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. *Clin Dermatol* 2007;25(6):581-8.
424. Wang F, Smith N, Maier L, Xia W, Hammerberg C, Chubb H, et al. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of IL-19, IL-20 and IL-24. *Br J Dermatol* 2012.
425. Prens E, Hegmans J, Lien RC, Debets R, Troost R, van Joost T, et al. Increased expression of interleukin-4 receptors on psoriatic epidermal cells. *Am J Pathol* 1996;148(5):1493-502.
426. Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. *J Am Acad Dermatol* 2012.
427. Boy MG, Wang C, Wilkinson BE, Chow VF, Clucas AT, Krueger JG, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. *J Invest Dermatol* 2009;129(9):2299-302.
428. Raychaudhuri SK, Raychaudhuri SP. NGF and its receptor system: a new dimension in the pathogenesis of psoriasis and psoriatic arthritis. *Ann N Y Acad Sci* 2009;1173:470-7.
429. Farber EM, Raychaudhuri SP. Is psoriasis a neuroimmunologic disease? *Int J Dermatol* 1999;38(1):12-5.
430. Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. *Proc Natl Acad Sci U S A* 2001;98(11):6162-7.
431. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. *J Exp Med* 2004;199(1):125-30.

432. Guenova E GK, Hötzenecker W, et al Efficient IL-4 therapy of psoriasis selectively abrogates IL-23 and Th17 responses in humans. . *J Invest Dermatol* 2009;129 (S1(S116)).
433. Harder J, Dressel S, Wittersheim M, Cordes J, Meyer-Hoffert U, Mrowietz U, et al. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. *J Invest Dermatol* 2010;130(5):1355-64.
434. Harder J, Schroder JM. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. *J Leukoc Biol* 2005;77(4):476-86.
435. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. *J Immunol* 2003;171(6):3262-9.
436. Albanesi C, Fairchild HR, Madonna S, Scarponi C, De Pita O, Leung DY, et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. *J Immunol* 2007;179(2):984-92.
437. de Koning HD, Kamsteeg M, Rodijk-Olthuis D, van Vlijmen-Willems IM, van Erp PE, Schalkwijk J, et al. Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. *J Invest Dermatol* 2011;131(1):263-6.
438. Kamsteeg M, Bergers M, de Boer R, Zeeuwen PL, Hato SV, Schalkwijk J, et al. Type 2 helper T-cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalent. *Am J Pathol* 2011;178(5):2091-9.
439. Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. *J Invest Dermatol* 2011;131(2):329-37.
440. Glaser R, Meyer-Hoffert U, Harder J, Cordes J, Wittersheim M, Kobliakova J, et al. The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. *J Invest Dermatol* 2009;129(3):641-9.
441. Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. *Ann N Y Acad Sci* 2011;1222:30-9.
442. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet* 2008;371(9625):1675-84.
443. Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. *J Dermatol* 2010;37(5):413-25.
444. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. *Cell Immunol* 2007;247(1):1-11.
445. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. *Br J Dermatol* 2008;159(5):1092-102.
446. James Krueger KL, Frédéric Baribaud, Mayte Suarez-Farinas, Carrie Brodmerkel. Determining the extent to which clinically effective treatment, ustekinumab oretanercept, reverses the molecular disease profile of psoriatic skin: Comparisons of lesional, non-lesional and normal skin. *Journal of investigative Dermatology, ESDR Meeting Abstracts* 2010.
447. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. *J Mol Med (Berl)* 2009;87(5):523-36.

448. Breternitz M, Flach M, Prassler J, Elsner P, Fluhr JW. Acute barrier disruption by adhesive tapes is influenced by pressure, time and anatomical location: integrity and cohesion assessed by sequential tape stripping. A randomized, controlled study. *Br J Dermatol* 2007;156(2):231-40.
449. Otkjaer K, Kragballe K, Funding AT, Clausen JT, Noerby PL, Steiniche T, et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. *Br J Dermatol* 2005;153(5):911-8.
450. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. *Exp Dermatol* 2006;15(12):991-1004.
451. Chio, Il, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, et al. TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation. *Nat Cell Biol* 2012;14(6):625-33.
452. Kirby B, Boffa MJ, Nayak N, Gallatin WM, Martin S, Griffiths CE. The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis. *Br J Dermatol* 2001;145(6):1027-8.
453. Zhu LJ, Landolt-Marticorena C, Li T, Yang X, Yu XQ, Gladman DD, et al. Altered expression of TNF-alpha signaling pathway proteins in systemic lupus erythematosus. *J Rheumatol* 2010;37(8):1658-66.
454. Katagiri K, Imamura M, Kinashi T. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. *Nat Immunol* 2006;7(9):919-28.
455. Schwarzbich MA, Gutknecht M, Salih J, Salih HR, Brossart P, Rittig SM, et al. The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. *Cancer Immunol Immunother* 2012;61(2):193-202.
456. Gambichler T, Bechara FG, Scola N, Rotterdam S, Altmeyer P, Skrygan M. Serum levels of antimicrobial peptides and proteins do not correlate with psoriasis severity and are increased after treatment with fumaric acid esters. *Arch Dermatol Res* 2012;304(6):471-4.
457. Kanda N, Watanabe S. Increased serum human beta-defensin-2 levels in atopic dermatitis: relationship to IL-22 and oncostatin M. *Immunobiology* 2012;217(4):436-45.
458. Vordenbaumen S, Sander O, Bleck E, Schneider M, Fischer-Betz R. Cardiovascular disease and serum defensin levels in systemic lupus erythematosus. *Clin Exp Rheumatol* 2012;30(3):364-70.
459. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. *N Engl J Med* 1999;341(17):1284-91.
460. Hassikou H, Tabache F, Baaj M, Safi S, Hadri L. Sweet's syndrome in Behcet's disease. *Joint Bone Spine* 2007;74(5):495-6.
461. Chun SI, Su WP, Lee S, Rogers RS, 3rd. Erythema nodosum-like lesions in Behcet's syndrome: a histopathologic study of 30 cases. *J Cutan Pathol* 1989;16(5):259-65.
462. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. *Lancet* 1990;335(8697):1078-80.
463. Shimizu J, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-gamma in patients with Behcet's disease. *Clin Exp Immunol* 2012;168(1):68-74.
464. Lin Y, Huang R, Chen LP, Lisoukov H, Lu ZH, Li S, et al. Profiling of cytokine expression by biotin-labeled-based protein arrays. *Proteomics* 2003;3(9):1750-7.
465. Sahin MT, Ozturkcan S, Turel-Ermertcan A, Yurtman-Havluclu D, Bilac C. Behcet's disease associated with hidradenitis suppurativa. *J Eur Acad Dermatol Venereol* 2007;21(3):428-9.
466. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. *Trends Mol Med* 2005;11(1):43-8.
467. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol* 2009;23 Suppl 2:1-70.

468. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. *Br J Dermatol* 2003;149(2):363-9.
469. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE). *J Dtsch Dermatol Ges* 2009;7(7):603-11.
470. Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. *Br J Dermatol* 2010;162(2):427-34.
471. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG. Resolved psoriasis lesions retain expression of a subset of disease-related genes. *J Invest Dermatol* 2011;131(2):391-400.
472. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. *J Allergy Clin Immunol* 2009;124(5):1022-10 e1-395.
473. Dudoit S, Gentleman RC, Quackenbush J. Open source software for the analysis of microarray data. *Biotechniques* 2003;Suppl:45-51.
474. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. *J Immunol* 2007;178(4):2229-40.
475. Okamoto K, Iwai Y, Oh-Hora M, Yamamoto M, Morio T, Aoki K, et al. IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. *Nature* 2010;464(7293):1381-5.
476. Yamamoto M, Yamazaki S, Uematsu S, Sato S, Hemmi H, Hoshino K, et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. *Nature* 2004;430(6996):218-22.
477. Lehmann JC, Listopad JJ, Rentzsch CU, Igney FH, von Bonin A, Hennekes HH, et al. Dimethyl-fumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. *J Invest Dermatol* 2007;127(4):835-45.
478. Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. *Clin Immunol* 2012;142(1):44-8.
479. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain* 2011;134(Pt 3):678-92.
480. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. *N Engl J Med* 2011;365(7):620-8.
481. Korver JE, van Duijnhoven MW, Pasch MC, van Erp PE, van de Kerkhof PC. Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. *Br J Dermatol* 2006;155(4):688-94.
482. Waseem A, Dogan B, Tidman N, Alam Y, Purkis P, Jackson S, et al. Keratin 15 expression in stratified epithelia: downregulation in activated keratinocytes. *J Invest Dermatol* 1999;112(3):362-9.
483. de Koning HD, van den Bogaard EH, Bergboer JG, Kamsteeg M, van Vlijmen-Willems IM, Hitomi K, et al. Expression profile of cornified envelope structural proteins and keratinocyte differentiation-regulating proteins during skin barrier repair. *Br J Dermatol* 2012;166(6):1245-54.
484. Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, et al. Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. *PLoS One* 2012;7(2):e31465.
485. Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, Lowes MA. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. *J Invest Dermatol* 2010;130(11):2654-63.

486. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). *Proc Natl Acad Sci U S A* 2005;102(52):19057-62.
487. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. *J Exp Med* 2007;204(13):3183-94.
488. Ghoreschi K, Bruck J, Kellerer C, Deng C, Peng H, Rothfuss O, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. *J Exp Med* 2011;208(11):2291-303.
489. Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis. *J Invest Dermatol* 2012;132(11):2552-64.
490. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA* 2006;296(14):1735-41.
491. Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. *Autoimmun Rev* 2010;9(12):835-9.
492. Knoflach M, Kiechl S, Mantovani A, Cuccovillo I, Bottazzi B, Xu Q, et al. Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies. *PLoS One* 2012;7(2):e31474.
493. Capon F, Burden AD, Trembath RC, Barker JN. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. *J Invest Dermatol* 2012;132(3 Pt 2):915-22.
494. Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, et al. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. *J Invest Dermatol* 2010;130(7):1829-40.
495. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum* 2007;56(9):2905-12.
496. Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. *Arch Dermatol Res* 2011;303(6):381-8.
497. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. *J Am Acad Dermatol* 2007;57(1):1-27.
498. Lawry M. Biological therapy and nail psoriasis. *Dermatol Ther* 2007;20(1):60-7.
499. de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. *Dermatology* 1996;193(4):300-3.
500. Reich K. Approach to managing patients with nail psoriasis. *J Eur Acad Dermatol Venereol* 2009;23 Suppl 1:15-21.
501. Hermann RC, Taylor RS, Ellis CN, Williams NA, Weiner ND, Flynn GL, et al. Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. *Skin Pharmacol* 1988;1(4):246-9.
502. Tosti A, Guerra L, Bardazzi F, Lanzarini M. Topical ciclosporin in nail psoriasis. *Dermatologica* 1990;180(2):110.
503. Cannavo SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. *Dermatology* 2003;206(2):153-6.
504. Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. *Ophthalmology* 1998;105(9):1715-20.

505. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. *Lancet* 2005;366(9494):1367-74.
506. Pinkus H, Mehregan AH. The primary histologic lesion of seborrheic dermatitis and psoriasis. *J Invest Dermatol* 1966;46(1):109-16.
507. Heng MC, Allen SG, Haberfelde G, Song MK. Electron microscopic and immunocytochemical studies of the sequence of events in psoriatic plaque formation following tape-stripping. *Br J Dermatol* 1991;125(6):548-56.
508. Hacker SM, Rasmussen JE. The effect of flash lamp-pulsed dye laser on psoriasis. *Arch Dermatol* 1992;128(6):853-5.
509. Herd RM, Dover JS, Arndt KA. Basic laser principles. *Dermatol Clin* 1997;15(3):355-72.
510. Katugampola GA, Rees AM, Lanigan SW. Laser treatment of psoriasis. *Br J Dermatol* 1995;133(6):909-13.
511. Ros AM, Garden JM, Bakus AD, Hedblad MA. Psoriasis response to the pulsed dye laser. *Lasers Surg Med* 1996;19(3):331-5.
512. Hern S, Allen MH, Sousa AR, Harland CC, Barker JN, Levick JR, et al. Immunohistochemical evaluation of psoriatic plaques following selective photothermolysis of the superficial capillaries. *Br J Dermatol* 2001;145(1):45-53.
513. Zelickson BD, Mehregan DA, Wendelschfer-Crabb G, Ruppman D, Cook A, O'Connell P, et al. Clinical and histologic evaluation of psoriatic plaques treated with a flashlamp pulsed dye laser. *J Am Acad Dermatol* 1996;35(1):64-8.
514. Erceg A, Bovenschen HJ, van de Kerkhof PC, Seyger MM. Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. *Br J Dermatol* 2006;155(1):110-4.
515. de Leeuw J, Tank B, Bjerring PJ, Koetsveld S, Neumann M. Concomitant treatment of psoriasis of the hands and feet with pulsed dye laser and topical calcipotriol, salicylic acid, or both: a prospective open study in 41 patients. *J Am Acad Dermatol* 2006;54(2):266-71.
516. Hamakawa M, Sugihara A, Okamoto H, Horio T. Ultraviolet B radiation suppresses Langerhans cell migration in the dermis by down-regulation of alpha4 integrin. *Photodermatol Photoimmunol Photomed* 2006;22(3):116-23.
517. Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P, Heftler NS, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. *J Exp Med* 1995;182(6):2057-68.
518. Ozawa M, Ferenczi K, Kikuchi T, Cardinale I, Austin LM, Coven TR, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. *J Exp Med* 1999;189(4):711-8.
519. Weischer M, Blum A, Eberhard F, Rocken M, Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. *Acta Derm Venereol* 2004;84(5):370-4.
520. Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. *Br J Dermatol* 2008;159(4):931-5.
521. De Leeuw J, Van Lingen RG, Both H, Tank B, Nijsten T, Martino Neumann HA. A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet B-TL01 in plaque type psoriasis. *Dermatol Surg* 2009;35(1):80-91.
522. Schwarz T. Mechanisms of UV-induced immunosuppression. *Keio J Med* 2005;54(4):165-71.
523. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? *Angiogenesis* 2007;10(3):149-66.
524. Henno A, Blacher S, Lambert C, Colige A, Seidel L, Noel A, et al. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. *Br J Dermatol* 2009;160(3):581-90.

525. Iljin K, Karkkainen MJ, Lawrence EC, Kimak MA, Uutela M, Taipale J, et al. VEGFR3 gene structure, regulatory region, and sequence polymorphisms. *FASEB J* 2001;15(6):1028-36.
526. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. *N Engl J Med* 2007;356(6):580-92.
527. Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. *J Invest Dermatol* 2009;129(2):302-8.
528. Bonnekoh B, Bockelmann R. Keratin 17/interferon-gamma autoimmune loop as a vicious circle driving psoriasis pathogenesis. *J Am Acad Dermatol* 2007;56(1):162; author reply 62-4.
529. Taibjee SM, Cheung ST, Laube S, Lanigan SW. Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. *Br J Dermatol* 2005;153(5):960-6.
530. Misery L. Skin, immunity and the nervous system. *Br J Dermatol* 1997;137(6):843-50.
531. Ramirez-Carozzi V, Sambandam A, Luis E, Lin Z, Jeet S, Lesch J, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. *Nat Immunol* 2011;12(12):1159-66.
532. Tortola L, Rosenwald E, Abel B, Blumberg H, Schafer M, Coyle AJ, et al. Psoriasisform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. *J Clin Invest* 2012.
533. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. *J Leukoc Biol* 1994;55(2):234-40.
534. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. *Immunol Rev* 2007;220:251-69.
535. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. *Nat Med* 2007;13(10):1173-5.
536. Schon MP, Schon M, Klotz KN. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. *J Invest Dermatol* 2006;126(6):1338-47.
537. Hay DL, Howitt SG, Conner AC, Schindler M, Smith DM, Poyner DR. CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS. *Br J Pharmacol* 2003;140(3):477-86.
538. Ma W, Dumont Y, Vercauteren F, Quirion R. Lipopolysaccharide induces calcitonin gene-related peptide in the RAW264.7 macrophage cell line. *Immunology* 2010;130(3):399-409.
539. Psoriatic patients show enhanced cathelicidin expression after injury and this is normalized by TNF- α inhibition. *Journal of investigative dermatology*; 2011.
540. Zasloff M. Magainins, a class of antimicrobial peptides from *Xenopus* skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. *Proc Natl Acad Sci U S A* 1987;84(15):5449-53.
541. Swindell WR, Xing X, Stuart PE, Chen CS, Aphale A, Nair RP, et al. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. *PLoS One* 2012;7(3):e34594.
542. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF- κ B pathways. *Nat Genet* 2009;41(2):199-204.
543. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *N Engl J Med* 2012;367(16):1519-28.
544. Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. *J Immunol* 2002;169(1):424-33.
545. Racz E, Prens EP. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. *Expert Rev Mol Med* 2009;11:e38.
546. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. *J Immunol* 2011;187(1):490-500.

547. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, Gudjonsson JE, Johnston A. Psoriasis--as an autoimmune disease caused by molecular mimicry. *Trends Immunol* 2009;30(10):494-501.
548. Wang F, Smith N, Maier L, Xia W, Hammerberg C, Chubb H, et al. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. *Br J Dermatol* 2012;167(1):92-102.
549. Cox AJ, Watson W. Histological variations in lesions of psoriasis. *Arch Dermatol* 1972;106(4):503-6.
550. Holubar K. Franjo Kogoj and the spongiform pustule. *Am J Dermatopathol* 1985;7(2):191-5.
551. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N, et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. *J Immunol* 2011;187(5):2783-93.
552. Vogl TJ, Straub R, Lehnert T, Eichler K, Luder-Luhr T, Peters J, et al. [Percutaneous thermoablation of pulmonary metastases. Experience with the application of laser-induced thermotherapy (LITT) and radiofrequency ablation (RFA), and a literature review]. *Rofo* 2004;176(11):1658-66.
553. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI. Intra-neuronal substance P contributes to the severity of experimental arthritis. *Science* 1984;226(4674):547-9.
554. Koopman FA, Stoof SP, Straub RH, Van Maanen MA, Vervoordeldonk MJ, Tak PP. Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis. *Mol Med* 2011;17(9-10):937-48.
555. Momsen OH, Kiil J. Dermatome shaving of psoriasis. Seven years experience in 112 patients. *Scand J Plast Reconstr Surg Hand Surg* 1993;27(2):143-7.
556. Yosipovitch G, Chan Y H, Tay Y K, Goh C L. Thermosensory abnormalities and blood flow dysfunction in psoriatic skin. *Br J Dermatol* 2003; 149: 492-497.
557. Dallos A, Kiss M, Polyanka H, Dobozy A, Kemeny L, Husz S. Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes. *Neuropeptides* 2006; 40: 251-263.
558. Guenova E, Volz T, Sauer K, Kaesler S, Muller MR, Wolbing F, et al. IL-4-mediated fine tuning of IL-12p70 production by human DC. *Eur J Immunol* 2008; 38: 3138-49.
559. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nat Genet* 2012; 44: 1341-48.

The printing of this thesis was financially supported by Janssen BV, Tobrix BV, Oldekamp Medisch BV, Merck Sharp & Dohme BV, Roche BV, Abbvie BV, Astellas Pharma BV, Galderma SA, LEO Pharma BV, Pfizer BV, Fagron BV, Tebu-Bio BV, Eucerin, and Louis Widmer Nederland.



'Dokter, mijn psoriasis is en blijft weg!' . Het is deze uitspraak die aan de basis ligt van dit proefschrift. Zenuwletsel met als gevolg een doof aanvoelende huid lijkt lokaal gepaard te gaan met verdwijning van psoriasis. Daarnaast zorgt therapie gericht tegen de ontstekingsbevorderende stoffen IL-12 en IL-23 voor een langdurige verbetering van psoriasis.

Zoals bij zoveel toevallige ontdekkingen, is het niet zo simpel om een allesomvattende verklaring te bieden voor deze therapeutische successen.

Momenteel lijken de oorzaak en het mechanisme van ontstaan van psoriasis multifactorieel, waarbij bijna alle onderdelen van de huid betrokken zijn. Dit brengt ook een breed scala aan interventie mogelijkheden met zich mee.

Dit proefschrift onderzocht de therapeutische werking van een aantal behandelingen en geeft antwoorden op vragen als:

- Op welke processen in de psoriasis plaque grijpen perifere zenuwen in?
- IL-4 grijpt aan op T cellen en dendritische cellen, maar is er ook een direct effect op keratinocyten (opperhuid) cellen?
- Wat zijn de effecten van anti-IL-12/23 p40 therapie op niet-aangedane huid van psoriasis patiënten?
- Is het moleculaire effect van fumaraten vergelijkbaar met dat van anti-TNF therapie?
- Is het de cyclosporine of de olie-basis die psoriasis nagels verbeterd?
- Hoe leidt laser behandeling van oppervlakkige bloedvaten in psoriasis tot remissie?